




CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Proposed Grant Awards

May 19, 2021





CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS

FROM: JAMES WILLSON, M.D., CHIEF SCIENTIFIC OFFICER

SUBJECT: ACADEMIC RESEARCH FY2021 REVIEW CYCLE 1; AND RECRUITMENT AWARD RECOMMENDATIONS FY2021, CYCLES 21.6, 21.7, 21.8 AND 21.9.

DATE: MAY 19, 2021

The Scientific Review Committee (SRC) and Program Integration Committee (PIC) recommendations for FY2021 review cycle 1 and recruitment cycles 21.6, 21.7, 21.8 and 21.9 include 21 awards from three grant mechanisms totaling **\$60,320,920** as displayed in Table 1. After the SRC made its recommendations, CPRIT was notified prior to the PIC meeting on May 4, 2021, that the University of Texas Southwestern Medical Center withdrew RR210032, a Recruitment of Established Investigators award. The application was removed from consideration by the PIC and is not part of the recommendations made to the Oversight Committee. Note applications are ranked by overall score.

Table 1:

Grant Mechanism	SRC Recommendations	
	Awards	Funding
Research Training Awards	8	\$30,320,920
Recruitment of Rising Stars	2	\$8,000,000
Recruitment of First-Time, Tenure Track Faculty Members	11	\$22,000,000
Total	21	\$60,320,920

Program Priorities Addressed:

The applications proposed to the Program Integration Committee (PIC) for funding address the following Academic Research Program Priorities: recruitment of outstanding cancer researchers to Texas, childhood cancers, hepatocellular cancer and CPRIT’s Long Term Goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products. The program priorities addressed by the proposed slate of awards are displayed in Table 2 and Attachment 1.

Table 2:

Program Priorities Addressed by Grant Recommendations		
# Awards*	Program Priorities	Funding*
13	Recruitment of outstanding cancer researchers to Texas	\$30,000,000
8	CPRIT's Long Term Goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.	\$30,320,920
1	Childhood Cancers	\$2,000,000
2	Hepatocellular Cancer	\$4,000,000
*Some grant awards address more than one program priority and are double counted.		

1. Research Training Awards (RFA R-21.1 RTA) Slate

Peer Review Recommendations:

Fifteen applications were submitted, and the Scientific Review Council recommended eight Research Training Awards (RTA) totaling \$30,320,920. The Scientific Review Council recommended a reduction in the level of effort for the PI of application RP210037 from 30% to 20% with a corresponding budget reduction, which is the budget amount recommended to the PIC.

Purpose of Research Training Awards:

Supports applications for integrated institutional research training programs to support promising individuals who seek specialized training in the area of cancer research. Successful applicant institutions are expected to provide trainees with broad access to research opportunities across disciplinary lines and to maintain high standards for intellectual rigor and creativity.

Research Training Awards Funding Levels:

Up to \$800,000 per year. Exceptions permitted if extremely well justified; maximum duration: 5 years.

RP210028**PI:** Khandan Keyomarsi, Ph.D.**Applicant Organization:** The University of Texas M.D Anderson Cancer Center**Application Title:** The Future of Cancer Research: Training Program for Basic and Translational Scientists**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **1.4****Recommended Total Budget Award and Duration:** \$4,000,000**CPRIT Priorities Addressed:** CPRIT's Long Term Goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.**Description:**

The overall goal of this training program is to promote fundamental, interdisciplinary, and innovative training in cancer research at MD Anderson, and enhance the diversity of trained scientists, essential to groom future leaders in this research arena. To accomplish this goal, a comprehensive training plan will include 3 tracks: the CPRIT TRIUMPH (Translational Research in Multidisciplinary Programs) postdoctoral, the CPRIT graduate scholar, and the CPRIT summer undergraduate programs.

RP210041**PI:** Melanie Cobb, Ph.D.**Applicant Organization:** The University of Texas Southwestern Medical Center**Application Title:** Cancer Intervention and Prevention Discoveries Program**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **1.7****Recommended Total Budget Award and Duration:** \$3,748,675**CPRIT Priorities Addressed:** CPRIT's Long Term Goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.**Description:**

Through structured experiences, the Cancer Intervention and Prevention Discoveries (CIPD) Program aims to establish a powerful cohort of cancer-focused trainees who forge links between basic and clinical initiatives at UT Southwestern to become leading cancer investigators of the future. This is accomplished by training in cutting-edge research, instilling critical thinking, focusing on innovation, and bridging exceptional discovery science training to a translational, population-based and clinical frame of reference.

RP210037**PI:** Margaret Spitz, M.D., Ph.D.**Applicant Organization:** Baylor College of Medicine**Application Title:** Systems Epidemiology for Cancer Training Program (SECT Program)**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **1.8****Recommended Total Budget Award and Duration:** \$3,593,867 (This is the reduced budget amount recommended by the SRC based on a reduction of effort for the PI; the PIC approved the budget as recommended by the SRC).**CPRIT Priorities Addressed:** CPRIT's Long Term Goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.**Description:**

Cancer epidemiology continues to evolve as high-throughput technologies create an exciting interface between epidemiology, molecular biology, and big data science. Bioinformatics is the interdisciplinary field that merges traditional epidemiology with these disciplines to analyze complex biological data. This project defines the approach as "Systems Epidemiology" by applying novel computational analytics to explore mechanistic underpinnings of epidemiologic studies into cancer risk and outcome, and to translate findings to strategies that mitigate cancer risk. The long-term goal is to train a diverse research workforce to be independent, productive scientists with a focus on prevention, clinical, or translational cancer research relevant for Texas.

RP210043**PI:** Peter Davies, M.D., Ph.D.**Applicant Organization:** Texas A&M University System Health Science Center**Application Title:** Cancer Therapeutics Training Program (CTTP).**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **2.5****Recommended Total Budget Award and Duration:** \$3,136,872**CPRIT Priorities Addressed:** CPRIT's Long Term Goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.**Description:**

The goal of the Program will be to address the need in Texas for a cadre of trained scientists equipped with the essential skills and knowledge necessary to translate basic cancer research discoveries into commercially viable cancer therapeutics. The CTTP will be organized as a partnership between the Gulf Coast Consortia (GCC) Innovative Drug Discovery and Development Consortium (GCC-IDDD) and four partner institutions, Texas A&M University, University of Texas Health Science Center – Houston, Texas Southern University and Baylor College of Medicine.

RP210042**PI:** Maria Fernandez, Ph.D.**Applicant Organization:** The University of Texas Health Science Center at Houston**Application Title:** Collaborative Training of a New Cadre of Innovative Cancer Prevention Researchers**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **2.9****Recommended Total Budget Award and Duration:** \$3,998,230**CPRIT Priorities Addressed:** CPRIT's Long Term Goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.**Description:**

The primary focus of this project is on cancer prevention along each step of the cancer control continuum. The program priorities are to: build researcher capacity in Texas to conduct a full range of cancer prevention research important for reducing the cancer burden, particularly among the underserved; 2) bolster the quality and quantity of outstanding cancer prevention researchers who are proponents and practitioners of team science, especially those from underrepresented minority (UMR) groups; 3) increase cancer health equity among all Texans; and 4) accelerate discovery and broad-scale dissemination of effective cancer prevention interventions.

RP210045**PI:** Zhongming Zhao, Ph.D.**Applicant Organization:** The University of Texas Health Science Center at Houston**Application Title:** Biomedical Informatics, Genomics and Translational Cancer Research Training Program (BIG-TCR)**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **2.9****Recommended Total Budget Award and Duration:** \$3,998,553**CPRIT Priorities Addressed:** CPRIT's Long Term Goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.**Description:**

This project will establish a unique collaborative Biomedical Informatics, Genomics, and Translational Cancer Research Training Program (BIG-TCR) at UTHealth. BIG-TCR aims to provide a highly interactive, innovative, and interdisciplinary training environment to train the next-generation cancer researchers and leaders, by leveraging UTHealth's research programs in cancer biology, stem cell biology, pharmacology and drug discovery, genomics and other omics programs, data science, artificial intelligence, clinical informatics and translational medicine.

BIG-TCR will have three training components: PhD training program, postdoctoral training program and undergraduate summer internship program.

RP210046

PI: Jamboor Vishwanatha, Ph.D.

Applicant Organization: University of North Texas Health Science Center at Fort Worth

Application Title: HSC Scholars in Cancer Research

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **2.9**

Recommended Total Budget Award and Duration: \$3,870,641

CPRIT Priorities Addressed: CPRIT's Long Term Goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Description:

This project will promote biomedical and osteopathic medical students at the University of North Texas Health Science Center (UNTHSC) to pursue careers in cancer and health disparities. This program will support the development of creative and innovative research education programs for the students in PhD, clinical research management and dual degree (osteopathic medicine/PhD) programs. The specific programs offered through HSC Scholars in Cancer Research' recruit health professional participants at various levels (undergraduate to early post-doctoral) and provides research training to stimulate career development in the area of cancer.

RP210027

PI: Jeffrey Rosen, Ph.D.

Applicant Organization: Baylor College of Medicine

Application Title: Baylor College of Medicine Comprehensive Cancer Training Program

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **3.0**

Recommended Total Budget Award and Duration: \$3,974,082

CPRIT Priorities Addressed: CPRIT's Long Term Goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Description:

The overall goal of this training program is to facilitate the training of the next generation of outstanding cancer biology researchers to help ensure that a diverse pool of highly trained scientists and physician-scientists are available to meet the State's and nation's basic, clinical and translational cancer research needs. The comprehensive cancer biology training program will involve undergraduate, graduate PhD, postdoctoral, and clinical fellow trainees with an emphasis on both basic and translational cancer research.

2. RECRUITMENT OF RISING STARS SLATE FY21.6, FY21.7, FY21.8 and FY21.9

Peer Review Recommendations

The applications were evaluated and scored by the Scientific Review Council (SRC) to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, scientific merit of the proposed research program, his/her long-term contribution to and impact on the field of cancer research, and strength of the institutional commitment to the candidate.

Purpose of Recruitment of Rising Stars Awards:

The aim is to recruit outstanding early-stage investigators to Texas, who have demonstrated the promise for continued and enhanced contributions to the field of cancer research.

Funding levels for Recruitment of Rising Stars Awards:

Up to \$4 million over a period of 5 years.

Recommended Awards:

Five Recruitment of Rising Stars grant applications were submitted and two were recommended by the Scientific Review Council for an award.

RR210031

Candidate: Jeremy Wilusz, Ph.D.

Funding Mechanism: Recruitment of Rising Stars

Applicant Organization: Baylor College of Medicine

Original Organization of Nominee: University of Pennsylvania

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **2.0**

Recommended Total Budget Award and Duration: \$4,000,000

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas;
Population Disparities

Description:

Jeremy Wilusz, Ph.D., is recommended for a Rising Star award to support his recruitment to Baylor College of Medicine from the University of Pennsylvania. Dr. Wilusz is a leader in RNA biology. He obtained his Ph.D. with David Spector at Cold Spring Harbor in 2019 and did his post-doctoral training with Nobel Laureate Phillip Sharp. He joined the faculty at University of Pennsylvania in 2014 and is currently an Associate Professor. He has an NIH Outstanding Investigator R35 grant. He plans to study deregulation of circular transcriptional regulation and RNA processing in triple negative breast cancer and to use this knowledge to generate novel therapeutic approaches to these tumors.

RR210042**Candidate:** Stephanie Seidlits, Ph.D.**Funding Mechanism:** Recruitment of Rising Stars**Applicant Organization:** University of Texas at Austin**Original Organization of Nominee:** University of California Los Angeles**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **2.0****Recommended Total Budget Award and Duration:** \$4,000,000**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas**Description:**

Stephanie Seidlits, Ph.D., is recommended for a Rising Star award to support her recruitment to The University of Texas at Austin from UCLA. Dr. Seidlits graduated with a BS in Bioengineering from Rice University in 2004 and with a PhD in Biomedical Engineering from UT Austin in 2010. After completing a postdoctoral fellowship at Northwestern in 2014, she was appointed as an Assistant Professor of Bioengineering at UCLA in 2014 and holds ACS and NCI grants. Her research focuses on developing models that mimic the brain tumor environment of glioblastoma to study tumor invasion and test personalized therapeutic approaches.

3. RECRUITMENT FIRST-TIME TENURE TRACK FACULTY MEMBERS SLATE FY21.6, FY21.7, FY21.8 and FY21.9

Peer Review Recommendations

The applications were evaluated and scored by the Scientific Review Council to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, his/her scientific merit of the proposed research program, his/her long-term contribution to and impact on the field of cancer research, and strength of the institutional commitment to the candidate.

Purpose of First Time Tenure Track Faculty Recruitment

The aim is to recruit and support very promising emerging investigators, pursuing their first faculty appointment in Texas, who can make outstanding contributions to the field of cancer research.

Funding levels for First Time Tenure Track Faculty Members Recruitment

Up to \$2 million over a period of up to 5 years.

Recommended Projects:

Sixteen Recruitment of First-Time Tenure Track Faculty Members grant applications were submitted and eleven were recommended by the Scientific Review Council for an award.

Below is a listing of the candidates with their associated expertise.

RR210028

Candidate: Julea Vlassakis, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: Rice University

Original Organization of Nominee: The University of California Berkeley

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **1.0**

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas, Childhood Cancer

Description:

Julea Vlassakis, Ph.D., is recommended for a First-Time, Tenure-Track Faculty Member award to support her recruitment to Rice University from The University of California Berkeley where she is completing her post-doctoral research. She plans to use cryo-EM and other advanced techniques to uncover small-molecule inhibitors of key enzymes involved in the malignant phenotype in Ewing's sarcoma. She has received a Burroughs Wellcome Fund career development award that has supported the final two years of her post-doc and will support the first three years of her independent lab.

RR210035

Candidate: Chen Yao, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas Southwestern Medical Center

Original Organization of Nominee: National Institutes of Health

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

Chen Yao, Ph.D., is recommended for a First-Time, Tenure-Track Faculty Member award to support her recruitment to UT Southwestern from the NIH. She has received an NIH Director's new innovator award to evaluate whether stem-like CD8 T cells can be harnessed to enhance T-cell based immunotherapy against HIV. At UT Southwestern she plans to focus on renal cell carcinoma to explore how CD8 T cells can be manipulated to expand the clinical impact of immune checkpoint inhibitors.

RR210044**Candidate:** Jason Sheltzer, Ph.D.**Funding Mechanism:** Recruitment of First Time Tenure Track Faculty Member**Applicant Organization:** The University of Texas M.D. Anderson Cancer Center**Original Organization of Nominee:** Cold Spring Harbor Laboratory**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **1.0****Recommended Total Budget Award and Duration:** \$2,000,000.**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas**Description:**

Jason Sheltzer, Ph.D., is recommended for a First-Time, Tenure-Track Faculty Member award to support his recruitment to MD Anderson from Cold Spring Harbor Laboratory (CSHL). He obtained his BS in Molecular Biology at Princeton and a PhD at MIT. He skipped a Postdoc and went straight to CSHL as a Fellow where he has been since 2015. He has already demonstrated his ability as an independent investigator with grants from the NIH, ACS RPG, and a DoD Breast Cancer Breakthrough award. At MD Anderson he plans to develop CDK11 inhibition as a strategy to treat aggressive malignancies.

RR210039**Candidate:** Cornelius Y. Taabazuig, Ph.D.**Funding Mechanism:** Recruitment of First Time Tenure Track Faculty Member**Applicant Organization:** Baylor College of Medicine**Original Organization of Nominee:** Memorial Sloan-Kettering Cancer Center**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **1.0****Recommended Total Budget Award and Duration:** \$2,000,000.**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas**Description:**

Cornelius Y. Taabazuig, Ph.D. is recommended for a First-Time, Tenure-Track Faculty Member award to support his recruitment to Baylor College of Medicine from Memorial Sloan-Kettering Cancer Center. His postdoctoral work led to the discovery of crosstalk between the key cell death pathways of pyroptosis and apoptosis and paved the way for novel cancer immunotherapy approaches harnessing cell death pathways. At Baylor Dr. Taabazuig proposes to capitalize on these mechanistic insights and focus his laboratory's efforts on developing new immunotherapies.

RR210029

Candidate: Dongyin Guan, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: Baylor College of Medicine

Original Organization of Nominee: University of Pennsylvania

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.4

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas, Hepatocellular Cancer

Description:

Dongyin Guan, Ph.D., is recommended for a First-Time, Tenure-Track Faculty Member award to support his recruitment to Baylor College of Medicine from University of Pennsylvania where he plans to investigate the role clock regulators play in nonalcoholic steatohepatitis and hepatocellular carcinoma. He has received an NIH K01 career development award that will support his independent lab.

RR210037

Candidate: Blair Benham-Pyle, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: Baylor College of Medicine

Original Organization of Nominee: Stowers Institute for Medical Research

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.8

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

Blair Benham-Pyle, Ph.D., is recommended for a First-Time, Tenure-Track Faculty Member award to support her recruitment to Baylor College of Medicine from the Stowers Institute for Medical Research in Kansas City. She plans to address the role of Wnt-driven signaling in stem cell expansion and its contribution to colorectal and pancreatic cancers. The proposed research is both novel and associated with a high degree of risk as the hypothetical role of the Wnt-pathway in cancer is the opposite of the current dogma.

RR210050

Candidate: Cassandra Callmann, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas at Austin

Original Organization of Nominee: Northwestern University

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **1.8**

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas, Hepatocellular Cancer

Description:

Cassandra Callmann, Ph.D., is recommended for a First-Time, Tenure-Track Faculty Member award to support her recruitment to UT Austin from Northwestern University. Dr. Callmann earned her Ph.D. from the University of California-San Diego where she designed drug-loaded nanomaterials to create drug depots in tumor tissue and developed new carrier strategies for drug delivery. At Northwestern University she has developed spherical nucleic acids as immunotherapeutics for triple-negative breast cancer, as well as launching the frontier of rational vaccinology, in which vaccine components are organized in optimized structural arrangements to maximize potency. In addition to an impressive publication record, Dr. Callmann has been awarded seven patents related to therapeutics. At UT Austin she plans to design and develop carbohydrate-polymer conjugates to modulate the organization of tumor microenvironments and harness the principle of “immunocamouflage” to prolong the circulation of therapeutic nanoparticles.

RR210033

Candidate: Brian Christopher Miller, M.D., Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas Southwestern Medical Center

Original Organization of Nominee: Dana Farber/Harvard Cancer Center

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **2.0**

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

Brian Christopher Miller, M.D., Ph.D., is a physician scientist recommended for a First-Time, Tenure-Track Faculty Member award to support his recruitment to UT Southwestern from the Dana Farber/Harvard Cancer Center. His research plans will address the resistance mechanisms involved in PD-1 immunotherapy. He has received an NIH K08 career development award that will support his independent lab.

RR210033

Candidate: Sihan Wu, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas Southwestern Medical Center

Original Organization of Nominee: University of California San Diego

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

Sihan Wu, Ph.D., is recommended for a First-Time, Tenure-Track Faculty Member award to support his recruitment to UT Southwestern from the University of California San Diego. He will join the UT Southwestern Children's Research Institute as an Assistant Professor where he plans to continue his studies of the role of extrachromosomal DNAs in cancer cells.

RR210040

Candidate: Joshua Riback, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: Baylor College of Medicine

Original Organization of Nominee: Princeton University

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

Joshua Riback, Ph.D., is recommended for a First-Time, Tenure-Track Faculty Member award to support his recruitment to Baylor College of Medicine from Princeton. Dr. Riback has an extremely impressive background in the biophysics of liquid phase separation (LLPS), a very exciting area of cell biology. He made critical contributions to this area both as a graduate student at the University of Chicago and as a post doc at Princeton. He plans to continue to use the approaches he developed to study the impact of Myc or fusion protein expression on the formation and function of LLPS in cancer that has the potential to provide new insight into basic cancer biology.


RR210048**Candidate:** Courtney M. Schroeder, Ph.D.**Funding Mechanism:** Recruitment of First Time Tenure Track Faculty Member**Applicant Organization:** The University of Texas Southwestern Medical Center**Original Organization of Nominee:** Fred Hutchinson Cancer Research Center**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0**Recommended Total Budget Award and Duration:** \$2,000,000.**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas**Description:**

Courtney M. Schroeder, Ph.D., is recommended for a First-Time, Tenure-Track Faculty Member award to support her recruitment to UT Southwestern from the Fred Hutchinson Cancer Center.

Dr. Schroeder has a unique background in cytoskeletal biology, evolutionary analysis, and cell fitness, and was the first to identify several novel sperm-specific actin-related proteins and show the key role of one of these in reproductive fitness. At UT Southwestern she will investigate how the selective re-expression of these unique cytoskeletal proteins in cancer contributes to tumorigenesis.

Attachment #1

*Academic Research Program Priorities Addressed by Recommended Awards (*Some grant awards address more than one program priority and are double counted.)						
Scale	Recruitment of outstanding cancer researchers to Texas	A broad range of innovative, investigator-initiated research projects	CPRIT's Long Term Goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products. Computational biology and analytic methods	Childhood Cancers	Hepatocellular Cancer	Population Disparities



Attachment #2
RFA Descriptions

- **Research Training Awards (RFA R-21.1 RTA):**
Supports applications for integrated institutional research training programs to support promising individuals who seek specialized training in the area of cancer research. Successful applicant institutions are expected to provide trainees with broad access to research opportunities across disciplinary lines and to maintain high standards for intellectual rigor and creativity.
Award: Up to \$400,000 in total costs per year over a period of five years.
- **Recruitment of Established Investigators (RFA R-21-1 REI):**
Recruits outstanding senior research faculty with distinguished professional careers and established cancer research programs to academic institutions in Texas.
Award: Up to \$6 million over a period of five years.
- **Recruitment of Rising Stars (RFA R-21-1 RRS):**
Recruits outstanding early-stage investigators to Texas, who have demonstrated the promise for continued and enhanced contributions to the field of cancer research.
Award: Up to \$4 million over a period of five years.
- **Recruitment of First-Time Tenure Track Faculty Members (RFA R-21-1. RFT):**
Supports very promising emerging investigators, pursuing their first faculty appointment in Texas, who have the ability to make outstanding contributions to the field of cancer research.
Award: Up to \$2 million over a period up to five years.



2401 Gillham Road
Kansas City, Missouri 64108
(816) 234-3000

April 20, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cpriti.texas.gov

Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Research Training Awards (RTA).

The SRC met on March 25, 2021 to consider the applications recommended by the peer review panel following their meeting held on February 18, 2021.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$30,320,920. Please note that the Peer Review Panel and SRC recommended a reduced budget of \$3,593,867 for application # RP210037.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,

A handwritten signature in black ink that reads "Tom Curran".

Tom Curran, PhD, FRS
Senior Vice President, Executive Director and Chief Scientific Officer
Children's Mercy Research Institute, Children's Mercy Kansas City
Donald J. Hall Eminent Scholar in Pediatric Research
Professor of Pediatrics
UMKC School of Medicine
Professor of Cancer Biology
University of Kansas School of Medicine
Adjunct Professor of Biomedical Sciences
Kansas City University of Medicine & Biosciences
P: (816) 731-7007 | M: (267) 438-1844
E: tcurran@cmh.edu | W: childrensmercy.org

Rank	ID	Award Mechanism	Score	Application Title	PI	PI Organization	Recommended Budget
1	RP210028	RTA-Renewal	1.4	The Future of Cancer Research: Training Program for Basic and Translational Scientists	Keyomarsi, Khandan	The University of Texas M. D. Anderson Cancer Center	\$4,000,000
2	RP210041	RTA-Renewal	1.7	Cancer Intervention and Prevention Discoveries Program	Cobb, Melanie	The University of Texas Southwestern Medical Center	\$3,748,675
3	RP210037	RTA-Renewal	1.8	Systems Epidemiology for Cancer Training Program (SECT Program)	Spitz, Margaret	Baylor College of Medicine	\$3,593,867*
4	RP210043	RTA	2.5	Cancer Therapeutics Training Program (CTTP)	Davies, Peter	Texas A&M University System Health Science Center	\$3,136,872
5	RP210046	RTA-Renewal	2.9	HSC Scholars in Cancer Research	Vishwanatha, Jamboor	University of North Texas Health Science Center at Fort Worth	\$3,870,641
6	RP210042	RTA-Renewal	2.9	Collaborative Training of a New Cadre of Innovative Cancer Prevention Researchers	Fernandez, Maria	The University of Texas Health Science Center at Houston	\$3,998,230
7	RP210045	RTA	2.9	Biomedical Informatics, Genomics, and Translational Cancer Research Training Program (BIG-TCR)	Zhao, Zhongming	The University of Texas Health Science Center at Houston	\$3,998,553
8	RP210027	RTA-Renewal	3.0	Baylor College of Medicine Comprehensive Cancer Training Program	Rosen, Jeffrey	Baylor College of Medicine	\$3,974,082

*Panel and SRC Recommended a reduced budget of \$3,593,867 (a total reduction of \$62,005)

RTA = Research Training Award

2401 Gillham Road
Kansas City, Missouri 64108
(816) 234-3000

April 20, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov


Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of recruitment grant recommendations. The SRC met on January 21, 2021 (REC Cycle 21.6), March 11, 2021 (REC Cycles 21.7 and 21.8) and April 15, 2021 (REC Cycle 21.9) to review the applications submitted to CPRIT under the Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time Tenure Track Faculty Members.

The projects on the attached list are numerically ranked in the order the SRC recommends the applications be funded. Recommended funding amounts and the overall evaluation scores are stated for each grant application. There were no recommended changes to funding amounts, goals, timelines, or project objectives requested. The total amount for the applications recommended is \$36,000,000.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting candidates at all career levels that have demonstrated academic excellence, innovation, excellent training, a commitment to cancer research and exceptional potential for achieving future impact in basic, translational, population based or clinical research.

Sincerely yours,



Tom Curran, PhD, FRS
Senior Vice President, Executive Director and Chief Scientific Officer
Children's Mercy Research Institute, Children's Mercy Kansas City
Donald J. Hall Eminent Scholar in Pediatric Research
Professor of Pediatrics
UMKC School of Medicine
Professor of Cancer Biology
University of Kansas School of Medicine
Adjunct Professor of Biomedical Sciences
Kansas City University of Medicine & Biosciences
P: (816) 731-7007 | M: (267) 438-1844
E: tcurran@cmh.edu | W: childrensmercy.org

Rank	App. ID	Mechanism	Candidate	Organization	Budget	Overall Score
1	RR210028	RFTFM	Julea Vlassakis, Ph.D.	Rice University	\$2,000,000	1.0
2	RR210035	RFTFM	Chen Yao, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
3	RR210032	REI	James H. Hurley, Ph.D.	The University of Texas Southwestern Medical Center	\$6,000,000	1.0
4	RR210044	RFTFM	Jason Sheltzer, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
5	RR210039	RFTFM	Cornelius Y. Taabazuing, Ph.D.	Baylor College of Medicine	\$2,000,000	1.0
6	RR210029	RFTFM	Dongyin Guan, Ph.D.	Baylor College of Medicine	\$2,000,000	1.4
7	RR210037	RFTFM	Blair Benham-Pyle, Ph.D.	Baylor College of Medicine	\$2,000,000	1.8
8	RR210050	RFTFM	Cassandra Callmann, Ph.D.	The University of Texas at Austin	\$2,000,000	1.8
9	RR210031	RRS	Jeremy Wilusz, Ph.D.	Baylor College of Medicine	\$4,000,000	2.0
10	RR210034	RFTFM	Sihan Wu, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
11	RR210033	RFTFM	Brian Christopher Miller, M.D., Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
12	RR210040	RFTFM	Joshua Riback, Ph.D.	Baylor College of Medicine	\$2,000,000	2.0
13	RR210048	RFTFM	Courtney M. Schroeder, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
14	RR210042	RRS	Stephanie Seidlits, Ph.D.	The University of Texas at Austin	\$4,000,000	2.0

REI = Recruitment of Established Investigators

RRS = Recruitment of Rising Stars

RFTFM = Recruitment of First-Time Tenure-Track Faculty Members



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 WAIVER
DATE: FEBRUARY 1, 2021

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I have granted Chief Scientific Officer Dr. Jim Willson a waiver from the general prohibition against communicating with a grant applicant while CPRIT is accepting and reviewing applications. The waiver is applicable to communication with Dr. Lynne Cossman, Dean of the College for Health, Community and Policy at The University of Texas San Antonio regarding a recruitment application that CPRIT withdrew from consideration because it did not demonstrate required application elements. Dr. Willson will speak to Dr. Cossman regarding the goals and eligibility requirements for the recruitment award. This may result in the submission of a revised application. No Oversight Committee action related to this waiver is necessary.

Discussion

The Chief Scientific Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while CPRIT is accepting applications for the review cycle. The communication restriction is one way that we prevent even the appearance of unequal treatment in the grant review process.

During the FY 2021 recruitment cycle, The University of Texas at San Antonio submitted an application that CPRIT withdrew prior to Scientific Review Council (SRC) evaluation because the application did not include all required elements. Dr. Willson intends to speak with Dr. Cossman, the inaugural dean of the UTSA College for Health, Community, and Policy about the goals and eligibility requirements for recruitment applications. Speaking with a grant applicant after an unsuccessful review is a normal part of Chief Scientific Officer's duties and assists the grant applicant in preparing better applications for future submission. However, because the recruitment application process is "always open," such communication between Dr. Willson and Dr. Cossman may unintentionally violate CPRIT's restriction on communication policy.

Approving this waiver does not favor any future application over any other grant applications. All recruitment applications will receive the same rigorous evaluation by the Scientific Review Council (SRC). Dr. Willson does not discuss any substantive issues with the SRC related to applications under review and plays no role in the SRC's decision to recommend an award to CPRIT.

The Oversight Committee does not need to take any action regarding this waiver. Should UTSA submit a recruitment application that the SRC reviews during the FY 2021 review cycle, CPRIT will include Dr. Willson's waiver as part of the grant record.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

FY 2021 – Cycle 1
Research Training Awards

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-21.1-RTA

Research Training Awards

Applications for this award mechanism are subject to institutional limits. Applicants are advised to consult with their institution's Office of Research and Sponsored Programs (or equivalent).

Please also refer to the Instructions for Applicants document, which will be posted on July 8, 2020

Application Receipt Opening Date: July 8, 2020

Application Receipt Closing Date: October 28, 2020

FY2021

Fiscal Year Award Period

September 1, 2020–August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. RESEARCH OBJECTIVES	6
4. FUNDING INFORMATION	7
5. ELIGIBILITY	9
6. RESUBMISSION POLICY	10
7. RENEWAL POLICY	10
8. RESPONDING TO THIS RFA	10
8.1. APPLICATION SUBMISSION GUIDELINES	10
8.1.1. <i>Submission Deadline Extension</i>	11
8.2. APPLICATION COMPONENTS	11
8.2.1. <i>Abstract and Significance (5,000 characters)</i>	11
8.2.2. <i>Layperson’s Summary (2,000 characters)</i>	12
8.2.3. <i>Goals and Objectives</i>	12
8.2.4. <i>Timeline (1 page)</i>	12
8.2.5. <i>Renewal Summary (5 pages not including tables)</i>	12
8.2.6. <i>Research Training Plan (20 pages)</i>	13
8.2.7. <i>Publications/References</i>	14
8.2.8. <i>Budget and Justification</i>	14
8.2.9. <i>Biographical Sketches (5 pages each)</i>	15
8.2.10. <i>Current and Pending Support</i>	16
8.2.11. <i>Institutional Support (3 pages)</i>	16
8.3. FORMATTING INSTRUCTIONS	16
9. APPLICATION REVIEW	17
9.1. FULL PEER REVIEW	17
9.2. CONFIDENTIALITY OF REVIEW	18
9.3. REVIEW CRITERIA	19
9.3.1. <i>Primary Criteria</i>	19
9.3.2. <i>Secondary Criteria</i>	21
10. KEY DATES	22
11. AWARD ADMINISTRATION	22
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	23
13. CONTACT INFORMATION	24
13.1. HELPDESK.....	24
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	24

RFA VERSION HISTORY

6/18/20 RFA released

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expand access to innovative clinical trials

2. RATIONALE

The goal of this award is to facilitate the training of the next generation of outstanding cancer researchers to help ensure that a diverse pool of highly trained scientists is available in adequate numbers and in appropriate research areas to address the state's and the nation's basic, population-based, clinical, and translational cancer research needs. Training is expected to be directed toward building the broad research competence required to ensure that trainees are prepared to assume leadership roles in cancer research. This award supports the training of highly qualified individuals, both predoctoral and postdoctoral, who have the potential to become productive, independent research scientists or physician-scientists and who intend to pursue careers focused on cancer research.

Committed institutional support is required, especially in the form of superb research opportunities, excellent instruction and mentoring, and state-of-the-art facilities. Trainees are expected to be immersed in a highly interactive and supportive didactic and research program that facilitates research and instruction in cancer-related areas that will contribute to innovative approaches to key problems and will help bring novel solutions and potential therapies into practice. The training environment should be enriched by programmatic elements such as seminars from visiting researchers, journal clubs, internal research seminars, videoconferencing with collaborating institutions (if applicable), and attendance at relevant national and/or international scientific meetings. Each supported trainee is expected to identify an appropriate mentor and/or mentor committee that will be responsible for providing critical teaching, advising, and leadership experience.

In addition to support of MD, DO, DNS, PhD, and postdoctoral research training, potential opportunities include the following:

- Master's degree-level programs to train clinical investigators. Trainees may be in predoctoral programs or clinical fellowship positions, or they should have just received their first faculty appointment as an instructor or assistant professor.

- Master's degree-level programs to facilitate trainees' pursuit of research careers as high-level laboratory support personnel. When trained, such individuals would be capable of training others in a laboratory with regard to sophisticated technical issues and of performing research with only modest levels of supervision. CPRIT encourages innovative approaches to training such individuals. Programs whose goals are to produce trainees with a conventional master's degree in a relevant biomedical or related science by successful completion of a relatively modest research project are not appropriate.
- Undergraduate summer research internship programs, particularly those directed at underrepresented minorities.

3. RESEARCH OBJECTIVES

This RFA solicits applications for *integrated institutional research training programs* to support promising individuals who seek specialized training in the area of cancer research. The goals of the Research Training Awards are to attract outstanding predoctoral (eg, PhD, DNS, or MD/PhD), and postdoctoral trainees committed to pursuing a career in basic, population-based, translational, or clinical cancer research; to expand the skills and expertise of trainees to promote the next generation of investigators and leaders in cancer research; to position most trainees for independent research careers; and to support the development of high-quality, innovative, and creative research that, if successful, could provide the basis for a significant impact on cancer prevention, detection, and/or treatment. Successful applicant institutions are expected to provide trainees with broad access to research opportunities across disciplinary lines and to maintain high standards for intellectual rigor and creativity.

Awards in response to this RFA will be made for institutional programs; individual fellowship applications will not be considered.

It is expected that the research training experience will provide the following:

- A strong foundation in research design, methods, and analytic techniques appropriate to the proposed research project
- The development or enhancement of the supported trainee's ability to conceptualize and think through research problems with increasing independence
- An understanding of how basic discoveries are translated to clinical practice
- Experience in conducting, presenting, and publishing independent research

- Instruction in the responsible conduct of research
- The opportunity to interact with members of the scientific community at relevant seminars, scientific meetings, and workshops
- A well-conceived career plan to increase the trainee's ability to compete successfully for additional support for his or her career development as an independent investigator

Individuals from underrepresented racial and ethnic groups, individuals with disabilities, and individuals from disadvantaged backgrounds are especially encouraged to participate in CPRIT's training programs, and a plan for recruiting such individuals is a requirement for this award. Successful applicants will be expected to report demographic data by program type and trainee in annual progress reports, which will serve as an important evaluative component of the program.

In addition to predoctoral and postdoctoral research training, applicants may propose master's degree-level programs to train clinical investigators; undergraduate summer research internship programs, particularly those directed at recruitment of underrepresented minorities; and master's degree-level programs to encourage the pursuit of alternative careers in laboratory support positions.

CPRIT expects outcomes of supported activities to directly and indirectly benefit subsequent cancer research efforts, cancer public health policy, or the continuum of cancer care—from prevention to treatment and cure. To fulfill this vision, trainees may pursue any research topic or issue related to cancer biology, causation, prevention, detection or screening, treatment, or cure. Each supported trainee and his or her mentor and institution are jointly responsible for planning, directing, and executing the proposed research training program.

Attracting the finest trainees to Texas laboratories and academic institutions is critically important for the local cancer research enterprises, but it is acknowledged that a significant number of those trained in Texas may ultimately seek positions elsewhere.

4. FUNDING INFORMATION

Applicants may request a maximum of \$800,000 in total costs per year for up to 5 years.

Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

Support may be requested as follows for the various types of trainees in an institutional training program:

- **PhD trainees** may request support for stipend (up to \$28,000 per year, which may be supplemented with other available funds) and benefits and an allowance per trainee of \$1,000 per year that may be used for travel to relevant scientific meetings if the trainee is making a presentation (oral or poster). Funds for tuition may also be requested (to a maximum of \$6,000 per year). Individual trainees may be supported for up to 4 years, but they cannot be supported by this mechanism until it is clear that their **mentor and research program are highly relevant to cancer**.
- **MD/DO/PhD trainees** may request support equal to that of PhD trainees (above). Funds may be used only during the time of research training, not during medical school years.
- **Postdoctoral trainees** may request NIH-scale salary support plus benefits and an allowance per trainee of \$2,000 per year for travel to scientific meetings. Appointments may be made for up to 3 years. Individuals holding PhD, MD/PhD, MD/DO, DNS, DO or MD degrees are eligible for postdoctoral fellowship support provided that the training supported by CPRIT is for research (basic, population-based, translational, or clinical).

Support may also be requested for the following types of institutional training programs:

- **Undergraduate summer internship programs** may request up to \$6,000 per trainee for summer stipend and housing allowance.
- **Master's degree-level programs to support research careers as laboratory support personnel** may request stipend support (\$28,000 per year) plus benefits. Appointments may be made for up to 2 years. Funds for tuition may also be requested (to a maximum of \$6,000 per year).
- **Master's degree-level programs to train clinical investigators** may request \$28,000 per year plus benefits if trainees are predoctoral (eg, an MD/MS training program). Funds may not be used while trainees are in medical school. Programs may request \$50,000 per year plus benefits if trainees are clinical fellows or faculty members. It is anticipated that institutions will supplement stipends for trainees at this level. Funds for tuition may be requested (to a maximum of \$6,000 per year).

5. ELIGIBILITY

- The applicant must be a Texas-based institution of higher education or a component of a university system with appropriately accredited degree-granting training programs (if support is requested for training leading to a degree).
- The Principal Investigator (PI) must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- An institution may submit only 1 new or renewal application under this RFA during this funding cycle. An exception will be made for institutions submitting applications for cancer prevention training; in this case, institutions may submit 1 prevention training program application and 1 additional application in another aspect of cancer research (new or renewal).
- For the purposes of this RFA, an institution is defined as that component of a university system that has its own president.
- There must be only 1 PI, but Co-PIs may direct individual components of the overall program described in the application.
- An institution may apply for as many components of the training program as are appropriate for the institution.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.

- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not those individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 10](#) and [section 11](#). All statutory provisions and relevant administrative rules can be found at www.cprit.state.tx.us.

6. RESUBMISSION POLICY

Resubmissions are not allowed in this cycle as CPRIT last offered the RTA in April 2016. A RTA application that was unfunded after a single review should be submitted as a new application under this RFA.

7. RENEWAL POLICY

Institutions that received a CPRIT Research Training Award (RTA) with a current contract end dates of February 28, 2021, November 30, 2021 or February 28, 2022 are eligible to submit a renewal application for this RFA, with the requirement that the original award contract be early terminated should the renewal application be funded.

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. The Co-PI, if applicable, must also

create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on July 8, 2020, and must be submitted by 4 PM central time on October 28, 2020. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the [CPRIT Helpdesk](#), within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the *Instructions for Applicants* document for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 5](#) will be administratively withdrawn without review.

8.2.1. Abstract and Significance (5,000 characters)

Clearly describe the proposed training program. Explain program goals and provide an outline of the proposed didactic and research training activities and an overview of the institutional infrastructure and commitment. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the Research Training Plan. Clearly address how the proposed program, if successful, will have a major impact on cancer and will increase the number of underrepresented minorities in the field.

8.2.2. Layperson’s Summary (2,000 characters)

Provide a layperson’s summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer research addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early diagnosis, prevention, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding.

Do not include any proprietary information in the Layperson’s Summary. The Layperson’s Summary will also be used by advocate reviewers ([section 9.1](#)) in evaluating the significance and impact of the proposed work.

8.2.3. Goals and Objectives

Concisely state the specific goals and objectives to be achieved by the training plan described in the application. Goals and objectives should be listed for each year of the project. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success. Note recruitment, diversity and retention goals and objectives are required, as they represent a core RFA component.

8.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.5. Renewal Summary (5 pages not including tables)

Applicants preparing a renewal are expected to describe and demonstrate with data how the CPRIT funded program has supported the training of independent research scientists or physician-scientists who are pursuing careers focused on cancer research.

Provide a summary highlighting the progress of each component of the training program.

Provide demographic information on trainees supported (gender, race, ethnicity, and trainees with disabilities) and include summary information about publications, patents, follow-on funds, and other impactful data. **NOTE:** only provide data for CPRIT funded trainees.

Provide information on each predoctoral and postdoctoral trainee supported over the funding period in a tabular format using Table 1 for predoctoral trainees and Table 2 for postdoctoral trainees (note that Table 1 and Table 2 require the same data as the NIH T32 application).

NOTE: only provided data for CPRIT funded trainees.

Provide information on publications for each predoctoral and postdoctoral trainee supported in a tabular format using Table 3. Refer to the sample Tables in the document located in [Current Funding Opportunities](#) for Academic Research in CARS. **NOTE:** only provide data for CPRIT funded trainees.

8.2.6. Research Training Plan (20 pages)

Background: Present the rationale behind the proposed training plan, emphasizing how the proposed project will support the development of dedicated investigators in cancer research.

Program Goals: Concisely state the goals and objectives to be achieved by the research training plan described in the application. These need not be fully repeated (as entered in [section 8.2.3](#)) and may be only summarized.

Training Plan: Provide a description of proposed courses/classes, seminars, and opportunities for interaction with other groups and scientists. Describe both formal program requirements and opportunities for professional development. Training in career skills (eg, grant writing and presentation skills) is strongly encouraged. Elaborate on the research environment and available research facilities and equipment and discuss the relationship of the proposed research projects to trainees' careers. A training plan must be described for each type of program for which support is requested.

Selection of Trainees and Mentors: Describe the process and major criteria that will be used to select trainees to be supported by this program. Describe the process and major criteria that will be used to select mentors for this program.

Note the following eligibility criteria for trainees supported by this mechanism:

1. All supported trainees must reside in Texas during the time the training program that is the subject of the grant is conducted.

2. All trainees must be officially enrolled in the appropriate institutional training program.
3. Trainees may be citizens or noncitizen nationals of the United States or international citizens who hold student visas.
4. Excluding summer interns, trainees must have at least a baccalaureate degree and show evidence of both high academic performance in the sciences and keen interest in research in areas of high priority to the participating institution. In addition, trainees who are degree candidates must be enrolled in an accredited program and be sponsored by a mentor for the research component.

PI: Outline the responsibilities of the PI in the overall management, administration, and evaluation of the program. Describe how the PI's scientific background, leadership, and administrative capabilities will enable him or her to coordinate and oversee the proposed research training program. Describe the research training record of the PI and, if applicable, Co-PIs.

Recruitment Plan/Diversity Recruitment: Include a recruitment and retention plan for recruiting trainees from both outside and inside the applicant institution and for attracting trainees from complementary disciplines (eg, from the physical, computational, and engineering sciences) to cancer research. Provide plans for enhancing the diversity of the trainee pool by recruiting from underrepresented groups and a plan for career mentoring such trainees (**this will be an important factor in the evaluation of the application**). Applications that do not address recruitment and retention will be considered incomplete.

Responsible Conduct of Research: Describe the plan to provide instruction in the responsible conduct of research, including the rationale, subject matter, appropriateness, format, frequency, and duration of instruction. The amount and nature of faculty participation must be described.

8.2.7. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

8.2.8. Budget and Justification

Provide an outline and justification of the budget for the entire proposed period of support.

Applicants may request a maximum of \$800,000 in total costs per year for up to 5 years.

Allowable costs include trainee stipends (see limits in [section 4](#)), benefits, and travel allowances (as indicated in [section 4](#)). Tuition (up to a maximum of \$6,000 per year) may be included for

those in degree-granting programs. The budget should be based on the number of trainee slots requested for each type of training activity. Justification of the number of trainees requested must be compelling and based on the number of exceptionally well-qualified individuals who are likely to be available and who deserve such support as well as funds currently available from other training programs to support them. An appropriate and modest level of salary support may be requested for the PI, Co-PIs, and administrative staff.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.state.tx.us. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The annual salary (also referred to as direct salary or institutional base salary) that an individual may receive under a CPRIT award for FY 2021 is \$200,000; CPRIT FY 2021 is from September 1, 2020, through August 31, 2021. Salary does not include fringe benefits and/or facilities and administrative (F&A) costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

8.2.9. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research.

A biographical sketch must be provided for the PI and, if applicable, the Co-PI (as required by the online application receipt system). Up to 10 additional biographical sketches for key

personnel may be provided. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

8.2.10. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title and a 2-line summary of the goal of the project.

8.2.11. Institutional Support (3 pages)

Each application must be accompanied by a letter of institutional support from the president or provost indicating support and commitment to the training program. The letter could include, but is not limited to, information about laboratory space, shared laboratory facilities and equipment, funds for curriculum development, support for additional trainees in the program, and initiatives to support recruitment of underrepresented minorities. A maximum of 3 pages may be provided.

Applications that are missing 1 or more of these components, exceed the specified page, word, or budget limits, or that do not meet the eligibility requirements listed above will be administratively rejected without review.

8.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English.
- **Document Format:** PDF only.
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point).
- **Line Spacing:** Single.
- **Page Size:** 8.5 x 11 inches.
- **Margins:** 0.75 inch, all directions.
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.

- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

9. APPLICATION REVIEW

9.1. Full Peer Review

Applications will undergo a 2-stage peer review process: (1) Full peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 9.3](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT

Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

Applicants will be notified of peer review panel assignment prior to the peer review meeting dates.

9.2. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice

regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

9.3. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

9.3.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed training program. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed program. Primary criteria include the following:

Primary Review Criteria for New Applications

Overall Evaluation of Training Potential: What is the likelihood that the training program will serve as a sound foundation to enhance a supported trainee's potential for, and commitment to, a productive, independent scientific research career in a cancer-related field?

Research Training Plan: Will the training plan provide trainees with individualized and supervised experiences that will enable them to develop the research skills needed to be independent researchers or physician-scientists? Is the training plan customizable for students from diverse academic backgrounds and differing educational philosophies?

PI and Mentors: Do the PI and mentors have excellent research qualifications (including publications in high-quality journals and peer-reviewed research support) and track records of mentoring that are appropriate for the proposed training program?

Trainees: Are high-quality individuals routinely recruited at the applicant institution's existing training programs? Are the qualifications and interests of these potential trainees appropriate for the training program described by the applicant institution? Are there sufficient numbers of

highly meritorious potential trainees to fill the slots requested? Is there a plan to enhance the diversity of trainees by recruiting from underrepresented groups?

Institutional Environment and Commitment to Training: Is there a high-quality institutional environment for the scientific development of trainees? Is there appropriate institutional commitment to fostering training as investigators or physician-scientists? Are the research facilities, resources (eg, equipment, laboratory space, computer time, subject populations), and training opportunities adequate and appropriate?

Primary Review Criteria for Renewal Applications

Overall Evaluation of Training Outcomes and Future Potential: Does the proposed continuation of the program demonstrate a high likelihood of success based on the initial program's results and outcomes? Has the applicant sufficiently described results and findings of the previously funded application? What is the likelihood that the training program will continue to serve as a sound foundation to enhance a supported trainee's potential for, and commitment to, a productive, independent scientific research career in a cancer-related field? Has the program recruited underrepresented minority trainees?

Research Training Plan: Has the training plan provided, and will the plan continue to provide, trainees with individualized and supervised experiences that will enable them to develop the research skills needed to be independent researchers or physician-scientists? Is the training plan customizable for students from diverse academic backgrounds and differing educational philosophies?

PI and Mentors: Do the PI and mentors have excellent research qualifications (including publications in high-quality journals and peer-reviewed research support) and track records of mentoring that are appropriate for the proposed training program?

Trainees: Have high-quality individuals been recruited into the training programs? Are the qualifications and interests of these potential trainees appropriate for the training program described by the applicant institution? Have there been sufficient numbers of highly meritorious candidates to fill the available slots? Have efforts been made to enhance the diversity of trainees by recruiting from underrepresented groups? Has appropriate progress been demonstrated by trainees?

Institutional Environment and Commitment to Training: Is there a high-quality institutional environment for the scientific development of trainees? Is there appropriate institutional commitment to fostering training as investigators or physician-scientists? Are the research facilities, resources (eg, equipment, laboratory space, computer time, subject populations), and training opportunities adequate and appropriate?

9.3.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the value of the proposed training program.

Secondary criteria include the following:

Relevance to Cancer Research: Does the proposed training program have a high degree of *direct* relevance to cancer research? Does the program include high priority areas of emphasis for CPRIT (prevention and early detection, rare and intractable cancers, computational biology, cancers of special interest in Texas)?

Project Leadership: Is the program managed by strong leadership in a position to organize and manage the proposed training activities?

Responsible Conduct of Research: Does the applicant institution have acceptable plans to provide instruction in the responsible conduct of research?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.state.tx.us.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Senior Manager for Research.

Tel: 512-305-8491

Email: Help@CPRITGrants.org

Website: www.cprit.state.tx.us

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
21.1 Academic Research Review Panel – Research Training
Awards – 1 (21.1 ACR-RTA1)
Observation Report

Report No. 2021-02-18 21.1_ACR-RTA1
Program Name: Academic Research
Panel Name: 21.1 Academic Research Review Panel – Research Training Awards
– 1 (21.1_ACR-RT1)
Panel Date: February 18, 2021
Report Date: February 25, 2021

BACKGROUND

As part of CPRIT’s ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.1 Academic Research Review Panel – Research Training Awards – 1 (21.1_ACR-RT1) meeting. The meeting was chaired by Martin McMahon and one (1) application was chaired by Nagi Kumar and conducted via Zoom videoconference on February 18, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT’s established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number of applications: Ten (10) applications were discussed, and five (5) applications were not discussed
- Panelists: Two (2) panel chairs, twelve (12) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions
- CPRIT Oversight Committee Members: Zero (0)

There were six (6) Conflicts of Interest (COI) identified prior to and/or during the meeting. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.1 Scientific Review Council (21.1 SRC) Observation

Report

Report No. 2021-03-25 21.1_SRC
Program Name: Academic Research
Panel Name: 21.1 Scientific Review Council (21.1_SRC)
Panel Date: March 25, 2021
Report Date: April 5, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.1 Scientific Review Council (21.1_SRC) meeting. The meeting was chaired by Thomas Curran and conducted via teleconference on March 25, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: eight (8) applications were discussed
- Panelists: One (1) panel chair and four (4) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: one (1)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interests (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 21.1

Academic Research Cycle 21.1 Awards Announced at the May 19, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 21.1 include *Research Training Awards*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/PI	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee:			
RP210041	Melanie Cobb	The University of Texas Southwestern Medical Center	Li, Christopher
RP210042	Maria Fernandez	The University of Texas Health Science Center at Houston	Paskett, Electra; Brandon, Thomas
Applications not considered by the PIC or Oversight Committee:			
RP210026	Shine Chang	The University of Texas M.D. Anderson Cancer Center	Paskett, Electra; Mucci, Lorelei; Brandon, Thomas

De-Identified Overall Evaluation Scores

Research Training Awards

Academic Research Cycle 21.1

Application ID	Final Overall Evaluation Score
RP210028*	1.4
RP210041*	1.7
RP210037*	1.8
RP210043*	2.5
RP210046*	2.9
RP210042*	2.9
RP210045*	2.9
RP210027*	3.0
ca	3.7
cb	3.7
cc	3.7
cd	4.1
ce	5.0
cf	6.3
cg	7.0

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

2401 Gillham Road
Kansas City, Missouri 64108
(816) 234-3000

April 20, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Margo and Mr. Roberts,


The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Research Training Awards (RTA).

The SRC met on March 25, 2021 to consider the applications recommended by the peer review panel following their meeting held on February 18, 2021.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$30,320,920. Please note that the Peer Review Panel and SRC recommended a reduced budget of \$3,593,867 for application # RP210037.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Tom Curran, PhD, FRS
Senior Vice President, Executive Director and Chief Scientific Officer
Children's Mercy Research Institute, Children's Mercy Kansas City
Donald J. Hall Eminent Scholar in Pediatric Research
Professor of Pediatrics
UMKC School of Medicine
Professor of Cancer Biology
University of Kansas School of Medicine
Adjunct Professor of Biomedical Sciences
Kansas City University of Medicine & Biosciences
P: (816) 731-7007 | M: (267) 438-1844
E: tcurran@cmh.edu | W: childrensmercy.org

Rank	ID	Award Mechanism	Score	Application Title	PI	PI Organization	Recommended Budget
1	RP210028	RTA-Renewal	1.4	The Future of Cancer Research: Training Program for Basic and Translational Scientists	Keyomarsi, Khandan	The University of Texas M. D. Anderson Cancer Center	\$4,000,000
2	RP210041	RTA-Renewal	1.7	Cancer Intervention and Prevention Discoveries Program	Cobb, Melanie	The University of Texas Southwestern Medical Center	\$3,748,675
3	RP210037	RTA-Renewal	1.8	Systems Epidemiology for Cancer Training Program (SECT Program)	Spitz, Margaret	Baylor College of Medicine	\$3,593,867*
4	RP210043	RTA	2.5	Cancer Therapeutics Training Program (CTTP)	Davies, Peter	Texas A&M University System Health Science Center	\$3,136,872
5	RP210046	RTA-Renewal	2.9	HSC Scholars in Cancer Research	Vishwanatha, Jamboor	University of North Texas Health Science Center at Fort Worth	\$3,870,641
6	RP210042	RTA-Renewal	2.9	Collaborative Training of a New Cadre of Innovative Cancer Prevention Researchers	Fernandez, Maria	The University of Texas Health Science Center at Houston	\$3,998,230
7	RP210045	RTA	2.9	Biomedical Informatics, Genomics, and Translational Cancer Research Training Program (BIG-TCR)	Zhao, Zhongming	The University of Texas Health Science Center at Houston	\$3,998,553
8	RP210027	RTA-Renewal	3.0	Baylor College of Medicine Comprehensive Cancer Training Program	Rosen, Jeffrey	Baylor College of Medicine	\$3,974,082

*Panel and SRC Recommended a reduced budget of \$3,593,867 (a total reduction of \$62,005)

RTA = Research Training Award



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**FY 2021 – Cycle 6 through Cycle 9
*Recruitment of First-Time, Tenure-Track
Faculty Members***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-21.1-RFT

Recruitment of First-Time Tenure-Track Faculty Members

**Please also refer to the Instructions for Applicants document,
which will be posted on June 23, 2020**

Application Receipt Dates:

June 23, 2020-June 21, 2021

FY2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. RECRUITMENT OBJECTIVES	5
4. INSTITUTIONAL COMMITMENT	6
5. FUNDING INFORMATION	7
6. ELIGIBILITY	7
7. RESUBMISSION POLICY	10
8. RESPONDING TO THIS RFA	10
8.1. APPLICATION SUBMISSION GUIDELINES	10
8.2. APPLICATION COMPONENTS	11
8.2.1. <i>Summary of Nomination (2,000 characters)</i>	11
8.2.2. <i>Institutional Commitment (3 pages)</i>	11
8.2.3. <i>Letter of Support from Department Chair (1 page)</i>	13
8.2.4. <i>Curriculum Vitae (CV)</i>	13
8.2.5. <i>Summary of Goals and Objectives (2,000 characters)</i>	14
8.2.6. <i>Research (4 pages)</i>	14
8.2.7. <i>Research Collaboration/Synergy Plan (2 pages)</i>	14
8.2.8. <i>Publications</i>	15
8.2.9. <i>Timeline (1 page)</i>	15
8.2.10. <i>Current and Pending Support</i>	15
8.2.11. <i>Letters of Recommendation</i>	15
8.2.12. <i>Research Environment (1 page)</i>	15
8.2.13. <i>Descriptive Biography (Up to 2 pages)</i>	15
9. APPLICATION REVIEW	16
9.1. REVIEW PROCESS.....	16
9.1.1. <i>Confidentiality of Review</i>	16
9.2. REVIEW CRITERIA.....	17
10. KEY DATES	19
11. AWARD ADMINISTRATION	19
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	20
13. CONTACT INFORMATION	21
13.1. HELPDESK.....	21
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	21

RFA VERSION HISTORY

Rev 6/23/20 RFA release

Rev 9/24/20 Section 8.2.2 – Institutional Commitment

- Added new statement that must be included in the Institutional Commitment Letter regarding the institution's financial commitment required to meet the 50% match.

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expand access to innovative clinical trials

2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract very promising investigators who are pursuing their first faculty appointment at the level of assistant professor (first-time, tenure-track faculty members). These individuals must have demonstrated academic excellence, innovation during predoctoral and/or postdoctoral research training, commitment to pursuing cancer research, and exceptional potential for achieving future impact in basic, translational, population-based, or clinical research. Awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research, thereby advancing cancer research efforts and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, or treatment. Candidates with research programs addressing CPRIT's priority areas for research are encouraged. These include implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions, computational biology and analytic methods, childhood cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

3. RECRUITMENT OBJECTIVES

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. All candidates are expected to have completed their doctoral and fellowship training and to have clearly demonstrated truly superior ability as evidenced by their accomplishments during training, proposed research plan, publication record, and letters of recommendation. This CPRIT-supported initiative is designed to enhance innovative programs of excellence by providing research support for promising, early-stage investigators **seeking their first tenure-track position.**

CPRIT will provide start-up funding for newly independent investigators, with the goal of augmenting and expanding the institution's efforts in cancer research. Candidates will be expected to develop research projects within the sponsoring institution. Projects should be

appropriate for a newly independent investigator and should foster the development of preliminary data that can be used to prepare applications for future independent research project grants to further both the investigator's research career and the CPRIT mission. The institution will be expected to work with each newly recruited research faculty member to design and execute a faculty career development plan consistent with his or her research emphasis. Relevance to cancer research and to CPRIT's priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who are well prepared to pursue careers in patient-oriented research and who have demonstrated exceptional potential to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and encouraged.

Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

4. INSTITUTIONAL COMMITMENT

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of a First-Time Tenure-Track Faculty must therefore be complemented by a strong institutional commitment to the candidate's career development that includes financial commitments that are in addition to the CPRIT award. The institutional commitment should be clearly documented in the application (see [section 8.2.2](#)) and include the amount and sources of salary support and all additional financial support that will be available to the candidate's research program through the course of the CPRIT award. The financial commitments made to the candidate for his or her research program by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

5. FUNDING INFORMATION

This award is up to 5 years and is not renewable, although individuals may apply for other future CPRIT funding as appropriate. Grant funds of up to \$2,000,000 (total costs) for the 5-year period may be requested. Funding is to be used by the candidate to support his or her research program. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-cost extension. In addition, funds for extraordinary equipment needs may be awarded in the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

Funds from this CPRIT award may not be used for salary support of this candidate or to construct or renovate laboratory space.

No annual limit on the number of grant application submissions by Institutions has been set.

Note: Depending on the availability of funds, nominations submitted in response to this Request for Applications (RFA) during the current receipt period may be announced and awarded either in the current fiscal year (prior to August 31, 2021) or in the first quarter of the next fiscal year (starting September 1, 2021).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- Candidates must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific candidate.

- A candidate may be nominated by only 1 institution. If more than 1 institution is interested in a given candidate, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- There is no limit to the number of applications that an institution may submit during a review cycle.
- A candidate who has already accepted a position as assistant professor tenure track at the recruiting institution prior to the time that the Scientific Review Council reviews the candidate for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with recruiting highly sought-after candidates who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating institution of the Scientific Review Council's review decision following the Scientific Review Council meeting. If a position is offered to the candidate during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.
- The candidate must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment.** The candidate must devote at least 70% time to research activities. Candidates whose major responsibilities are clinical care, teaching, or administration are not eligible.
- At the time of the application, the candidate must **not** hold an appointment at the rank of assistant professor or above (or equivalent) at an accredited academic institution, research institution, industry, government agency, or private foundation not primarily based in Texas. Candidates holding non-tenure-track appointments at the rank of assistant professor are **not** eligible for this award. Examples of such appointments include research assistant professor, adjunct research assistant professor, assistant professor (non-tenure track).
- The candidate **may or may not** reside in Texas at the time the application is submitted and may be nominated for a faculty position at the Texas institution where he or she is completing postdoctoral training.

- *Applications nominating a candidate for a faculty position at the Texas institution where he or she is completing postdoctoral training that do not clearly demonstrate a subsequent career pathway to independence for the candidate will not be looked upon with favor.*
- Successful candidates will be offered tenure-track academic positions at the rank of assistant professor.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

Resubmissions will not be accepted for the Recruitment of First-Time, Tenure-Track Faculty Members award mechanism. Any nomination for the Recruitment of First-Time, Tenure-Track Faculty Members that was previously submitted to CPRIT and reviewed but was not recommended for funding may not be resubmitted. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles.

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. Candidates must be nominated by the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (Nominator) must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

Dependent upon available funding, applications will be accepted on a continuous basis throughout FY21. In order to manage the timely review of nominations, it is anticipated that applications submitted by 11:59 PM central time on the 20th day of each month will be reviewed by the 15th day of the following month. For an application to be considered for review during the monthly cycle, that application must be submitted on or before 11:59 PM central time. In the event that the 20th falls on Saturday or Sunday, applications may be submitted on or before 11:59 PM central time the following Monday. CPRIT will not extend the submission deadline. During periods when CPRIT does not receive an adequate number of applications, the review may be extended into the following month. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the *Instructions for Applicants* document that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,000 characters)

Provide a brief summary of the nomination. Include the candidate's name, organization from which the candidate is being recruited, and also the department and/or entity within the nominator's organization where the candidate will hold the faculty position.

8.2.2. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of a First-Time Tenure-Track Faculty must therefore be complemented by a strongly documented institutional commitment to the candidate's career development that includes financial commitments that are in addition to the CPRIT award.

The following guidelines should be followed when documenting the institutional commitment to the candidate:

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the amount and sources of salary support and all additional financial support that will be available to the candidate's research program through the course of the CPRIT award. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.
- The Institutional Commitment letter must include the following statement regarding the institution's financial commitment required to meet the 50% match.

- This institutional financial commitment will not be offset by funds from a career transition award (K99/R00) or an investigator-initiated award received by the candidate. If an award dictates that such funds must be used for salary, the corresponding amount of institutional funds committed to pay the candidate's salary will be re-directed to allow the candidate to use them for program support.
- Institutional Commitment as described above must be presented in a table (example below), that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.
- Include a brief job description for the candidate should recruitment be successful.
- Describe the institutional environment and any professional commitments to the candidate including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the candidate.
- Institutions may provide additional information in support of a candidate's research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a candidate's cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.
- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.

Example of an acceptable Institutional Commitment table:

Candidates Name, Institutional Commitments					
	Year 1	Year 2	Year 3	Year 4	Year 5
Salary/Benefits					

Research Support					
Administrative Support					
Moving Expenses					

Total =

Note: CPRIT acknowledges that the Institutional Commitments by category may change during the course of the award; however, the total financial commitment to the candidate must remain equal to or greater than 50% of the CPRIT award.

8.2.3. Letter of Support from Department Chair (1 page)

Provide the letter of support from and signed by the chair of the department to which the candidate is being recruited. The following information should be included in the letter:

Recruitment Activities: The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this candidate.

Caliber of Candidate: The letter should include a description of the caliber of the candidate and justification of the nomination of the candidate by the institution.

Description of Candidate Duties and Certification of 70% Time Commitment to Research:

While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the candidate’s time must be available for research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% time will be spent on research must be included.

The letter of support from the department chair must also do the following:

1. Describe how the candidate will be independent and autonomous in developing his or her research program at the institution;
2. Present a plan for mentoring that includes the design and execution of a faculty career development plan for the candidate.

8.2.4. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the candidate. Only articles that have been published or that have been accepted for publication (“in press”) should be cited.

8.2.5. Summary of Goals and Objectives (2,000 characters)

List goals and objectives to be achieved during this award. **This section must be completed by the candidate.**

8.2.6. Research (4 pages)

Summarize the key elements of the candidate's research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, goals, and projected impact of the focus of the research program. Highlight the innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the candidate. References cited in this section must be included within the stated page limit. Any appropriate citation format is acceptable; official journal abbreviations should be used.**

Candidates for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

"I understand that I do not need to have made a commitment to <*nominating institution*> before this application has been submitted. However, I also understand that only 1 Texas institution may nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.

8.2.7. Research Collaboration/Synergy Plan (2 pages)

Institutions may provide additional information in support of a candidate's research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a candidate's cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

8.2.8. Publications

Provide the 3 most significant publications that have resulted from the candidate's research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication ("in press") should be submitted.

8.2.9. Timeline (1 page)

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.10. Current and Pending Support

State the funding source, duration, and title of all current and pending research support held by the candidate. If the candidate has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.11. Letters of Recommendation

Provide 3 letters of recommendation from individuals who are in a position to detail the candidate's academic and scientific research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research.

8.2.12. Research Environment (1 page)

Clearly and concisely describe the research environment available to support the candidate's research program, including core facilities, training programs, and collaborative opportunities.

8.2.13. Descriptive Biography (Up to 2 pages)

Provide a brief descriptive biography of the candidate, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the candidate's goals if selected to receive the award.

This section of the application must be prepared by the candidate. If the application is approved for funding, this section will be made publicly available on CPRIT's website.

Candidates are advised not to include information that they consider confidential or proprietary when preparing this section.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

9. APPLICATION REVIEW

9.1. Review Process

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Applications may be submitted continuously in response to this RFA but will generally be reviewed on a monthly basis by the CPRIT Scientific Review Council. Council members may seek additional ad hoc evaluations of candidates. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment.

Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to the CPRIT Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee. The review process is described more fully in CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

9.1.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the candidate and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the candidate. Recruitment efforts are not likely to be successful unless there is a strong commitment from both CPRIT and the host institution.** It is not necessary that a candidate agree to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have reasonable expectation that the recruitment will be successful if an award is granted by CPRIT.

Review criteria will focus on the overall impression of the candidate, his or her proposed research program, and his or her long-term contribution to and impact on the field of cancer research. Questions to be considered by the reviewers are as follows:

Quality of the Candidate: Has the candidate demonstrated academic excellence? Has the candidate received excellent predoctoral and postdoctoral training? Does the candidate show exceptional potential for achieving future impact on basic, translational, clinical, or population-based cancer research in the future? Has the candidate demonstrated a commitment to cancer research? Has the candidate demonstrated independence or the potential for independence?

Scientific Merit of Proposed Research: Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it have a significant impact on the field of cancer research? Will the proposed research generate preliminary data that can be used for the preparation of applications for future independent research project grants?

Relevance of Candidate's Research: Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term? Does the research contribute to basic, translational, clinical, or population-based cancer research?

Letters of Recommendation: Do the letters of recommendation detail the candidate's academic and clinical research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources to support the candidate's research? Is there evidence of strong institutional support? Will the candidate be free of major administrative/clinical responsibilities so that he or she can focus on growing his or her research? Has the institution identified a mentor who will design and execute a faculty career development plan for the candidate?

10. KEY DATES

RFA

RFA Release

June 23, 2020

Application Receipt and Review Timeline

Application Receipt System opens 7 AM CT	Application Receipt	Anticipated Application Review	Application Closing Date
June 23, 2020	Continuous – dependent upon available funding	Monthly by the 15 th day of the month	June 21, 2021

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT’s Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT’s Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, Texas [Administrtrive Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. CPRIT requires funding acknowledgement on all print and visual materials, which are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos and media materials. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Senior Program Manager for Academic Research.

Tel: 512-305-8491

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

21.6 Scientific Review Council Recruitment Review

(21.6 SRC-REC6) Observation Report

Report No. 2020-01-21 21.6_SRC-REC6
Program Name: Academic Research
Panel Name: 21.6 Scientific Review Council Recruitment Review (21.6_SRC-REC6)
Panel Date: January 21, 2021
Report Date: February 17, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.6 Scientific Review Council Recruitment Review (21.6_SRC-REC21.6) meeting. The meeting was chaired by R. Kolodner and conducted via teleconference on January 21, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number of applications: Four (4) applications were discussed
- Panelists: One (1) panel chair, seven (5) expert reviewers and two (2) Ad Hoc Reviewers who present only for the review of specific application
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT) **21.7-8 Scientific Review Council Recruitment Review (21.7-8 SRC-REC7-8) Observation Report**

Report No. 2020-03-11 21.7-8_SRC-REC7-8
Program Name: Academic Research
Panel Name: 21.7-8 Scientific Review Council Recruitment Review (21.7-8_SRC-REC7-8)
Panel Date: March 11, 2021
Report Date: March 16, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.7-8 Scientific Review Council Recruitment Review (21.7-8_SRC-REC7-8) meeting. The meeting was chaired by Thomas Curran, in lieu of Richard Kolodner, and conducted via videoconference on March 11, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: eight (8) applications were discussed
- Panelists: One (1) panel chair and five (5) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were (2) Conflicts of Interest (COI) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to read 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.9 Scientific Review Council Recruitment Review

(21.9 SRC-REC9) Observation Report

Report No. 2021-04-15 21.9_SRC-REC9
Program Name: Academic Research
Panel Name: 21.9 Scientific Review Council Recruitment Review (21.9_SRC-REC9)
Panel Date: April 15, 2021
Report Date: April 30, 2020

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.9 Scientific Review Council Recruitment Review (21.9_SRC-REC9) meeting. The meeting was chaired by Thomas Curran and conducted via videoconference on April 15, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed
- Panelists: One (1) panel chair and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: One (1)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycles 21.6 through 21.9

Academic Research Recruitment Cycles 21.6 through 21.9 Awards Announced at the May 19, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment Cycles 21.6 through 21.9 include *Recruitment of Rising Stars*; *Recruitment of First-Time, Tenure-Track Faculty Members*; and *Recruitment of Established Investigators*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/PI	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee:			
RR210029	Marcy Dickinson	Baylor College of Medicine	Jones, Peter
RR210033	W.P. Andrew Less	The University of Texas Southwestern Medical Center	Brown, Myles
Applications not considered by the PIC or Oversight Committee:			
RR210036	Jeralynn Crossman	The University of Texas at San Antonio	Brown, Myles
RR210045	Sterling Johnston	The University of Texas at Austin	Brown, Myles

T.A.C. Section 702.19 Waiver



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 WAIVER
DATE: FEBRUARY 1, 2021

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I have granted Chief Scientific Officer Dr. Jim Willson a waiver from the general prohibition against communicating with a grant applicant while CPRIT is accepting and reviewing applications. The waiver is applicable to communication with Dr. Lynne Cossman, Dean of the College for Health, Community and Policy at The University of Texas San Antonio regarding a recruitment application that CPRIT withdrew from consideration because it did not demonstrate required application elements. Dr. Willson will speak to Dr. Cossman regarding the goals and eligibility requirements for the recruitment award. This may result in the submission of a revised application. No Oversight Committee action related to this waiver is necessary.

Discussion

The Chief Scientific Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while CPRIT is accepting applications for the review cycle. The communication restriction is one way that we prevent even the appearance of unequal treatment in the grant review process.

During the FY 2021 recruitment cycle, The University of Texas at San Antonio submitted an application that CPRIT withdrew prior to Scientific Review Council (SRC) evaluation because the application did not include all required elements. Dr. Willson intends to speak with Dr. Cossman, the inaugural dean of the UTSA College for Health, Community, and Policy about the goals and eligibility requirements for recruitment applications. Speaking with a grant applicant after an unsuccessful review is a normal part of Chief Scientific Officer's duties and assists the grant applicant in preparing better applications for future submission. However, because the recruitment application process is "always open," such communication between Dr. Willson and Dr. Cossman may unintentionally violate CPRIT's restriction on communication policy.

Approving this waiver does not favor any future application over any other grant applications. All recruitment applications will receive the same rigorous evaluation by the Scientific Review Council (SRC). Dr. Willson does not discuss any substantive issues with the SRC related to applications under review and plays no role in the SRC's decision to recommend an award to CPRIT.

The Oversight Committee does not need to take any action regarding this waiver. Should UTSA submit a recruitment application that the SRC reviews during the FY 2021 review cycle, CPRIT will include Dr. Willson's waiver as part of the grant record.

De-Identified Overall Evaluation Scores

Recruitment of First-Time, Tenure-Track Faculty Members

Academic Research Cycles 21.6 through 21.9

Application ID	Final Overall Evaluation Score
RR210028*	1.0
RR210035*	1.0
RR210044*	1.0
RR210039*	1.0
RR210029*	1.4
RR210037*	1.8
RR210050*	1.8
RR210040*	2.0
RR210048*	2.0
RR210034*	2.0
RR210033*	2.0
ba	2.9
bb	3.9
bc	4.0

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

2401 Gillham Road
Kansas City, Missouri 64108
(816) 234-3000

April 20, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov


Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of recruitment grant recommendations. The SRC met on January 21, 2021 (REC Cycle 21.6), March 11, 2021 (REC Cycles 21.7 and 21.8) and April 15, 2021 (REC Cycle 21.9) to review the applications submitted to CPRIT under the Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time Tenure Track Faculty Members.

The projects on the attached list are numerically ranked in the order the SRC recommends the applications be funded. Recommended funding amounts and the overall evaluation scores are stated for each grant application. There were no recommended changes to funding amounts, goals, timelines, or project objectives requested. The total amount for the applications recommended is \$36,000,000.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting candidates at all career levels that have demonstrated academic excellence, innovation, excellent training, a commitment to cancer research and exceptional potential for achieving future impact in basic, translational, population based or clinical research.

Sincerely yours,



Tom Curran, PhD, FRS
Senior Vice President, Executive Director and Chief Scientific Officer
Children's Mercy Research Institute, Children's Mercy Kansas City
Donald J. Hall Eminent Scholar in Pediatric Research
Professor of Pediatrics
UMKC School of Medicine
Professor of Cancer Biology
University of Kansas School of Medicine
Adjunct Professor of Biomedical Sciences
Kansas City University of Medicine & Biosciences
P: (816) 731-7007 | M: (267) 438-1844
E: tcurran@cmh.edu | W: childrensmercy.org

Rank	App. ID	Mechanism	Candidate	Organization	Budget	Overall Score
1	RR210028	RFTFM	Julea Vlassakis, Ph.D.	Rice University	\$2,000,000	1.0
2	RR210035	RFTFM	Chen Yao, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
3	RR210032	REI	James H. Hurley, Ph.D.	The University of Texas Southwestern Medical Center	\$6,000,000	1.0
4	RR210044	RFTFM	Jason Sheltzer, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
5	RR210039	RFTFM	Cornelius Y. Taabazuing, Ph.D.	Baylor College of Medicine	\$2,000,000	1.0
6	RR210029	RFTFM	Dongyin Guan, Ph.D.	Baylor College of Medicine	\$2,000,000	1.4
7	RR210037	RFTFM	Blair Benham-Pyle, Ph.D.	Baylor College of Medicine	\$2,000,000	1.8
8	RR210050	RFTFM	Cassandra Callmann, Ph.D.	The University of Texas at Austin	\$2,000,000	1.8
9	RR210031	RRS	Jeremy Wilusz, Ph.D.	Baylor College of Medicine	\$4,000,000	2.0
10	RR210034	RFTFM	Sihan Wu, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
11	RR210033	RFTFM	Brian Christopher Miller, M.D., Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
12	RR210040	RFTFM	Joshua Riback, Ph.D.	Baylor College of Medicine	\$2,000,000	2.0
13	RR210048	RFTFM	Courtney M. Schroeder, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
14	RR210042	RRS	Stephanie Seidlits, Ph.D.	The University of Texas at Austin	\$4,000,000	2.0

REI = Recruitment of Established Investigators

RRS = Recruitment of Rising Stars

RFTFM = Recruitment of First-Time Tenure-Track Faculty Members



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

FY 2021– Cycle 6 through Cycle 9
Recruitment of Rising Stars

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS

RFA R-21.1-RRS

Recruitment of Rising Stars

**Please also refer to the Instructions for Applicants document,
which will be posted on June 23, 2020**

Application Receipt Dates:

June 23, 2020-June 21, 2021

FY 2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. RECRUITMENT OBJECTIVES	5
4. INSTITUTIONAL COMMITMENT	6
5. FUNDING INFORMATION	7
6. ELIGIBILITY	8
7. RESUBMISSION POLICY	9
8. RESPONDING TO THIS RFA	10
8.1. APPLICATION SUBMISSION GUIDELINES	10
8.2. APPLICATION COMPONENTS	11
8.2.1. <i>Summary of Nomination (2,000 characters)</i>	11
8.2.2. <i>Institutional Commitment (3 pages)</i>	11
8.2.3. <i>Letter of Support from Department Chair (1 page)</i>	13
8.2.4. <i>Curriculum Vitae (CV)</i>	13
8.2.5. <i>Summary of Goals and Objectives (2,000 characters)</i>	13
8.2.6. <i>Research (4 pages)</i>	14
8.2.7. <i>Research Collaboration/Synergy Plan (2 pages)</i>	14
8.2.8. <i>Publications</i>	14
8.2.9. <i>Timeline (1 page)</i>	15
8.2.10. <i>Current and Pending Support</i>	15
8.2.11. <i>Research Environment (1 page)</i>	15
8.2.12. <i>Descriptive Biography (Up to 2 pages)</i>	15
9. APPLICATION REVIEW	16
9.1. REVIEW PROCESS.....	16
9.1.1. <i>Confidentiality of Review</i>	16
9.2. REVIEW CRITERIA.....	17
10. KEY DATES	18
11. AWARD ADMINISTRATION	18
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	19
13. CONTACT INFORMATION	20
13.1. HELPDESK.....	20
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	20

RFA VERSION HISTORY

Rev 6/23/20 RFA release

Rev 10/26/20 Section 8.2.2 – Institutional Commitment

- Added new statement that must be included in the Institutional Commitment Letter regarding the institution's financial commitment required to meet the 50% match.

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expand access to innovative clinical trials

2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract individuals whose work has outstanding merit, who show a marked capacity for self-direction, and who demonstrate the promise for continued and enhanced contributions to the field of cancer research (“Rising Stars”). Awards are intended to provide institutions with a competitive edge in recruiting the world’s best talent in cancer research, thereby advancing cancer research efforts and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, or treatment. Candidates with research programs addressing CPRIT’s priority areas for research are encouraged. These include implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions, computational biology and analytic methods, childhood cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

3. RECRUITMENT OBJECTIVES

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. Having already demonstrated extraordinary accomplishments during their initial years of independent research, Rising Stars represent a unique blend of scholastic aptitude, scientific rigor, and commitment to exploring transformational research through the development of creative ideas with high potential.

Candidates who have not historically worked in cancer research but are proposing creative hypotheses and research plans for this field are encouraged to apply. Similarly, candidates pursuing original and potentially high-impact basic science programs that have the potential to be translated toward clinical investigations or provide “proof of principle” are also encouraged to apply. It is expected that the candidate will contribute significantly to and have a major impact on the institution’s overall cancer research initiative. Funding will be given for exceptional candidates who will continue to develop new research methods and techniques in the life, population-based, physical, engineering, or computational sciences and apply them to solving

outstanding problems in cancer research that have been inadequately addressed or for which there may be an absence of an established paradigm or technical framework.

Ideal candidates will have specific expertise in cancer-related areas needed to address an institutional priority. Candidates are expected to be approximately at the career level of a late assistant/early associate professor or equivalent. This funding mechanism considers expertise, accomplishments, and breadth of experience vital metrics for guiding CPRIT's investment in that person's originality, insight, and potential for continued contribution. Relevance to cancer research and to CPRIT's priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who carry out patient-oriented research and who have demonstrated exceptional ability to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and encouraged.

Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

4. INSTITUTIONAL COMMITMENT

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of a Rising Star must be complemented by a strong institutional commitment to the recruitment. The institutional commitment should be clearly documented in the application (see [section 8.2.2](#)) and include the amount and sources of salary support and all additional financial support that will be available to the candidate's research program through the course of the CPRIT award. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

5. FUNDING INFORMATION

This is a 5-year award and is not renewable. Grant funds of up to \$4,000,000 (total costs) over a 5-year period may be requested. Exceptions to this limit will be entertained only if there is compelling written justification. Annual allocations of this award are at the discretion of the awardee as long as the total award does not exceed \$4,000,000. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-cost extension. In addition, funds for extraordinary equipment needs may be awarded in the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

Funds from this award mechanism may be used for salary support of this candidate but may not be used to construct or renovate laboratory space.

No annual limit on the number of grant application submissions by institutions has been set.

Note that the annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award for FY 2021 is limited to a maximum of \$200,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$200,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

Note: Depending on the availability of funds, nominations submitted in response to this Request for Applications (RFA) during the current receipt period may be announced and awarded either in the current fiscal year (prior to August 31, 2021) or in the first quarter of the next fiscal year (starting September 1, 2021).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- Candidates must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific candidate.
- A candidate may be nominated by only 1 institution. If more than 1 institution is interested in a given candidate, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- There is no limit to the number of applications that an institution may submit during a review cycle.
- A candidate who has already accepted a position at the recruiting institution prior to the time that the Scientific Review Council reviews the candidate for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with recruiting highly sought-after candidates who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating institution of the Scientific Review Council's review decision following the Review Council meeting. If a position is offered to the candidate during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.
- The candidate must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment**. The candidate must devote at least 70% time to research activities. Candidates whose major responsibilities are clinical care, teaching, or administration are not eligible.
- At the time of the application, the candidate should hold an appointment at the rank of **assistant or associate professor tenure track or tenured** (or equivalent) at an accredited

academic institution, research institution, industry, government agency, or private foundation not primarily based in Texas. The candidate must not reside in Texas at the time the application is submitted.

- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cpriti.texas.gov.

7. RESUBMISSION POLICY

Resubmissions will not be accepted for the Recruitment of Rising Stars award mechanism. Any nomination for the Recruitment of Rising Stars that was previously submitted to CPRIT and

reviewed but was not recommended for funding may not be resubmitted. A nomination for the Recruitment of Rising Stars that was previously submitted to CPRIT for the Recruitment of First-Time, Tenure Track Faculty Member or Recruitment of Rising Stars and reviewed and recommended for funding but declined by the candidate may be submitted in response to this RFA if the candidate meets the eligibility criteria described in [section 6](#) and the application is not in the same fiscal year as the previous application. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles. Applications being resubmitted according to the criteria permitted by this section should be submitted as a new application (refer to the IFA for more details).

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. Candidates must be nominated by the institution's president, provost, vice president for research, or appropriate dean. The individual submitting the application (Nominator) must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

Dependent upon available funding, applications will be accepted on a continuous basis throughout FY21. In order to manage the timely review of nominations, it is anticipated that applications submitted by 11:59 PM central time on the 20th day of each month will be reviewed by the 15th day of the following month. For an application to be considered for review during the monthly cycle, that application must be submitted on or before 11:59 PM central time. In the event that the 20th falls on Saturday or Sunday, applications may be submitted on or before 11:59 PM central time the following Monday. CPRIT will not extend the submission deadline. During periods when CPRIT does not receive an adequate number of applications, the review

may be extended into the following month. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the *Instructions for Applicants* document that will be available when the application receipt system opens.

Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,000 characters)

Provide a brief summary of the nomination. Include the candidate's name, organization from which the candidate is being recruited, and also the department and/or entity within the nominator's organization where the candidate will hold the faculty position.

8.2.2. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of a Rising Stars must be complemented by a strongly documented institutional commitment to the recruitment. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

The following guidelines should be followed when documenting the institutional commitment to the candidate:

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the amount and sources of salary support and all additional financial support that will be available to the candidate's research program through the course of the CPRIT award. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

- The Institutional Commitment letter must include the following statement regarding the institution's financial commitment required to meet the 50% match.
 - This institutional financial commitment will not be offset by funds from an investigator-initiated award received by the candidate. If an award dictates that such funds must be used for salary, the corresponding amount of institutional funds committed to pay the candidate's salary will be re-directed to allow the candidate to use them for program support.
- Institutional Commitment as described above must be presented in a table (example below), that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.
- Include a brief job description for the candidate should recruitment be successful.
- Describe the institutional environment and any professional commitments to the candidate including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the candidate.
- Institutions may provide additional information in support of a candidate's research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a candidate's cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.
- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.

Example of an acceptable Institutional Commitment table:

Candidate's Name, Institutional Commitments					
	Year 1	Year 2	Year 3	Year 4	Year 5
Salary/Benefits					
Research Support					
Administrative Support					
Moving Expenses					

Total =

Note: CPRIT acknowledges that the Institutional Commitments by category may change during the course of the award; however, the total financial commitment to the candidate must remain equal to or greater than 50% of the CPRIT award.

8.2.3. Letter of Support from Department Chair (1 page)

Provide the letter of support from and signed by the chair of the department to which the candidate is being recruited. The following information should be included in the letter:

Recruitment Activities: The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this candidate.

Caliber of Candidate: The letter should include a description of the caliber of the candidate and justification of the nomination of the candidate by the institution.

Description of Candidate Duties and Certification of 70% Time Commitment to Research:

While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the candidate's time must be available for research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% time will be spent on research must be included.

8.2.4. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the candidate.

8.2.5. Summary of Goals and Objectives (2,000 characters)

List goals and objectives to be achieved during this award. **This section must be completed by the candidate.**

8.2.6. Research (4 pages)

Summarize the key elements of the candidate’s research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, goals, and projected impact of the focus of the research program. Highlight the innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the candidate. References cited in this section must be included within the stated page limit. Any appropriate citation format is acceptable; official journal abbreviations should be used.**

Candidates for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

“I understand that I do not need to have made a commitment to *<nominating institution>* before this application has been submitted. However, I also understand that only 1 Texas institution may nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.”

8.2.7. Research Collaboration/Synergy Plan (2 pages)

Institutions may provide additional information in support of a candidate’s research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a candidate’s cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

8.2.8. Publications

Provide the 5 most significant publications that have resulted from the candidate’s research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication (“in press”) should be submitted.

8.2.9. Timeline (1 page)

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.10. Current and Pending Support

State the funding source, duration, and title of all current and pending research support held by the candidate. If the candidate has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.11. Research Environment (1 page)

Briefly describe the research environment available to support the candidate's research program, including core facilities, training programs, and collaborative opportunities.

8.2.12. Descriptive Biography (Up to 2 pages)

Provide a brief descriptive biography of the candidate, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the candidate's goals if selected to receive the award.

This section of the application must be prepared by the candidate. If the application is approved for funding, this section will be made publicly available on CPRIT's website.

Candidates are advised not to include information that they consider confidential or proprietary when preparing this section.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

9. APPLICATION REVIEW

9.1. Review Process

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Applications may be submitted continuously in response to this RFA but will generally be reviewed on a monthly basis by the CPRIT Scientific Review Council. Council members may seek additional ad hoc evaluations of candidates. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment.

Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to the CPRIT Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee. The review process is described more fully in CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

9.1.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the candidate and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the candidate. Recruitment efforts are not likely to be successful unless there is a strong commitment from CPRIT and the host institution.** It is not necessary that a candidate agree to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have reasonable expectation that recruitment will be successful if an award is granted by CPRIT.

Review criteria will focus on the overall impression of the candidate, his/her proposed research program, and his/her long-term contribution to and impact on the field of cancer research.

Questions to be considered by the reviewers are as follows:

Quality of the Candidate: Has the candidate demonstrated extraordinary accomplishments during his or her initial years of independent research? Does the candidate show promise of making important contributions with significant impact to basic, translational, clinical, or population-based cancer research in the future? Has the candidate demonstrated strong self-direction, motivation, and commitment for transformative cancer research?

Scientific Merit of Proposed Research: Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it have a significant impact on the field of cancer research? Will it expand the boundaries of

cancer research beyond traditional methodology by incorporating novel and interdisciplinary techniques?

Relevance of Candidate’s Research: Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term? Does the research contribute to basic, translational, clinical, or population-based cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources to support the candidate’s research? Is there evidence of strong institutional support? Will the candidate be free of major administrative/clinical responsibilities so that he or she can focus on maintaining and enhancing his or her research program? Will the candidate be provided with adequate professional development opportunities to grow as a leader?

10. KEY DATES

RFA

RFA Release June 23, 2020

Application Receipt and Review Timeline

Application Receipt System opens 7 AM CT	Application Receipt	Anticipated Application Review	Application Closing Date
June 23, 2020	Continuous – dependent upon available funding	Monthly by the 15 th day of the month	June 21, 2021

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal

monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. CPRIT requires funding acknowledgement on all print and visual materials that are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos, and media materials. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must

be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, Texas Administrative Code, [Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Senior Program Manager for Academic Research.

Tel: 512-305-8491

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

21.6 Scientific Review Council Recruitment Review

(21.6 SRC-REC6) Observation Report

Report No. 2020-01-21 21.6_SRC-REC6
Program Name: Academic Research
Panel Name: 21.6 Scientific Review Council Recruitment Review (21.6_SRC-REC6)
Panel Date: January 21, 2021
Report Date: February 17, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.6 Scientific Review Council Recruitment Review (21.6_SRC-REC21.6) meeting. The meeting was chaired by R. Kolodner and conducted via teleconference on January 21, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number of applications: Four (4) applications were discussed
- Panelists: One (1) panel chair, seven (5) expert reviewers and two (2) Ad Hoc Reviewers who present only for the review of specific application
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to read 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT) **21.7-8 Scientific Review Council Recruitment Review (21.7-8 SRC-REC7-8) Observation Report**

Report No. 2020-03-11 21.7-8_SRC-REC7-8
Program Name: Academic Research
Panel Name: 21.7-8 Scientific Review Council Recruitment Review (21.7-8_SRC-REC7-8)
Panel Date: March 11, 2021
Report Date: March 16, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is 21.7-8 Scientific Review Council Recruitment Review (21.7-8_SRC-REC7-8) meeting. The meeting was chaired by Thomas Curran, in lieu of Richard Kolodner, and conducted via videoconference on March 11, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: eight (8) applications were discussed
- Panelists: One (1) panel chair and five (5) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were (2) Conflicts of Interest (COI) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.9 Scientific Review Council Recruitment Review

(21.9 SRC-REC9) Observation Report

Report No. 2021-04-15 21.9_SRC-REC9
Program Name: Academic Research
Panel Name: 21.9 Scientific Review Council Recruitment Review (21.9_SRC-REC9)
Panel Date: April 15, 2021
Report Date: April 30, 2020

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.9 Scientific Review Council Recruitment Review (21.9_SRC-REC9) meeting. The meeting was chaired by Thomas Curran and conducted via videoconference on April 15, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed
- Panelists: One (1) panel chair and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: One (1)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycles 21.6 through 21.9

Academic Research Recruitment Cycles 21.6 through 21.9 Awards Announced at the May 19, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment Cycles 21.6 through 21.9 include *Recruitment of Rising Stars*; *Recruitment of First-Time, Tenure-Track Faculty Members*; and *Recruitment of Established Investigators*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/PI	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee:			
RR210029	Marcy Dickinson	Baylor College of Medicine	Jones, Peter
RR210033	W.P. Andrew Less	The University of Texas Southwestern Medical Center	Brown, Myles
Applications not considered by the PIC or Oversight Committee:			
RR210036	Jeralynn Crossman	The University of Texas at San Antonio	Brown, Myles
RR210045	Sterling Johnston	The University of Texas at Austin	Brown, Myles

T.A.C. Section 702.19 Waiver



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 WAIVER
DATE: FEBRUARY 1, 2021

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I have granted Chief Scientific Officer Dr. Jim Willson a waiver from the general prohibition against communicating with a grant applicant while CPRIT is accepting and reviewing applications. The waiver is applicable to communication with Dr. Lynne Cossman, Dean of the College for Health, Community and Policy at The University of Texas San Antonio regarding a recruitment application that CPRIT withdrew from consideration because it did not demonstrate required application elements. Dr. Willson will speak to Dr. Cossman regarding the goals and eligibility requirements for the recruitment award. This may result in the submission of a revised application. No Oversight Committee action related to this waiver is necessary.

Discussion

The Chief Scientific Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while CPRIT is accepting applications for the review cycle. The communication restriction is one way that we prevent even the appearance of unequal treatment in the grant review process.

During the FY 2021 recruitment cycle, The University of Texas at San Antonio submitted an application that CPRIT withdrew prior to Scientific Review Council (SRC) evaluation because the application did not include all required elements. Dr. Willson intends to speak with Dr. Cossman, the inaugural dean of the UTSA College for Health, Community, and Policy about the goals and eligibility requirements for recruitment applications. Speaking with a grant applicant after an unsuccessful review is a normal part of Chief Scientific Officer's duties and assists the grant applicant in preparing better applications for future submission. However, because the recruitment application process is "always open," such communication between Dr. Willson and Dr. Cossman may unintentionally violate CPRIT's restriction on communication policy.

Approving this waiver does not favor any future application over any other grant applications. All recruitment applications will receive the same rigorous evaluation by the Scientific Review Council (SRC). Dr. Willson does not discuss any substantive issues with the SRC related to applications under review and plays no role in the SRC's decision to recommend an award to CPRIT.

The Oversight Committee does not need to take any action regarding this waiver. Should UTSA submit a recruitment application that the SRC reviews during the FY 2021 review cycle, CPRIT will include Dr. Willson's waiver as part of the grant record.

De-Identified Overall Evaluation Scores

Recruitment of Rising Stars

Academic Research Recruitment Cycles 21.6 through 21.9

Application ID	Final Overall Evaluation Score
RR210031*	2.0
RR210042*	2.0

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

2401 Gillham Road
Kansas City, Missouri 64108
(816) 234-3000

April 20, 2021

Mr. Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov


Dear Mr. Margo and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of recruitment grant recommendations. The SRC met on January 21, 2021 (REC Cycle 21.6), March 11, 2021 (REC Cycles 21.7 and 21.8) and April 15, 2021 (REC Cycle 21.9) to review the applications submitted to CPRIT under the Recruitment of Established Investigators, Recruitment of Rising Stars and Recruitment of First-Time Tenure Track Faculty Members.

The projects on the attached list are numerically ranked in the order the SRC recommends the applications be funded. Recommended funding amounts and the overall evaluation scores are stated for each grant application. There were no recommended changes to funding amounts, goals, timelines, or project objectives requested. The total amount for the applications recommended is \$36,000,000.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting candidates at all career levels that have demonstrated academic excellence, innovation, excellent training, a commitment to cancer research and exceptional potential for achieving future impact in basic, translational, population based or clinical research.

Sincerely yours,



Tom Curran, PhD, FRS
Senior Vice President, Executive Director and Chief Scientific Officer
Children's Mercy Research Institute, Children's Mercy Kansas City
Donald J. Hall Eminent Scholar in Pediatric Research
Professor of Pediatrics
UMKC School of Medicine
Professor of Cancer Biology
University of Kansas School of Medicine
Adjunct Professor of Biomedical Sciences
Kansas City University of Medicine & Biosciences
P: (816) 731-7007 | M: (267) 438-1844
E: tcurran@cmh.edu | W: childrensmercy.org

Rank	App. ID	Mechanism	Candidate	Organization	Budget	Overall Score
1	RR210028	RFTFM	Julea Vlassakis, Ph.D.	Rice University	\$2,000,000	1.0
2	RR210035	RFTFM	Chen Yao, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
3	RR210032	REI	James H. Hurley, Ph.D.	The University of Texas Southwestern Medical Center	\$6,000,000	1.0
4	RR210044	RFTFM	Jason Sheltzer, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
5	RR210039	RFTFM	Cornelius Y. Taabazuing, Ph.D.	Baylor College of Medicine	\$2,000,000	1.0
6	RR210029	RFTFM	Dongyin Guan, Ph.D.	Baylor College of Medicine	\$2,000,000	1.4
7	RR210037	RFTFM	Blair Benham-Pyle, Ph.D.	Baylor College of Medicine	\$2,000,000	1.8
8	RR210050	RFTFM	Cassandra Callmann, Ph.D.	The University of Texas at Austin	\$2,000,000	1.8
9	RR210031	RRS	Jeremy Wilusz, Ph.D.	Baylor College of Medicine	\$4,000,000	2.0
10	RR210034	RFTFM	Sihan Wu, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
11	RR210033	RFTFM	Brian Christopher Miller, M.D., Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
12	RR210040	RFTFM	Joshua Riback, Ph.D.	Baylor College of Medicine	\$2,000,000	2.0
13	RR210048	RFTFM	Courtney M. Schroeder, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
14	RR210042	RRS	Stephanie Seidlits, Ph.D.	The University of Texas at Austin	\$4,000,000	2.0

REI = Recruitment of Established Investigators

RRS = Recruitment of Rising Stars

RFTFM = Recruitment of First-Time Tenure-Track Faculty Members



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210027
Research Training Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Research Training Awards Request for Applications* (RFA). CPRIT received 15 applications in response to this RFA. This application was assigned to the Research Training Awards panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.


Melanie Cleveland
Notary Public, State of Texas

CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Research
MECHANISM: Research Training Awards
APPLICATION ID: RP210027
APPLICATION TITLE: Baylor College of Medicine Comprehensive Cancer Training Program
APPLICANT NAME: Rosen, Jeffrey M
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 21.1_Research Training Awards

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/27/2020	04/12/2021	
	RFA Approved by CSO (revised)	06/16/2020	04/12/2021	
	RFA published in Texas.gov eGrants	06/29/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) opened	07/08/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) closed	10/28/2020	04/12/2021	
	Date application submitted	09/18/2020	04/12/2021	
	Method of submission	CARS	04/12/2021	
	Within receipt period	YES	04/12/2021	
	Request for extension to submit application after CARS closed	NA	04/12/2021	
	Request for extension for late application submission accepted	NA	04/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	11/18/2020	04/12/2021
		Donation(s) made to CPRIT / foundation	NO	04/12/2021
		Assigned to primary reviewers	12/10/2020	04/12/2021
Applicant notified of review panel assignment		11/30/2020	04/12/2021	
Primary Reviewer 1 COI signed		11/16/2020	04/12/2021	
Primary Reviewer 2 COI signed		11/27/2020	04/12/2021	
Primary Reviewer 3 COI signed		11/24/2020	04/12/2021	
Primary (Advocate) Reviewer 4 COI signed		11/16/2020	04/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	NA	04/12/2021	
	Primary Reviewer 2 critique submitted	NA	04/12/2021	
	Primary Reviewer 3 critique submitted	NA	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	NA	04/12/2021	
	COI indicated by non-primary reviewer	NA	04/12/2021	
	Preliminary Evaluation score summary sent to Chair	NA	04/12/2021	
	Recommended for full review	NA	04/12/2021	
	Applicant notified of outcome	NA	04/12/2021	
Peer Review Meeting	Assigned to primary reviewers	12/10/2020	04/12/2021	
	Primary Reviewer 1 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 2 COI signed	11/27/2020	04/12/2021	
	Primary Reviewer 3 COI signed	11/24/2020	04/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 1 critique submitted	02/05/2021	04/12/2021	
	Primary Reviewer 2 critique submitted	02/06/2021	04/12/2021	
	Primary Reviewer 3 critique submitted	02/06/2021	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	01/22/2021	04/12/2021	
	COI indicated by non-primary reviewer	NONE	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	Discussed at Peer Review Meeting	YES	04/12/2021	
	Peer Review Meeting	02/18/2021	04/12/2021	
	Post review statements signed	02/21/2021	04/12/2021	
	Third Party Observer Report	02/25/2021	04/12/2021	
	Score report delivered to CSO	03/05/2021	04/12/2021	
	Recommended for SRC review	YES	04/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	SRC Meeting	03/25/2021	04/12/2021	
	Third Party Observer Report	04/05/2021	04/12/2021	
	Recommended for grant award	YES	04/12/2021	
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021	
PIC Review	COI indicated by PIC member	None	05/04/2021	
	COI recused from participation	NA	05/04/2021	
	PIC Review Meeting	05/04/2021	05/04/2021	
	Recommended for grant award	YES	05/04/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	NA		
	COI Indicated by Oversight Committee member	NA		
	COI Recused from participation	NA		
	Donation(s) made to CPRIT / foundation	NA		
	Presented to CPRIT Oversight Committee	NA		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	NA		
	Advance authority approved by Oversight Committee	NA		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210028
Research Training Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Research Training Awards Request for Applications* (RFA). CPRIT received 15 applications in response to this RFA. This application was assigned to the Research Training Awards panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Research
MECHANISM: Research Training Awards
APPLICATION ID: RP210028
APPLICATION TITLE: The Future of Cancer Research: Training Program for Basic and Translational Scientists
APPLICANT NAME: Keyomarsi, Khandan
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 21.1_Research Training Awards

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/27/2020	04/12/2021	
	RFA Approved by CSO (revised)	06/16/2020	04/12/2021	
	RFA published in Texas.gov eGrants	06/29/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) opened	07/08/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) closed	10/28/2020	04/12/2021	
	Date application submitted	10/26/2020	04/12/2021	
	Method of submission	CARS	04/12/2021	
	Within receipt period	YES	04/12/2021	
	Request for extension to submit application after CARS closed	NA	04/12/2021	
	Request for extension for late application submission accepted	NA	04/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	11/18/2020	04/12/2021
		Donation(s) made to CPRIT / foundation	NO	04/12/2021
Assigned to primary reviewers		12/10/2020	04/12/2021	
Applicant notified of review panel assignment		11/30/2020	04/12/2021	
Primary Reviewer 1 COI signed		11/16/2020	04/12/2021	
Primary Reviewer 2 COI signed		11/16/2020	04/12/2021	
Primary Reviewer 3 COI signed		11/17/2020	04/12/2021	
Primary (Advocate) Reviewer 4 COI signed		11/16/2020	04/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	NA	04/12/2021	
	Primary Reviewer 2 critique submitted	NA	04/12/2021	
	Primary Reviewer 3 critique submitted	NA	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	NA	04/12/2021	
	COI indicated by non-primary reviewer	NA	04/12/2021	
	Preliminary Evaluation score summary sent to Chair	NA	04/12/2021	
	Recommended for full review	NA	04/12/2021	
	Applicant notified of outcome	NA	04/12/2021	
Peer Review Meeting	Assigned to primary reviewers	12/10/2020	04/12/2021	
	Primary Reviewer 1 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 2 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 3 COI signed	11/17/2020	04/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 1 critique submitted	01/22/2021	04/12/2021	
	Primary Reviewer 2 critique submitted	12/29/2020	04/12/2021	
	Primary Reviewer 3 critique submitted	02/09/2021	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	01/22/2021	04/12/2021	
	COI indicated by non-primary reviewer	NONE	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	Discussed at Peer Review Meeting	YES	04/12/2021	
	Peer Review Meeting	02/18/2021	04/12/2021	
	Post review statements signed	02/21/2021	04/12/2021	
	Third Party Observer Report	02/25/2021	04/12/2021	
	Score report delivered to CSO	03/05/2021	04/12/2021	
	Recommended for SRC review	YES	04/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	SRC Meeting	03/25/2021	04/12/2021	
	Third Party Observer Report	04/05/2021	04/12/2021	
	Recommended for grant award	YES	04/12/2021	
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021	
PIC Review	COI indicated by PIC member	None	05/04/2021	
	COI recused from participation	NA	05/04/2021	
	PIC Review Meeting	05/04/2021	05/04/2021	
	Recommended for grant award	YES	05/04/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	NA		
	COI Indicated by Oversight Committee member	NA		
	COI Recused from participation	NA		
	Donation(s) made to CPRIT / foundation	NA		
	Presented to CPRIT Oversight Committee	NA		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	NA		
	Advance authority approved by Oversight Committee	NA		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210037
Research Training Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Research Training Awards Request for Applications* (RFA). CPRIT received 15 applications in response to this RFA. This application was assigned to the Research Training Awards panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.

This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Research
MECHANISM: Research Training Awards
APPLICATION ID: RP210037
APPLICATION TITLE: Systems Epidemiology for Cancer Training Program (SECT Program)
APPLICANT NAME: Spitz, Margaret R
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 21.1_Research Training Awards

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/27/2020	04/12/2021	
	RFA Approved by CSO (revised)	06/16/2020	04/12/2021	
	RFA published in Texas.gov eGrants	06/29/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) opened	07/08/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) closed	10/28/2020	04/12/2021	
	Date application submitted	10/13/2020	04/12/2021	
	Method of submission	CARS	04/12/2021	
	Within receipt period	YES	04/12/2021	
	Request for extension to submit application after CARS closed	NA	04/12/2021	
	Request for extension for late application submission accepted	NA	04/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	NA	04/12/2021
		Donation(s) made to CPRIT / foundation	NO	04/12/2021
		Assigned to primary reviewers	12/10/2020	04/12/2021
Applicant notified of review panel assignment		11/30/2020	04/12/2021	
Primary Reviewer 1 COI signed		11/16/2020	04/12/2021	
Primary Reviewer 2 COI signed		11/27/2020	04/12/2021	
Primary Reviewer 3 COI signed		11/23/2020	04/12/2021	
Primary (Advocate) Reviewer 4 COI signed		11/25/2020	04/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	NA	04/12/2021	
	Primary Reviewer 2 critique submitted	NA	04/12/2021	
	Primary Reviewer 3 critique submitted	NA	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	NA	04/12/2021	
	COI indicated by non-primary reviewer	NA	04/12/2021	
	Preliminary Evaluation score summary sent to Chair	NA	04/12/2021	
	Recommended for full review	NA	04/12/2021	
	Applicant notified of outcome	NA	04/12/2021	
Peer Review Meeting	Assigned to primary reviewers	12/10/2020	04/12/2021	
	Primary Reviewer 1 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 2 COI signed	11/27/2020	04/12/2021	
	Primary Reviewer 3 COI signed	11/23/2020	04/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	11/25/2020	04/12/2021	
	Primary Reviewer 1 critique submitted	01/09/2021	04/12/2021	
	Primary Reviewer 2 critique submitted	02/06/2021	04/12/2021	
	Primary Reviewer 3 critique submitted	02/11/2021	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	02/02/2021	04/12/2021	
	COI indicated by non-primary reviewer	NONE	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	Discussed at Peer Review Meeting	YES	04/12/2021	
	Peer Review Meeting	02/18/2021	04/12/2021	
	Post review statements signed	02/21/2021	04/12/2021	
	Third Party Observer Report	02/25/2021	04/12/2021	
	Score report delivered to CSO	03/05/2021	04/12/2021	
	Recommended for SRC review	YES	04/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	SRC Meeting	03/25/2021	04/12/2021	
	Third Party Observer Report	04/05/2021	04/12/2021	
	Recommended for grant award	YES	04/12/2021	
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021	
PIC Review	COI indicated by PIC member	None	05/04/2021	
	COI recused from participation	NA	05/04/2021	
	PIC Review Meeting	05/04/2021	05/04/2021	
	Recommended for grant award	YES	05/04/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	NA		
	COI Indicated by Oversight Committee member	NA		
	COI Recused from participation	NA		
	Donation(s) made to CPRIT / foundation	NA		
	Presented to CPRIT Oversight Committee	NA		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	NA		
	Advance authority approved by Oversight Committee	NA		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210041
Research Training Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Research Training Awards Request for Applications* (RFA). CPRIT received 15 applications in response to this RFA. This application was assigned to the Research Training Awards panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Research
MECHANISM: Research Training Awards
APPLICATION ID: RP210041
APPLICATION TITLE: Cancer Intervention and Prevention Discoveries Program
APPLICANT NAME: Cobb, Melanie H
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 21.1_Research Training Awards

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/27/2020	04/12/2021	
	RFA Approved by CSO (revised)	06/16/2020	04/12/2021	
	RFA published in Texas.gov eGrants	06/29/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) opened	07/08/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) closed	10/28/2020	04/12/2021	
	Date application submitted	10/28/2020	04/12/2021	
	Method of submission	CARS	04/12/2021	
	Within receipt period	YES	04/12/2021	
	Request for extension to submit application after CARS closed	NA	04/12/2021	
	Request for extension for late application submission accepted	NA	04/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	11/18/2020	04/12/2021
		Donation(s) made to CPRIT / foundation	NO	04/12/2021
		Assigned to primary reviewers	12/10/2020	04/12/2021
Applicant notified of review panel assignment		11/30/2020	04/12/2021	
Primary Reviewer 1 COI signed		11/16/2020	04/12/2021	
Primary Reviewer 2 COI signed		12/02/2020	04/12/2021	
Primary Reviewer 3 COI signed		11/16/2020	04/12/2021	
Primary (Advocate) Reviewer 4 COI signed		11/25/2020	04/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	NA	04/12/2021	
	Primary Reviewer 2 critique submitted	NA	04/12/2021	
	Primary Reviewer 3 critique submitted	NA	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	NA	04/12/2021	
	COI indicated by non-primary reviewer	NA	04/12/2021	
	Preliminary Evaluation score summary sent to Chair	NA	04/12/2021	
	Recommended for full review	NA	04/12/2021	
	Applicant notified of outcome	NA	04/12/2021	
Peer Review Meeting	Assigned to primary reviewers	12/10/2020	04/12/2021	
	Primary Reviewer 1 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 2 COI signed	12/02/2020	04/12/2021	
	Primary Reviewer 3 COI signed	11/16/2020	04/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	11/25/2020	04/12/2021	
	Primary Reviewer 1 critique submitted	02/06/2021	04/12/2021	
	Primary Reviewer 2 critique submitted	02/09/2021	04/12/2021	
	Primary Reviewer 3 critique submitted	02/08/2021	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	02/06/2021	04/12/2021	
	COI indicated by non-primary reviewer	Christopher Li	04/12/2021	
	COI recused from participation	YES	04/12/2021	
	Discussed at Peer Review Meeting	YES	04/12/2021	
	Peer Review Meeting	02/18/2021	04/12/2021	
	Post review statements signed	02/21/2021	04/12/2021	
	Third Party Observer Report	02/25/2021	04/12/2021	
	Score report delivered to CSO	03/05/2021	04/12/2021	
	Recommended for SRC review	YES	04/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	SRC Meeting	03/25/2021	04/12/2021	
	Third Party Observer Report	04/05/2021	04/12/2021	
	Recommended for grant award	YES	04/12/2021	
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021	
PIC Review	COI indicated by PIC member	None	05/04/2021	
	COI recused from participation	NA	05/04/2021	
	PIC Review Meeting	05/04/2021	05/04/2021	
	Recommended for grant award	YES	05/04/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	NA		
	COI Indicated by Oversight Committee member	NA		
	COI Recused from participation	NA		
	Donation(s) made to CPRIT / foundation	NA		
	Presented to CPRIT Oversight Committee	NA		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	NA		
	Advance authority approved by Oversight Committee	NA		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210042
Research Training Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Research Training Awards Request for Applications* (RFA). CPRIT received 15 applications in response to this RFA. This application was assigned to the Research Training Awards panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Research
MECHANISM: Research Training Awards
APPLICATION ID: RP210042
APPLICATION TITLE: Collaborative Training of a New Cadre of Innovative Cancer Prevention Researchers
APPLICANT NAME: Fernandez, Maria E
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 21.1_Research Training Awards

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/27/2020	04/12/2021	
	RFA Approved by CSO (revised)	06/16/2020	04/12/2021	
	RFA published in Texas.gov eGrants	06/29/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) opened	07/08/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) closed	10/28/2020	04/12/2021	
	Date application submitted	10/28/2020	04/12/2021	
	Method of submission	CARS	04/12/2021	
	Within receipt period	YES	04/12/2021	
	Request for extension to submit application after CARS closed	NA	04/12/2021	
	Request for extension for late application submission accepted	NA	04/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	11/18/2020	04/12/2021
		Donation(s) made to CPRIT / foundation	NO	04/12/2021
Assigned to primary reviewers		12/10/2020	04/12/2021	
Applicant notified of review panel assignment		11/30/2020	04/12/2021	
Primary Reviewer 1 COI signed		11/18/2020	04/12/2021	
Primary Reviewer 2 COI signed		11/18/2020	04/12/2021	
Primary Reviewer 3 COI signed		11/16/2020	04/12/2021	
Primary (Advocate) Reviewer 4 COI signed		11/25/2020	04/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	NA	04/12/2021	
	Primary Reviewer 2 critique submitted	NA	04/12/2021	
	Primary Reviewer 3 critique submitted	NA	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	NA	04/12/2021	
	COI indicated by non-primary reviewer	NA	04/12/2021	
	Preliminary Evaluation score summary sent to Chair	NA	04/12/2021	
	Recommended for full review	NA	04/12/2021	
	Applicant notified of outcome	NA	04/12/2021	
Peer Review Meeting	Assigned to primary reviewers	12/10/2020	04/12/2021	
	Primary Reviewer 1 COI signed	11/18/2020	04/12/2021	
	Primary Reviewer 2 COI signed	11/18/2020	04/12/2021	
	Primary Reviewer 3 COI signed	11/16/2020	04/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	11/25/2020	04/12/2021	
	Primary Reviewer 1 critique submitted	02/01/2021	04/12/2021	
	Primary Reviewer 2 critique submitted	02/10/2021	04/12/2021	
	Primary Reviewer 3 critique submitted	01/09/2021	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	02/06/2021	04/12/2021	
	COI indicated by non-primary reviewer	Electra Paskett, Thomas Brandon	04/12/2021	
	COI recused from participation	YES	04/12/2021	
	Discussed at Peer Review Meeting	YES	04/12/2021	
	Peer Review Meeting	02/18/2021	04/12/2021	
	Post review statements signed	02/21/2021	04/12/2021	
	Third Party Observer Report	02/25/2021	04/12/2021	
Score report delivered to CSO	03/05/2021	04/12/2021		
Recommended for SRC review	YES	04/12/2021		
Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	SRC Meeting	03/25/2021	04/12/2021	
	Third Party Observer Report	04/05/2021	04/12/2021	
	Recommended for grant award	YES	04/12/2021	
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021	
PIC Review	COI indicated by PIC member	None	05/04/2021	
	COI recused from participation	NA	05/04/2021	
	PIC Review Meeting	05/04/2021	05/04/2021	
	Recommended for grant award	YES	05/04/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	NA		
	COI Indicated by Oversight Committee member	NA		
	COI Recused from participation	NA		
	Donation(s) made to CPRIT / foundation	NA		
	Presented to CPRIT Oversight Committee	NA		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	NA		
	Advance authority approved by Oversight Committee	NA		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210043
Research Training Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).


My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Research Training Awards Request for Applications (RFA)*. CPRIT received 15 applications in response to this RFA. This application was assigned to the Research Training Awards panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Research
MECHANISM: Research Training Awards
APPLICATION ID: RP210043
APPLICATION TITLE: Cancer Therapeutics Training Program (CTTP).
APPLICANT NAME: Davies, Peter J
ORGANIZATION: Texas A&M University System Health Science Center
PANEL NAME: 21.1_Research Training Awards

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/27/2020	04/12/2021	
	RFA Approved by CSO (revised)	06/16/2020	04/12/2021	
	RFA published in Texas.gov eGrants	06/29/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) opened	07/08/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) closed	10/28/2020	04/12/2021	
	Date application submitted	10/28/2020	04/12/2021	
	Method of submission	CARS	04/12/2021	
	Within receipt period	YES	04/12/2021	
	Request for extension to submit application after CARS closed	NA	04/12/2021	
	Request for extension for late application submission accepted	NA	04/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	NA	04/12/2021
		Donation(s) made to CPRIT / foundation	NO	04/12/2021
		Assigned to primary reviewers	12/10/2020	04/12/2021
Applicant notified of review panel assignment		11/30/2020	04/12/2021	
Primary Reviewer 1 COI signed		11/16/2020	04/12/2021	
Primary Reviewer 2 COI signed		11/16/2020	04/12/2021	
Primary Reviewer 3 COI signed		12/02/2020	04/12/2021	
Primary (Advocate) Reviewer 4 COI signed		11/16/2020	04/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	NA	04/12/2021	
	Primary Reviewer 2 critique submitted	NA	04/12/2021	
	Primary Reviewer 3 critique submitted	NA	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	NA	04/12/2021	
	COI indicated by non-primary reviewer	NA	04/12/2021	
	Preliminary Evaluation score summary sent to Chair	NA	04/12/2021	
	Recommended for full review	NA	04/12/2021	
	Applicant notified of outcome	NA	04/12/2021	
Peer Review Meeting	Assigned to primary reviewers	12/10/2020	04/12/2021	
	Primary Reviewer 1 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 2 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 3 COI signed	12/02/2020	04/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 1 critique submitted	02/08/2021	04/12/2021	
	Primary Reviewer 2 critique submitted	02/08/2021	04/12/2021	
	Primary Reviewer 3 critique submitted	02/09/2021	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	01/22/2021	04/12/2021	
	COI indicated by non-primary reviewer	NONE	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	Discussed at Peer Review Meeting	YES	04/12/2021	
	Peer Review Meeting	02/18/2021	04/12/2021	
	Post review statements signed	02/21/2021	04/12/2021	
	Third Party Observer Report	02/25/2021	04/12/2021	
	Score report delivered to CSO	03/05/2021	04/12/2021	
	Recommended for SRC review	YES	04/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	SRC Meeting	03/25/2021	04/12/2021	
	Third Party Observer Report	04/05/2021	04/12/2021	
	Recommended for grant award	YES	04/12/2021	
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021	
PIC Review	COI indicated by PIC member	None	05/04/2021	
	COI recused from participation	NA	05/04/2021	
	PIC Review Meeting	05/04/2021	05/04/2021	
	Recommended for grant award	YES	05/04/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	NA		
	COI Indicated by Oversight Committee member	NA		
	COI Recused from participation	NA		
	Donation(s) made to CPRIT / foundation	NA		
	Presented to CPRIT Oversight Committee	NA		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	NA		
	Advance authority approved by Oversight Committee	NA		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210045
Research Training Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(e).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Research Training Awards* Request for Applications (RFA). CPRIT received 15 applications in response to this RFA. This application was assigned to the Research Training Awards panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Research
MECHANISM: Research Training Awards
APPLICATION ID: RP210045
APPLICATION TITLE: Biomedical Informatics, Genomics and Translational Cancer Research Training Program (BIG-TCR)
APPLICANT NAME: Zhao, Zhongming
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 21.1_Research Training Awards

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/27/2020	04/12/2021	
	RFA Approved by CSO (revised)	06/16/2020	04/12/2021	
	RFA published in Texas.gov eGrants	06/29/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) opened	07/08/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) closed	10/28/2020	04/12/2021	
	Date application submitted	10/28/2020	04/12/2021	
	Method of submission	CARS	04/12/2021	
	Within receipt period	YES	04/12/2021	
	Request for extension to submit application after CARS closed	NA	04/12/2021	
	Request for extension for late application submission accepted	NA	04/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	NA	04/12/2021
		Donation(s) made to CPRIT / foundation	NO	04/12/2021
		Assigned to primary reviewers	12/10/2020	04/12/2021
Applicant notified of review panel assignment		11/30/2020	04/12/2021	
Primary Reviewer 1 COI signed		11/17/2020	04/12/2021	
Primary Reviewer 2 COI signed		11/23/2020	04/12/2021	
Primary Reviewer 3 COI signed		11/19/2020	04/12/2021	
Primary (Advocate) Reviewer 4 COI signed		11/16/2020	04/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	NA	04/12/2021	
	Primary Reviewer 2 critique submitted	NA	04/12/2021	
	Primary Reviewer 3 critique submitted	NA	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	NA	04/12/2021	
	COI indicated by non-primary reviewer	NA	04/12/2021	
	Preliminary Evaluation score summary sent to Chair	NA	04/12/2021	
	Recommended for full review	NA	04/12/2021	
	Applicant notified of outcome	NA	04/12/2021	
Peer Review Meeting	Assigned to primary reviewers	12/10/2020	04/12/2021	
	Primary Reviewer 1 COI signed	11/17/2020	04/12/2021	
	Primary Reviewer 2 COI signed	11/23/2020	04/12/2021	
	Primary Reviewer 3 COI signed	11/19/2020	04/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 1 critique submitted	02/09/2021	04/12/2021	
	Primary Reviewer 2 critique submitted	02/10/2021	04/12/2021	
	Primary Reviewer 3 critique submitted	02/08/2021	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	01/31/2021	04/12/2021	
	COI indicated by non-primary reviewer	NONE	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	Discussed at Peer Review Meeting	YES	04/12/2021	
	Peer Review Meeting	02/18/2021	04/12/2021	
	Post review statements signed	02/21/2021	04/12/2021	
	Third Party Observer Report	02/25/2021	04/12/2021	
	Score report delivered to CSO	03/05/2021	04/12/2021	
	Recommended for SRC review	YES	04/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	SRC Meeting	03/25/2021	04/12/2021	
	Third Party Observer Report	04/05/2021	04/12/2021	
	Recommended for grant award	YES	04/12/2021	
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021	
PIC Review	COI indicated by PIC member	None	05/04/2021	
	COI recused from participation	NA	05/04/2021	
	PIC Review Meeting	05/04/2021	05/04/2021	
	Recommended for grant award	YES	05/04/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	NA		
	COI Indicated by Oversight Committee member	NA		
	COI Recused from participation	NA		
	Donation(s) made to CPRIT / foundation	NA		
	Presented to CPRIT Oversight Committee	NA		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	NA		
	Advance authority approved by Oversight Committee	NA		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP210046
Research Training Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Research Training Awards* Request for Applications (RFA). CPRIT received 15 applications in response to this RFA. This application was assigned to the Research Training Awards panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."

Wayne R. Roberts


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.

Melanie Cleveland

Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Research
MECHANISM: Research Training Awards
APPLICATION ID: RP210046
APPLICATION TITLE: HSC Scholars in Cancer Research
APPLICANT NAME: Vishwanatha, Jamboor K
ORGANIZATION: University of North Texas Health Science Center at Fort Worth
PANEL NAME: 21.1_Research Training Awards

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/27/2020	04/12/2021	
	RFA Approved by CSO (revised)	06/16/2020	04/12/2021	
	RFA published in Texas.gov eGrants	06/29/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) opened	07/08/2020	04/12/2021	
	CPRIT Application Receipt System (CARS) closed	10/28/2020	04/12/2021	
	Date application submitted	10/28/2020	04/12/2021	
	Method of submission	CARS	04/12/2021	
	Within receipt period	YES	04/12/2021	
	Request for extension to submit application after CARS closed	NA	04/12/2021	
	Request for extension for late application submission accepted	NA	04/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	11/18/2020	04/12/2021
		Donation(s) made to CPRIT / foundation	NO	04/12/2021
		Assigned to primary reviewers	12/10/2020	04/12/2021
Applicant notified of review panel assignment		11/30/2020	04/12/2021	
Primary Reviewer 1 COI signed		11/27/2020	04/12/2021	
Primary Reviewer 2 COI signed		11/16/2020	04/12/2021	
Primary Reviewer 3 COI signed		11/18/2020	04/12/2021	
Primary (Advocate) Reviewer 4 COI signed		11/16/2020	04/12/2021	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	NA	04/12/2021	
	Primary Reviewer 2 critique submitted	NA	04/12/2021	
	Primary Reviewer 3 critique submitted	NA	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	NA	04/12/2021	
	COI indicated by non-primary reviewer	NA	04/12/2021	
	Preliminary Evaluation score summary sent to Chair	NA	04/12/2021	
	Recommended for full review	NA	04/12/2021	
	Applicant notified of outcome	NA	04/12/2021	
Peer Review Meeting	Assigned to primary reviewers	12/10/2020	04/12/2021	
	Primary Reviewer 1 COI signed	11/27/2020	04/12/2021	
	Primary Reviewer 2 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 3 COI signed	11/18/2020	04/12/2021	
	Primary (Advocate) Reviewer 4 COI signed	11/16/2020	04/12/2021	
	Primary Reviewer 1 critique submitted	02/06/2021	04/12/2021	
	Primary Reviewer 2 critique submitted	02/06/2021	04/12/2021	
	Primary Reviewer 3 critique submitted	02/05/2021	04/12/2021	
	Primary (Advocate) Reviewer 4 critique submitted	01/31/2021	04/12/2021	
	COI indicated by non-primary reviewer	NONE	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	Discussed at Peer Review Meeting	YES	04/12/2021	
	Peer Review Meeting	02/18/2021	04/12/2021	
	Post review statements signed	02/21/2021	04/12/2021	
	Third Party Observer Report	02/25/2021	04/12/2021	
	Score report delivered to CSO	03/05/2021	04/12/2021	
	Recommended for SRC review	YES	04/12/2021	
Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	SRC Meeting	03/25/2021	04/12/2021	
	Third Party Observer Report	04/05/2021	04/12/2021	
	Recommended for grant award	YES	04/12/2021	
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021	
PIC Review	COI indicated by PIC member	None	05/04/2021	
	COI recused from participation	NA	05/04/2021	
	PIC Review Meeting	05/04/2021	05/04/2021	
	Recommended for grant award	YES	05/04/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	NA		
	COI Indicated by Oversight Committee member	NA		
	COI Recused from participation	NA		
	Donation(s) made to CPRIT / foundation	NA		
	Presented to CPRIT Oversight Committee	NA		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	NA		
	Advance authority approved by Oversight Committee	NA		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210028
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Julea Vlassakis, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members Request for Applications (RFA)*. CPRIT received 17 applications in response to this recruitment cycles 21.6 through 21.9 RFA, including one application that was withdrawn. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”



 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 6 day of May, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210028
APPLICATION TITLE: Recruitment of First-Time, Tenure-Track Faculty Member - Dr. Julea Vlassakis
APPLICANT NAME: Nakhleh, Luay
ORGANIZATION: Rice University
PANEL NAME: Recruitment FY21_Cycle 7 and 8

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	12/22/2020	04/12/2021
	CPRIT Application Receipt Cycle closed	01/20/2021	04/12/2021
	Date application submitted	01/19/2021	04/12/2021
	Method of submission	CARS	04/12/2021
	Within receipt period	YES	04/12/2021
Receipt, Referral, and Assignment	Administrative review notification	01/26/2021	04/12/2021
	Donation(s) made to CPRIT / foundation	NO	04/12/2021
	Assigned to primary reviewers	03/03/2021	04/12/2021
	Applicant notified of review panel assignment	NA	04/12/2021
	Primary Reviewer 1 COI signed	02/25/2021	04/12/2021
	Primary Reviewer 2 COI signed	02/25/2021	04/12/2021
Peer Review Meeting	Primary Reviewer 1 critique submitted	03/09/2021	04/12/2021
	Primary Reviewer 2 critique submitted	03/09/2021	04/12/2021
	COI indicated by non-primary reviewer	NONE	04/12/2021
	COI recused from participation	NA	04/12/2021
	Discussed at Peer Review Meeting	YES	04/12/2021
	Peer Review Meeting	03/11/2021	04/12/2021
	Post review statements signed	03/12/2021	04/12/2021
	Third Party Observer Report	03/16/2021	04/12/2021
	Score report delivered to CSO	03/25/2021	04/12/2021
	Recommended for SRC review	YES	04/12/2021
Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021
	COI recused from participation	NA	04/12/2021
	SRC Meeting	03/11/2021	04/12/2021
	Third Party Observer Report	03/16/2021	04/12/2021
	Recommended for grant award	YES	04/12/2021
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210029
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Dongyin Guan, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 17 applications in response to this recruitment cycles 21.6 through 21.9 RFA, including one application that was withdrawn. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 6 day of May, 2021, by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210029
APPLICATION TITLE: First-Time, Tenure-Track: Dr. Dongyin Guan
APPLICANT NAME: Dickinson, Mary
ORGANIZATION: Baylor College of Medicine
PANEL NAME: Recruitment FY21_Cycle 7 and 8

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	12/22/2020	04/12/2021
	CPRIT Application Receipt Cycle closed	01/20/2021	04/12/2021
	Date application submitted	01/20/2021	04/12/2021
	Method of submission	CARS	04/12/2021
	Within receipt period	YES	04/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	NA
Donation(s) made to CPRIT / foundation		NO	04/12/2021
Assigned to primary reviewers		03/03/2021	04/12/2021
Applicant notified of review panel assignment		NA	04/12/2021
Primary Reviewer 1 COI signed		02/26/2021	04/12/2021
Primary Reviewer 2 COI signed		02/25/2021	04/12/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	03/09/2021
	Primary Reviewer 2 critique submitted	03/09/2021	04/12/2021
	COI indicated by non-primary reviewer	Peter Jones	04/12/2021
	COI recused from participation	YES	04/12/2021
	Discussed at Peer Review Meeting	YES	04/12/2021
	Peer Review Meeting	03/11/2021	04/12/2021
	Post review statements signed	03/12/2021	04/12/2021
	Third Party Observer Report	03/16/2021	04/12/2021
	Score report delivered to CSO	03/25/2021	04/12/2021
	Recommended for SRC review	YES	04/12/2021
	Final SRC Recommendation	COI indicated by SRC member	Peter Jones
COI recused from participation		YES	04/16/2021
SRC Meeting		03/11/2021	04/12/2021
Third Party Observer Report		03/16/2021	04/12/2021
Recommended for grant award		YES	04/12/2021
SRC Chair Notification to PIC and OC		04/22/2021	04/22/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210031
Recruitment of Rising Stars
Nomination of Jeremy Wilusz, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of Rising Stars* Request for Applications (RFA). CPRIT received five applications in response to this recruitment cycles 21.6 through 21.9 RFA. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 6 day of May, 2021, by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of Rising Stars
APPLICATION ID: RR210031
APPLICATION TITLE: Recruitment of Rising Star: Dr. Jeremy Wilusz
APPLICANT NAME: Dickinson, Mary
ORGANIZATION: Baylor College of Medicine
PANEL NAME: Recruitment FY21_Cycle 7 and 8

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	12/22/2020
	RFA Approved by CSO (revised)	10/22/2020	12/22/2020
	RFA published in Texas.gov eGrants	06/12/2020	12/22/2020
	CPRIT Application Receipt Cycle opened	12/22/2020	04/12/2021
	CPRIT Application Receipt Cycle closed	01/20/2021	04/12/2021
	CPRIT Application Receipt Cycle opened - 21.8	01/21/2021	04/12/2021
	CPRIT Application Receipt Cycle closed - 21.8	02/22/2021	04/12/2021
	Date application submitted	02/22/2021	04/12/2021
	Method of submission	CARS	04/12/2021
	Within receipt period	YES	04/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	NA
Donation(s) made to CPRIT / foundation		NO	04/12/2021
Assigned to primary reviewers		03/03/2021	04/12/2021
Applicant notified of review panel assignment		NA	04/12/2021
Primary Reviewer 1 COI signed		03/01/2021	04/12/2021
Primary Reviewer 2 COI signed		02/25/2021	04/12/2021
Peer Review Meeting	Primary Reviewer 1 critique submitted	03/08/2021	04/12/2021
	Primary Reviewer 2 critique submitted	03/08/2021	04/12/2021
	COI indicated by non-primary reviewer	NONE	04/12/2021
	COI recused from participation	NA	04/12/2021
	Discussed at Peer Review Meeting	YES	04/12/2021
	Peer Review Meeting	03/11/2021	04/12/2021
	Post review statements signed	03/12/2021	04/12/2021
	Third Party Observer Report	03/16/2021	04/12/2021
	Score report delivered to CSO	03/25/2021	04/12/2021
	Recommended for SRC review	YES	04/12/2021
Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021
	COI recused from participation	NA	04/12/2021
	SRC Meeting	03/11/2021	04/12/2021
	Third Party Observer Report	03/16/2021	04/12/2021
	Recommended for grant award	YES	04/12/2021
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021
PIC Review	Candidate not accepted position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210033
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Brian Christopher Miller, M.D., Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members Request for Applications (RFA)*. CPRIT received 17 applications in response to this recruitment cycles 21.6 through 21.9 RFA, including one application that was withdrawn. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”

Wayne R. Roberts
 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 6 day of May, 2021,
 by WAYNE R. ROBERTS.

Melanie Cleveland
 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210033
APPLICATION TITLE: Nomination of Brian Christopher Miller, M.D., Ph.D. for Recruitment of a CPRIT First-Time Tenure-Track Faculty Member Award
APPLICANT NAME: Lee, W. P. Andrew
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: Recruitment FY21_Cycle 7 and 8

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	12/22/2020	04/12/2021
	CPRIT Application Receipt Cycle closed	01/20/2021	04/12/2021
	CPRIT Application Receipt Cycle opened - 21.8	01/21/2021	04/12/2021
	CPRIT Application Receipt Cycle closed - 21.8	02/22/2021	04/12/2021
	Date application submitted	02/15/2021	04/12/2021
	Method of submission	CARS	04/12/2021
	Within receipt period	YES	04/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	02/26/2021
Donation(s) made to CPRIT / foundation		NO	04/12/2021
Assigned to primary reviewers		03/03/2021	04/12/2021
Applicant notified of review panel assignment		NA	04/12/2021
Primary Reviewer 1 COI signed		03/01/2021	04/12/2021
Primary Reviewer 2 COI signed		02/26/2021	04/12/2021
Peer Review Meeting	Primary Reviewer 1 critique submitted	03/08/2021	04/12/2021
	Primary Reviewer 2 critique submitted	03/09/2021	04/12/2021
	COI indicated by non-primary reviewer	Myles Brown	04/12/2021
	COI recused from participation	YES	04/12/2021
	Discussed at Peer Review Meeting	YES	04/12/2021
	Peer Review Meeting	03/11/2021	04/12/2021
	Post review statements signed	03/12/2021	04/12/2021
	Third Party Observer Report	03/16/2021	04/12/2021
	Score report delivered to CSO	03/25/2021	04/12/2021
	Recommended for SRC review	YES	04/12/2021
Final SRC Recommendation	COI indicated by SRC member	Myles Brown	04/16/2021
	COI recused from participation	YES	04/16/2021
	SRC Meeting	03/11/2021	04/12/2021
	Third Party Observer Report	03/16/2021	04/12/2021
	Recommended for grant award	YES	04/12/2021
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210034
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Sihan Wu, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 17 applications in response to this recruitment cycles 21.6 through 21.9 RFA, including one application that was withdrawn. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”

Wayne R. Roberts

Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 6 day of May, 2021, by WAYNE R. ROBERTS.

Melanie Cleveland
Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210034
APPLICATION TITLE: Nomination of Sihan Wu, Ph.D. for a CPRIT Recruitment of a First-Time Tenure-Track Faculty Member Award
APPLICANT NAME: Lee, W. P. Andrew
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: Recruitment FY21_Cycle 7 and 8

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020	
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020	
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020	
	CPRIT Application Receipt Cycle opened	12/22/2020	04/12/2021	
	CPRIT Application Receipt Cycle closed	01/20/2021	04/12/2021	
	CPRIT Application Receipt Cycle opened - 21.8	01/21/2021	04/12/2021	
	CPRIT Application Receipt Cycle closed - 21.8	02/22/2021	04/12/2021	
	Date application submitted	02/15/2021	04/12/2021	
	Method of submission	CARS	04/12/2021	
	Within receipt period	YES	04/12/2021	
	Receipt, Referral, and Assignment	Administrative review notification	NA	04/12/2021
		Donation(s) made to CPRIT / foundation	NO	04/12/2021
Assigned to primary reviewers		03/03/2021	04/12/2021	
Applicant notified of review panel assignment		NA	04/12/2021	
Primary Reviewer 1 COI signed		02/25/2021	04/12/2021	
Primary Reviewer 2 COI signed		03/01/2021	04/12/2021	
Peer Review Meeting		Primary Reviewer 1 critique submitted	03/08/2021	04/12/2021
	Primary Reviewer 2 critique submitted	03/09/2021	04/12/2021	
	COI indicated by non-primary reviewer	NONE	04/12/2021	
	COI recused from participation	NA	04/12/2021	
	Discussed at Peer Review Meeting	YES	04/12/2021	
	Peer Review Meeting	03/11/2021	04/12/2021	
	Post review statements signed	03/12/2021	04/12/2021	
	Third Party Observer Report	03/16/2021	04/12/2021	
	Score report delivered to CSO	03/25/2021	04/12/2021	
	Recommended for SRC review	YES	04/12/2021	
	Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021
COI recused from participation		NA	04/12/2021	
SRC Meeting		03/11/2021	04/12/2021	
Third Party Observer Report		03/16/2021	04/12/2021	
Recommended for grant award		YES	04/12/2021	
SRC Chair Notification to PIC and OC		04/22/2021	04/22/2021	
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	05/04/2021	
	COI indicated by PIC member	None	05/04/2021	
	COI recused from participation	NA	05/04/2021	
	PIC Review Meeting	05/04/2021	05/04/2021	
	Recommended for grant award	YES	05/04/2021	
Oversight Committee Approval	CEO Notification to Oversight Committee	NA		
	COI Indicated by Oversight Committee member	NA		
	COI Recused from participation	NA		
	Donation(s) made to CPRIT / foundation	NA		
	Presented to CPRIT Oversight Committee	NA		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	NA		
	Advance authority approved by Oversight Committee	NA		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210035
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Chen Yao, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 17 applications in response to this recruitment cycles 21.6 through 21.9 RFA, including one application that was withdrawn. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 6 day of May, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210035
APPLICATION TITLE: Nomination of Chen Yao, Ph.D. for a CPRIT Recruitment of a First-Time Tenure-Track Faculty Member Award
APPLICANT NAME: Lee, W. P. Andrew
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: Recruitment FY21_Cycle 7 and 8

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	12/22/2020	04/12/2021
	CPRIT Application Receipt Cycle closed	01/20/2021	04/12/2021
	CPRIT Application Receipt Cycle opened - 21.8	01/21/2021	04/12/2021
	CPRIT Application Receipt Cycle closed - 21.8	02/22/2021	04/12/2021
	Date application submitted	02/15/2021	04/12/2021
	Method of submission	CARS	04/12/2021
	Within receipt period	YES	04/12/2021
	Receipt, Referral, and Assignment	Administrative review notification	NA
Donation(s) made to CPRIT / foundation		NO	04/12/2021
Assigned to primary reviewers		03/03/2021	04/12/2021
Applicant notified of review panel assignment		NA	04/12/2021
Primary Reviewer 1 COI signed		02/25/2021	04/12/2021
Primary Reviewer 2 COI signed		02/25/2021	04/12/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	03/08/2021
	Primary Reviewer 2 critique submitted	03/09/2021	04/12/2021
	COI indicated by non-primary reviewer	NONE	04/12/2021
	COI recused from participation	NA	04/12/2021
	Discussed at Peer Review Meeting	YES	04/12/2021
	Peer Review Meeting	03/11/2021	04/12/2021
	Post review statements signed	03/12/2021	04/12/2021
	Third Party Observer Report	03/16/2021	04/12/2021
	Score report delivered to CSO	03/25/2021	04/12/2021
	Recommended for SRC review	YES	04/12/2021
	Final SRC Recommendation	COI indicated by SRC member	NA
COI recused from participation		NA	04/12/2021
SRC Meeting		03/11/2021	04/12/2021
Third Party Observer Report		03/16/2021	04/12/2021
Recommended for grant award		YES	04/12/2021
SRC Chair Notification to PIC and OC		04/22/2021	04/22/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210037
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Blair Benham-Pyle, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members Request for Applications (RFA)*. CPRIT received 17 applications in response to this recruitment cycles 21.6 through 21.9 RFA, including one application that was withdrawn. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”



 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 6 day of May, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210037
APPLICATION TITLE: First-Time, Tenure-Track: Dr. Blair Benham-Pyle
APPLICANT NAME: Dickinson, Mary
ORGANIZATION: Baylor College of Medicine
PANEL NAME: Recruitment FY21_Cycle 7 and 8

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	12/22/2020	04/12/2021
	CPRIT Application Receipt Cycle closed	01/20/2021	04/12/2021
	CPRIT Application Receipt Cycle opened - 21.8	01/21/2021	04/12/2021
	CPRIT Application Receipt Cycle closed - 21.8	02/22/2021	04/12/2021
	Date application submitted	02/22/2021	04/12/2021
	Method of submission	CARS	04/12/2021
	Within receipt period	YES	04/12/2021
Receipt, Referral, and Assignment	Administrative review notification	02/26/2021	04/12/2021
	Donation(s) made to CPRIT / foundation	NO	04/12/2021
	Assigned to primary reviewers	03/03/2021	04/12/2021
	Applicant notified of review panel assignment	NA	04/12/2021
	Primary Reviewer 1 COI signed	02/26/2021	04/12/2021
	Primary Reviewer 2 COI signed	02/25/2021	04/12/2021
Peer Review Meeting	Primary Reviewer 1 critique submitted	03/09/2021	04/12/2021
	Primary Reviewer 2 critique submitted	03/09/2021	04/12/2021
	COI indicated by non-primary reviewer	NONE	04/12/2021
	COI recused from participation	NA	04/12/2021
	Discussed at Peer Review Meeting	YES	04/12/2021
	Peer Review Meeting	03/11/2021	04/12/2021
	Post review statements signed	03/12/2021	04/12/2021
	Third Party Observer Report	03/16/2021	04/12/2021
	Score report delivered to CSO	03/25/2021	04/12/2021
	Recommended for SRC review	YES	04/12/2021
Final SRC Recommendation	COI indicated by SRC member	NA	04/12/2021
	COI recused from participation	NA	04/12/2021
	SRC Meeting	03/11/2021	04/12/2021
	Third Party Observer Report	03/16/2021	04/12/2021
	Recommended for grant award	YES	04/12/2021
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	

CPRIT retains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210039
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Cornelius Y. Taabazuing, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 17 applications in response to this recruitment cycles 21.6 through 21.9 RFA, including one application that was withdrawn. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 6 day of May, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210039
APPLICATION TITLE: First-Time, Tenure-Track Faculty: Dr. Cornelius Y. Taabazuing
APPLICANT NAME: Dickinson, Mary
ORGANIZATION: Baylor College of Medicine
PANEL NAME: Recruitment FY21_Cycle 9

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	02/23/2021	04/19/2021
	CPRIT Application Receipt Cycle closed	03/22/2021	04/19/2021
	Date application submitted	03/18/2021	04/19/2021
	Method of submission	CARS	04/19/2021
	Within receipt period	YES	04/19/2021
	Receipt, Referral, and Assignment	Administrative review notification	NA
Donation(s) made to CPRIT / foundation		NO	04/19/2021
Assigned to primary reviewers		04/01/2021	04/19/2021
Applicant notified of review panel assignment		NA	04/19/2021
Primary Reviewer 1 COI signed		03/27/2021	04/19/2021
Primary Reviewer 2 COI signed		03/26/2021	04/19/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	04/13/2021
	Primary Reviewer 2 critique submitted	04/13/2021	04/19/2021
	COI indicated by non-primary reviewer	NONE	04/19/2021
	COI recused from participation	NA	04/19/2021
	Discussed at Peer Review Meeting	YES	04/19/2021
	Peer Review Meeting	04/15/2021	04/19/2021
	Post review statements signed	04/15/2021	04/19/2021
	Third Party Observer Report	04/30/2021	04/30/2021
	Score report delivered to CSO	04/16/2021	04/19/2021
	Recommended for SRC review	YES	04/19/2021
	Final SRC Recommendation	COI indicated by SRC member	NA
COI recused from participation		NA	04/19/2021
SRC Meeting		04/15/2021	04/19/2021
Third Party Observer Report		04/30/2021	04/30/2021
Recommended for grant award		YES	04/19/2021
SRC Chair Notification to PIC and OC		04/22/2021	04/22/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210040
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Joshua Riback, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 17 applications in response to this recruitment cycles 21.6 through 21.9 RFA, including one application that was withdrawn. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 6 day of May, 2021,
 by WAYNE R. ROBERTS.



 Melanie Cleveland
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210040
APPLICATION TITLE: First-Time, Tenure-Track Faculty: Dr. Joshua Riback
APPLICANT NAME: Dickinson, Mary
ORGANIZATION: Baylor College of Medicine
PANEL NAME: Recruitment FY21_Cycle 9

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	02/23/2021	04/19/2021
	CPRIT Application Receipt Cycle closed	03/22/2021	04/19/2021
	Date application submitted	03/22/2021	04/19/2021
	Method of submission	CARS	04/19/2021
	Within receipt period	YES	04/19/2021
	Receipt, Referral, and Assignment	Administrative review notification	NA
Donation(s) made to CPRIT / foundation		NO	04/19/2021
Assigned to primary reviewers		04/01/2021	04/19/2021
Applicant notified of review panel assignment		NA	04/19/2021
Primary Reviewer 1 COI signed		03/30/2021	04/19/2021
Primary Reviewer 2 COI signed		03/26/2021	04/19/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	04/06/2021
	Primary Reviewer 2 critique submitted	04/13/2021	04/19/2021
	COI indicated by non-primary reviewer	NONE	04/19/2021
	COI recused from participation	NA	04/19/2021
	Discussed at Peer Review Meeting	YES	04/19/2021
	Peer Review Meeting	04/15/2021	04/19/2021
	Post review statements signed	04/15/2021	04/19/2021
	Third Party Observer Report	04/30/2021	04/30/2021
	Score report delivered to CSO	04/16/2021	04/19/2021
	Recommended for SRC review	YES	04/19/2021
	Final SRC Recommendation	COI indicated by SRC member	NA
COI recused from participation		NA	04/19/2021
SRC Meeting		04/15/2021	04/19/2021
Third Party Observer Report		04/30/2021	04/30/2021
Recommended for grant award		YES	04/19/2021
SRC Chair Notification to PIC and OC		04/22/2021	04/22/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210042
Recruitment of Rising Stars
Nomination of Stephanie Seidlits, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

"My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of Rising Stars* Request for Applications (RFA). CPRIT received five applications in response to this recruitment cycles 21.6 through 21.9 RFA. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT's third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT's grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT's third-party grants management vendor in my capacity as CPRIT's CEO to prepare this affidavit. Some information ("CEO Affidavit-Supporting Information") is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT's grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 6 day of May, 2021, by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of Rising Stars
APPLICATION ID: RR210042
APPLICATION TITLE: Recruitment of Rising Star Stephanie Seidlits
APPLICANT NAME: Wood, Sharon L
ORGANIZATION: The University of Texas at Austin
PANEL NAME: Recruitment FY21_Cycle 9

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	12/22/2020
	RFA Approved by CSO (revised)	10/22/2020	12/22/2020
	RFA published in Texas.gov eGrants	06/12/2020	12/22/2020
	CPRIT Application Receipt Cycle opened	02/23/2021	04/19/2021
	CPRIT Application Receipt Cycle closed	03/22/2021	04/19/2021
	Date application submitted	03/22/2021	04/19/2021
	Method of submission	CARS	04/19/2021
	Within receipt period	YES	04/19/2021
	Receipt, Referral, and Assignment	Administrative review notification	03/26/2021
Donation(s) made to CPRIT / foundation		NO	04/19/2021
Assigned to primary reviewers		04/01/2021	04/19/2021
Applicant notified of review panel assignment		NA	04/19/2021
Primary Reviewer 1 COI signed		03/25/2021	04/19/2021
Primary Reviewer 2 COI signed		03/27/2021	04/19/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	04/11/2021
	Primary Reviewer 2 critique submitted	04/09/2021	04/19/2021
	COI indicated by non-primary reviewer	NONE	04/19/2021
	COI recused from participation	NA	04/19/2021
	Discussed at Peer Review Meeting	YES	04/19/2021
	Peer Review Meeting	04/15/2021	04/19/2021
	Post review statements signed	04/15/2021	04/19/2021
	Third Party Observer Report	04/30/2021	04/30/2021
	Score report delivered to CSO	04/16/2021	04/19/2021
	Recommended for SRC review	YES	04/19/2021
	Final SRC Recommendation	COI indicated by SRC member	NA
COI recused from participation		NA	04/19/2021
SRC Meeting		04/15/2021	04/19/2021
Third Party Observer Report		04/30/2021	04/30/2021
Recommended for grant award		YES	04/19/2021
SRC Chair Notification to PIC and OC		04/22/2021	04/22/2021
PIC Review	Candidate not accepted position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210044
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Jason Sheltzer, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 17 applications in response to this recruitment cycles 21.6 through 21.9 RFA, including one application that was withdrawn. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”

Wayne R. Roberts

Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 6 day of May, 2021, by WAYNE R. ROBERTS.

Melanie Cleveland

Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210044
APPLICATION TITLE: Recruitment of First-Time, Tenure-Track Faculty Members - Jason Sheltzer
APPLICANT NAME: Draetta, Gulio
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: Recruitment FY21_Cycle 9

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	02/23/2021	04/19/2021
	CPRIT Application Receipt Cycle closed	03/22/2021	04/19/2021
	Date application submitted	03/22/2021	04/19/2021
	Method of submission	CARS	04/19/2021
	Within receipt period	YES	04/19/2021
Receipt, Referral, and Assignment	Administrative review notification	03/26/2021	04/19/2021
	Donation(s) made to CPRIT / foundation	NO	04/19/2021
	Assigned to primary reviewers	04/01/2021	04/19/2021
	Applicant notified of review panel assignment	NA	04/19/2021
	Primary Reviewer 1 COI signed	03/26/2021	04/19/2021
	Primary Reviewer 2 COI signed	03/27/2021	04/19/2021
Peer Review Meeting	Primary Reviewer 1 critique submitted	04/13/2021	04/19/2021
	Primary Reviewer 2 critique submitted	04/09/2021	04/19/2021
	COI indicated by non-primary reviewer	NONE	04/19/2021
	COI recused from participation	NA	04/19/2021
	Discussed at Peer Review Meeting	YES	04/19/2021
	Peer Review Meeting	04/15/2021	04/19/2021
	Post review statements signed	04/15/2021	04/19/2021
	Third Party Observer Report	04/30/2021	04/30/2021
	Score report delivered to CSO	04/16/2021	04/19/2021
	Recommended for SRC review	YES	04/19/2021
Final SRC Recommendation	COI indicated by SRC member	NA	04/19/2021
	COI recused from participation	NA	04/19/2021
	SRC Meeting	04/15/2021	04/19/2021
	Third Party Observer Report	04/30/2021	04/30/2021
	Recommended for grant award	YES	04/19/2021
	SRC Chair Notification to PIC and OC	04/22/2021	04/22/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	

CPRIT retains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210048
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Courtney M. Schroeder, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received 17 applications in response to this recruitment cycles 21.6 through 21.9 RFA, including one application that was withdrawn. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210048
APPLICATION TITLE: Nomination of Courtney M. Schroeder, Ph.D. for a CPRIT Recruitment of First-Time Tenure-Track Faculty Member
APPLICANT NAME: Lee, W. P. Andrew
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: Recruitment FY21_Cycle 9

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	02/23/2021	04/19/2021
	CPRIT Application Receipt Cycle closed	03/22/2021	04/19/2021
	Date application submitted	03/18/2021	04/19/2021
	Method of submission	CARS	04/19/2021
	Within receipt period	YES	04/19/2021
	Receipt, Referral, and Assignment	Administrative review notification	NA
Donation(s) made to CPRIT / foundation		NO	04/19/2021
Assigned to primary reviewers		04/01/2021	04/19/2021
Applicant notified of review panel assignment		NA	04/19/2021
Primary Reviewer 1 COI signed		03/27/2021	04/19/2021
Primary Reviewer 2 COI signed		03/30/2021	04/19/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	04/09/2021
	Primary Reviewer 2 critique submitted	04/06/2021	04/19/2021
	COI indicated by non-primary reviewer	NONE	04/19/2021
	COI recused from participation	NA	04/19/2021
	Discussed at Peer Review Meeting	YES	04/19/2021
	Peer Review Meeting	04/15/2021	04/19/2021
	Post review statements signed	04/15/2021	04/19/2021
	Third Party Observer Report	04/30/2021	04/30/2021
	Score report delivered to CSO	04/16/2021	04/19/2021
	Recommended for SRC review	YES	04/19/2021
	Final SRC Recommendation	COI indicated by SRC member	NA
COI recused from participation		NA	04/19/2021
SRC Meeting		04/15/2021	04/19/2021
Third Party Observer Report		04/30/2021	04/30/2021
Recommended for grant award		YES	04/19/2021
SRC Chair Notification to PIC and OC		04/22/2021	04/22/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR210050
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Cassandra Callmann, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members Request for Applications (RFA)*. CPRIT received 17 applications in response to this recruitment cycles 21.6 through 21.9 RFA, including one application that was withdrawn. This application was assigned to the Scientific Review Council for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:


- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On February 1, 2021, I granted Chief Scientific Officer, Dr. James Willson, a waiver from the general prohibition against communicating with a grant applicant, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 6 day of May, 2021, by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:31 PM

FY: 2021
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR210050
APPLICATION TITLE: Recruitment of First-Time, Tenure-Track Faculty - Dr. Cassandra Callmann
APPLICANT NAME: Matouschek, Andreas
ORGANIZATION: The University of Texas at Austin
PANEL NAME: Recruitment FY21_Cycle 9

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/08/2020	09/03/2020
	RFA Approved by CSO (revised)	09/24/2020	10/20/2020
	RFA published in Texas.gov eGrants	06/12/2020	09/03/2020
	CPRIT Application Receipt Cycle opened	02/23/2021	04/19/2021
	CPRIT Application Receipt Cycle closed	03/22/2021	04/19/2021
	Date application submitted	03/22/2021	04/19/2021
	Method of submission	CARS	04/19/2021
	Within receipt period	YES	04/19/2021
	Receipt, Referral, and Assignment	Administrative review notification	NA
Donation(s) made to CPRIT / foundation		NO	04/19/2021
Assigned to primary reviewers		04/01/2021	04/19/2021
Applicant notified of review panel assignment		NA	04/19/2021
Primary Reviewer 1 COI signed		03/27/2021	04/19/2021
Primary Reviewer 2 COI signed		03/26/2021	04/19/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	04/14/2021
	Primary Reviewer 2 critique submitted	04/13/2021	04/19/2021
	COI indicated by non-primary reviewer	NONE	04/19/2021
	COI recused from participation	NA	04/19/2021
	Discussed at Peer Review Meeting	YES	04/19/2021
	Peer Review Meeting	04/15/2021	04/19/2021
	Post review statements signed	04/15/2021	04/19/2021
	Third Party Observer Report	04/30/2021	04/30/2021
	Score report delivered to CSO	04/16/2021	04/19/2021
	Recommended for SRC review	YES	04/19/2021
	Final SRC Recommendation	COI indicated by SRC member	NA
COI recused from participation		NA	04/19/2021
SRC Meeting		04/15/2021	04/19/2021
Third Party Observer Report		04/30/2021	04/30/2021
Recommended for grant award		YES	04/19/2021
SRC Chair Notification to PIC and OC		04/22/2021	04/22/2021
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	05/04/2021
	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: CPRIT OVERSIGHT COMMITTEE
FROM: RAMONA MAGID, CHIEF PREVENTION OFFICER
SUBJECT: PREVENTION GRANT RECOMMENDATIONS – FY 2021 CYCLE 1
DATE: MAY 11, 2021

Summary and Recommendation:

The Program Integration Committee (PIC) has completed its review of the recommendations forwarded by the Prevention Review Council. The PIC recommends awarding 5 projects for FY 2021 Cycle 1 totaling \$11,202,949. All grant recommendations are presented in one slate.

Number	Grant Type	Amount
5	<i>Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations</i>	\$ 11,202,949

Background:

FY 2021 Cycle 1 (21.1)

CPRIT released one (1) RFA in August 2020 for the first review cycle of FY 2021. Twelve (12) prevention applications requesting \$26,133,587 underwent peer review by teleconference on January 19, 2021 and the programmatic review by the PRC was conducted March 4, 2021.

Program Priorities Addressed

All the recommended applications address one or more of the Prevention Program priorities. Some applications address more than one priority. See the attached chart for additional detail.

<u>Number of Applications Addressing Priorities</u>		
5	Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence	\$11,202,949
5	Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence	\$11,202,949
5	Prioritize underserved populations	\$11,202,949

Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

Mechanism:

This award mechanism seeks to support the coordination and expansion of evidence-based services to prevent cancer in underserved populations who do not have adequate access to cancer prevention interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community and use evidence-based models shown to work in similar communities to prevent and control these cancers. Currently funded CPRIT projects should propose to expand their programs to include additional types of prevention clinical services and/or an expansion of current clinical services into additional counties. In either case, the expansion must include delivery of services to nonmetropolitan and medically underserved counties in the state.

Award: Maximum of \$2.5M; Maximum duration of 5 years

Recommended projects (5): \$11,202,949

Twelve (12) applications were submitted in this mechanism. Five (5) expansion of cancer prevention services to rural and medically underserved populations projects are recommended.

Project Descriptions

PP210003	EPS	Taking Texas Tobacco Free among Substance Users within Community-based Healthcare Settings in Rural and Medically Underserved Areas Across Texas	Reitzel, Lorraine	University of Houston	1.4	\$1,998,572
----------	-----	--	-------------------	-----------------------	-----	-------------

CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations

The proposed project will positively affect employee and patient tobacco abstinence through increasing agencies' tobacco treatment capacity via the provision of education to employees, specialized training to clinicians, treatment resources, and technical assistance. TTTF will facilitate the implementation or refreshing of tobacco-free workplace policies with a sustainable plan for enforcement; integration of regular screenings (tobacco use assessments; TUAs) into clinical practice, regular treatment of tobacco dependence at the point-of-care through embedded, facilitating systems and expertise; incorporate tobacco education into new employee orientations and annual training endeavors to maintain/supplement gains acquired via active training efforts; and de-normalize tobacco use through increases in knowledge and competence in treating tobacco use.

PP210004	EPS.	BEST 3: The Breast Cancer Education Screening and Navigation Program in West and South Texas.	Shokar, Navkiran	Texas Tech University Health Sciences Center at El Paso	2.3	\$2,500,000
----------	------	---	------------------	---	-----	-------------

CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations

The BEST program expansion proposes to build on an effective, culturally tailored, comprehensive multicomponent intervention that uses a socioecological approach to address known barriers to breast cancer screening, diagnosis, and treatment in the region. The program serves populations of the underserved, rural populations, and cultural/ethnic minority populations. The program addresses several levels of the socioecological model for health, and includes research-tested outreach, education, clinical service delivery, patient navigation, dissemination, and implementation, and promotes uptake of sustainable system changes. This

project will increase the number of screening delivery sites from eight to 12 and will increase the clinical service area from 24 counties to 56 counties through new collaborations across the entire region.

PP210005	EPS	Southwest Coalition for Colorectal Cancer Screening (SuCCCeS) 2	Shokar, Navkiran	Texas Tech University Health Sciences Center at El Paso	2.9	\$2,500,000
----------	-----	---	------------------	---	-----	-------------

CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations

This project proposes to expand, in partnership with a large network of providers, the successful multi-faceted colorectal cancer (CRC) intervention, SuCCCeS. The program is a population-based screening program incorporating both community-based and healthcare system-based approaches to address identified barriers to reduce colorectal cancer disparities. The program targets CPRIT priority populations of the underserved, rural, geographically remote, and cultural/ethnic minorities. The program consists of outreach, education, clinical service delivery, patient navigation, dissemination and implementation approaches and promotes sustainable system change. It is also bilingual and culturally tailored and has been implemented uninterrupted for nine years with ongoing expansion and improvement to maintain program outcomes.

PP210016	EPS	Hep C - C.A.R.E (Colonias Advancing & Restoring Esperanza)	Villarreal, Roberto	University Health System	3.3	\$1,712,190
----------	-----	--	---------------------	--------------------------	-----	-------------

CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations

The proposed project plans to draw upon the successful implementation of the previously CPRIT funded HepVISTA program (Hepatitis C Viral Infection and Systematic Treatment Alliance) to expand HCV screening services to patients served by collaborating service partners in Webb, Jim Hogg, and Zapata Counties. The project will use Project ECHO to facilitate community and provider education and outreach. Opt-out screening and automatic orders for HCV screening will be implemented and confirmatory tests will be provided. Patient Navigators will also follow-up with patients who are diagnosed with HCV and schedule follow-up appointments for counseling, HCV education, provide referrals to in-house treatment, and Hepatitis B Virus vaccinations if needed.

PP210017	EPS	Get F.I.T. to Stay Fit, Stepping up to Fight Colorectal Cancer in the Panhandle	Obokhare, Izi	Texas Tech University Health Sciences Center	3.3	\$2,492,187
----------	-----	---	---------------	--	-----	-------------

CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize underserved populations

This proposed project plans to expand a multi-component evidence-based program focusing on increasing CRC screening rates in urban and rural low-income, undereducated groups, including minorities and refugees. The program is the only no-cost CRC education/screening program in the Panhandle. The project will serve men and women of all races/ethnicities who are uninsured/under-insured aged 45 to 75 years that are not up to date with CRC screening or who have never been screened. Project components include: outreach via social media/on-line platforms; community health workers; education via telehealth and updated videos to increase program access; tailored phone consultations and traditional face to face individual and group level education once COVID restrictions lift; no cost screening and diagnostic testing for eligible participants, and navigation for supporting test completion and referral to treatment, if necessary.

Prevention Program Priorities Addressed by Recommended Awards May 19, 2021

<p align="center">Prioritize populations disproportionately affected by cancer incidence, mortality or cancer risk prevalence</p>	<p align="center">Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality or cancer risk prevalence</p>	<p align="center">Prioritize underserved populations</p>
<p align="center">\$11,202,949 5 projects</p> <ul style="list-style-type: none"> • PP210003 • PP210004 • PP210005 • PP210016 • PP210017 	<p align="center">\$11,202,949 5 projects</p> <ul style="list-style-type: none"> • PP210003 • PP210004 • PP210005 • PP210016 • PP210017 	<p align="center">\$11,202,949 5 projects</p> <ul style="list-style-type: none"> • PP210003 • PP210004 • PP210005 • PP210016 • PP210017

Note: Some grant awards address more than one program priority and will be double counted.

Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Mr. Margo,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the cycle 21.1 Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations (EPS) awards.

The PRC met on March 4, 2021 to consider the applications recommended by the peer review panel following their January 19 meeting. The PRC recommends 5 projects totaling \$11,202,949.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 21.1 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP210003	EPS	Taking Texas Tobacco Free among Substance Users within Community-based Healthcare Settings in Rural and Medically Underserved Areas Across Texas	Reitzel, Lorraine R	University of Houston	1.4	1	\$1,998,572
PP210004	EPS	BEST 3: The Breast Cancer Education Screening and Navigation Program in West and South Texas.	Shokar, Navkiran K	Texas Tech University Health Sciences Center at El Paso	2.3	2	\$2,500,000
PP210005	EPS	Southwest Coalition for Colorectal Cancer Screening (SuCCCeS) 2	Shokar, Navkiran K	Texas Tech University Health Sciences Center at El Paso	2.9	3	\$2,500,000
PP210016	EPS	Hep C - C.A.R.E (Colonias Advancing & Restoring Esperanza)	Villarreal, Roberto	University Health System	3.3	4	\$1,712,190
PP210017	EPS	Get F.I.T. to Stay Fit, Stepping up to Fight Colorectal Cancer in the Panhandle	Obokhare , Izi D	Texas Tech University Health Sciences Center	3.3	5	\$2,492,187

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 STANDING WAIVER FOR FY 2021
DATE: AUGUST 28, 2020

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I grant CPRIT's Chief Prevention Officer Ramona Magid a waiver from the general prohibition against communicating with grant applicants. The waiver is applicable for FY 2021. Unlike the two communication waivers I granted Ms. Magid for each FY 2020 review cycle, this standing FY 2021 waiver will be effective for both review cycles planned for FY 2021. No Oversight Committee action related to this waiver is necessary.

Background and Discussion

The Chief Prevention Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while the application is pending a final decision. The restriction on communication prevents even the appearance of unequal treatment during the grant review process.

Traditionally, a chief program officer leads each CPRIT program with the assistance of a program manager. The program manager fields inquiries from and provides technical help to applicants completing their CPRIT grant applications. I promoted Ms. Magid to the Chief Prevention Officer position upon Dr. Becky Garcia's retirement in June 2019. However, the prevention program manager position has remained vacant since Ms. Magid's promotion. Until CPRIT fills the program manager position, she is the sole point of contact for the prevention program. The communication waiver is necessary so that Ms. Magid can assist grant applicants who have questions during the application process.

I previously granted Ms. Magid separate waivers for the two review cycles of FY 2020. It is unlikely that CPRIT will fill the prevention program manager position in FY 2021. Accordingly, I am granting a standing waiver for Ms. Magid for FY 2021 as long as she remains the sole point of contact for the prevention program. Approving this standing waiver does not favor any grant applicant over another. Ms. Magid will provide technical assistance only and will not comment on the substance of a grant application. CPRIT will include this waiver in the grant record for the FY 2021 prevention grant applications.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

FY 2021 – Cycle 1
*Expansion of Cancer Prevention Services to Rural and
Medically Underserved Populations*

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA P-21.1-EPS

**Expansion of Cancer Prevention Services to
Rural and Medically Underserved Populations**

**Please also refer to the Instructions for Applicants document,
which will be posted on August 17, 2020**

Application Receipt Opening Date: August 17, 2020

Application Receipt Closing Date: October 5, 2020

FY 2021

Fiscal Year Award Period

September 1, 2020-August 31, 2021

TABLE OF CONTENTS

1. ABOUT CPRIT	5
1.1 PREVENTION PROGRAM PRIORITIES	5
2. FUNDING OPPORTUNITY DESCRIPTION	6
2.1 SUMMARY	6
2.2 PROJECT OBJECTIVES	8
2.3 AWARD DESCRIPTION	9
2.4 PRIORITIES	12
2.5 SPECIFIC AREAS OF EMPHASIS	13
2.6 OUTCOME METRICS	15
2.7 ELIGIBILITY	16
2.8 RESUBMISSION POLICY	17
2.9 FUNDING INFORMATION	18
3. KEY DATES	19
4. APPLICATION SUBMISSION GUIDELINES	19
4.1 INSTRUCTIONS FOR APPLICANTS DOCUMENT	19
4.2 ONLINE APPLICATION RECEIPT SYSTEM	19
4.3 SUBMISSION DEADLINE EXTENSION	20
4.4 APPLICATION COMPONENTS	20
4.4.1 Abstract and Significance (5,000 characters)	20
4.4.2 Goals and Objectives (700 characters each)	21
4.4.3 Project Timeline (2 pages)	21
4.4.4 Project Plan (12 pages; fewer pages permissible)	21
4.4.5 People Reached (Indirect Contact)	24
4.4.6 Number of Services Delivered (Direct Contact)	24
4.4.7 Number of Clinical Services Delivered	25
4.4.8 Number of Unique People Served (Direct Contact)	25
4.4.9 References	25
4.4.10 Resubmission Summary	25
4.4.11 Most Recently Funded Relevant Project Summary (3 pages)	25
4.4.12 CPRIT Grants Summary	26
4.4.13 Budget and Justification	26
4.4.14 Current and Pending Support and Sources of Funding	28
4.4.15 Biographical Sketches	28
4.4.16 Collaborating Organizations	29
4.4.17 Letters of Commitment (10 pages)	29

5. APPLICATION REVIEW	29
5.1 REVIEW PROCESS OVERVIEW	29
5.2 REVIEW CRITERIA.....	31
5.2.1 <i>Primary Evaluation Criteria</i>	31
5.2.2 <i>Secondary Evaluation Criteria</i>	33
6. AWARD ADMINISTRATION.....	33
7. CONTACT INFORMATION.....	35
7.1 HELPDESK.....	35
7.2 PROGRAM QUESTIONS	35
8. RESOURCES.....	36
9. REFERENCES.....	37
APPENDIX A: KEY TERMS.....	38
APPENDIX B: WRITING GOALS AND OBJECTIVES.....	41

RFA VERSION HISTORY

Rev 8/3/2020 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$3 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1 Prevention Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Prevention Program's principles and priorities will also guide CPRIT staff and the Prevention Review Council on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles

- Fund evidence-based interventions and their dissemination
- Support the prevention continuum of primary, secondary, and tertiary (includes survivorship) prevention interventions

Prevention Program Priorities

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize underserved populations

2. FUNDING OPPORTUNITY DESCRIPTION

2.1 Summary

The ultimate goals of the CPRIT Prevention Program are to reduce overall cancer incidence and mortality and to improve the lives of individuals who have survived or are living with cancer.


The ability to reduce cancer death rates depends in part on the application of currently available evidence-based technologies and strategies. CPRIT fosters the prevention of cancer in Texas by providing financial support for a wide variety of evidence-based prevention interventions.

This award mechanism seeks to support the coordination and expansion of evidence-based services to prevent or screen for cancer in underserved populations who do not have adequate access to cancer prevention interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. The proposed project should be designed to reach and serve as many people as possible. Projects should identify cancers that cause the most burden in the community and use evidence-based models to prevent and control these cancers.


Eligible applicants include only those with currently or previously funded CPRIT Prevention projects.

Initial Expansion: For the first expansion application, eligible applicants should propose to expand their programs to include additional types of prevention clinical services or to expand current clinical services into additional counties. In either case, the expansion must include the delivery of services to nonmetropolitan (rural) and/or medically underserved counties in the state. These may be identified via Web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#).

Maintenance Expansion: For a subsequent expansion, additional clinical services and/or expansion to additional counties is optional; however, the counties and the services offered in the first expansion should not be decreased. The number of clinical services delivered during the maintenance expansion must be increased substantially if no further geographic or clinical service expansion is proposed.



Texas Medically Underserved Areas (MUA) and Populations (MUP)



Data source: US Health Resources and Services Administration Data Warehouse, October 2017

2.2 Project Objectives

CPRIT seeks to fund initial expansion evidence-based prevention projects that will do the following:

- Expand an eligible CPRIT project by adding and integrating the delivery of 1 or more of the following to an existing project:
 - Screenings, rescreenings, and diagnostics for breast, cervical, colorectal cancers; hepatitis C virus; genetic risk factors
 - Vaccinations against HPV and hepatitis B virus
 - Evidence-based interventions focused on tobacco prevention (prevent tobacco use or sustained abstinence) and tobacco cessation among youth and/or adults
- Expand an eligible CPRIT project by adding and integrating the delivery of services to additional nonmetropolitan and/or medically underserved counties.

CPRIT seeks to fund maintenance expansion evidence-based prevention projects that will do the following:

- Maintain, at a minimum, clinical service delivery and geographic area expansion as proposed in the previously funded expansion project. Further expansion of clinical services and geographic area are optional.
- Substantially increase the number of clinical services delivered if no further expansion is proposed.

Both initial and maintenance expansion evidence-based prevention projects funded by CPRIT will do the following:

- Coordinate the resources (clinical service providers, community organizations, etc) in nonmetropolitan and medically underserved areas (MUAs) to increase the availability of services and, where providers are available, help connect people with their local health care providers.
- Leverage the infrastructure, networks, and resources that have been put in place by CPRIT supported projects while minimizing startup time.
- Deliver comprehensive projects comprising all of the following: public and/or professional education, outreach, delivery of clinical services, follow-up navigation, and system and/or policy improvements.

- Offer effective and efficient systems of delivery of prevention services based on the existing body of knowledge about, and evidence for, cancer prevention in ways that far exceed current performance in a given service area.
- Implement policy changes and/or system improvements that are sustainable over time (eg, decrease wait times between positive screen and diagnostic tests and treatment through improved navigation, reminder systems, etc).

2.3 Award Description

CPRIT’s **Expansion of Cancer Prevention Services** grants are intended to fund the expansion of eligible projects that have demonstrated exemplary success, as evidenced by progress reports and project evaluations, and desire to further enhance their impact on priority populations. Detailed descriptions of **established infrastructure, results, barriers, outcomes, and impact of the most recently funded relevant project are required** (see outline of Project Plan, [section 4.4.4](#)).

Projects in the last year of a current grant or previously funded projects may apply for this expansion. Programs must have at least 1 full year of data to report before applying (see [section 2.7](#) eligibility criteria).

Applicants should not request funds for any of the above components if these components are already being funded from other sources. If clinical services are being provided and paid by others, the applicant must explain and report on the outcomes and services that are delivered to the people navigated by the program.

The following are required components of the project:

- **Initial Expansion:** Expansion to nonmetropolitan/MUA counties and/or offering additional clinical services are required for an initial expansion. To qualify for this Expansion RFA, CPRIT requires applicants to either add the delivery of 1 or more of the following clinical services to their project or to expand to additional nonmetropolitan and/or MUA counties.
 - Screenings and rescreenings for breast, cervical, colorectal cancers; hepatitis C virus; genetic risk factors
 - Vaccinations against HPV; hepatitis B virus
 - Evidence-based interventions focused on tobacco prevention (prevent tobacco use or sustained abstinence) and tobacco cessation among youth and/or adults

Expansion of eligible projects into nonmetropolitan/medically underserved geographic areas not well served by the CPRIT portfolio (see maps at <https://www.cprit.texas.gov/our-programs/prevention/portfolio-maps>), will receive priority consideration.

- **Maintenance Expansion:** The clinical service and/or geographic expansion from the previously funded CPRIT expansion project must be maintained, at a minimum. Further expansion is optional. If no further expansion of clinical services and/or geography is proposed, the number of clinical services delivered must be substantially increased from the initial expansion.
- **Comprehensive Projects:** Comprehensive projects include a continuum of services and systems and policy changes and comprise all of the following: Public and/or professional education and training, outreach, delivery of screening and diagnostic services, follow-up navigation, data collection and tracking, and systems improvement.

This mechanism will fund case management/patient navigation to screening, to diagnostic testing, and to treatment. Applicants must ensure that there is access to treatment services for patients with cancers or precancers that are detected as a result of the project and must describe the process for ensuring access to treatment services in their application.

- **Evidence Based:** CPRIT's service grants are intended to fund effective and efficient systems of delivery of prevention services based on the existing body of knowledge about and evidence for cancer prevention in ways that far exceed current performance in a given service area. The provision of clinical services, including rescreening at the appropriate interval, must comply with established and current national guidelines (eg, US Preventive Services Task Force [USPSTF], American Cancer Society, etc).

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data (eg, availability of resources and screening coverage) for the target population and target service region are required. If no baseline data exist, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline.

Clinical Service and Community Partner Networks. Applicants are strongly encouraged to coordinate and describe a collaboration of clinical service providers and community partners that can deliver outreach, education, clinical, and navigation services to the most counties and the most people possible in a selected service region. Partnerships with other organizations that can support and leverage resources (ie, community-based organizations, local and voluntary agencies, nonprofit agencies, groups that represent priority populations, etc) are encouraged. Letters of commitment or memoranda of understanding describing their specific role in the partnership will greatly strengthen the application. Leveraging of the infrastructure, existing networks, and other resources that were established for the eligible CPRIT-funded project are expected and should be well described.

Project Coordination and Technical Assistance. The overall program should be directed and overseen by the Program Director (PD) who is responsible for establishing and managing the network. Responsibilities of the PD include the following:

- Establishing any necessary subcontracts or memoranda of understanding with project partners and clinical service providers;
- Regularly communicating with partners to discuss progress and barriers, resolve potential problems, and provide technical assistance as needed throughout the duration of the project;
- Meeting all reporting requirements. CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area) in the provision of evidence-based services, changes in provider practice, systems changes, and cost-effectiveness.

If applicable, in cases where the project proposes to work with multiple clinical providers, the PD should facilitate the establishment of standard protocols for all clinical service providers in the network as well as standard systems, policies, and procedures for the participating clinical service providers and organizations. These may include, but are not limited to, patient tracking and timely follow-up of all abnormal screening results and/or diagnoses of cancer.

Under this RFA, CPRIT **will not** consider the following:

- **Continuation of currently funded projects.** Projects must include the required expansion criteria detailed in the RFA for an initial expansion, and a substantial increase in the number of clinical services provided is required for any subsequent expansion.

- **Projects focusing on computerized tomography screening for lung cancer for ages 55 to 77.** Applicants with projects including lung cancer CT screening should apply under CPRIT’s Tobacco Control and Lung Cancer Screening RFA.
- **New evidence-based cancer prevention services projects.** These applicants should apply under CPRIT’s Evidence-Based Cancer Prevention Services RFA.
- **Projects focused solely on systems and/or policy change or solely on education and/or outreach that do not include the delivery of cancer preventive clinical services.**
- **Projects focusing solely on case management/patient navigation services through the treatment phase of cancer.** Case management/patient navigation services must be paired with the delivery of a clinical cancer prevention service and reported to CPRIT.
- **Projects focused solely on counseling services with no additional evidence-based clinical services.**
- **Resources for the treatment of cancer or viral treatment for hepatitis.**
- **Prevention/intervention research** (Applicants interested in prevention research should review CPRIT’s Academic Research RFAs (available at <http://www.cprit.texas.gov>).

2.4 Priorities

Types of Cancer: Applications addressing the services listed in [section 2.2](#) Project Objectives and that are responsive to this RFA will be considered for funding.

The Prevention Program’s priorities for funding include the following:

1) **Populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.**

CPRIT programs must address underserved populations. Underserved populations are subgroups that are disproportionately affected by cancer. CPRIT-funded efforts must address 1 or more of these priority populations:

- Underinsured and uninsured individuals
- Medically unserved or underserved populations
- Racial, ethnic, and cultural minority populations
- Populations with low screening rates, high incidence rates, and high mortality rates, focusing on individuals never before screened or who are significantly out of compliance

with nationally recommended screening guidelines (more than 5 years for breast/cervical cancers).

The age of the priority population and frequency of screening for provision of clinical services described in the application must comply with established and current national guidelines (eg, USPSTF, American Cancer Society).

2) Geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.

While disparities and needs exist across the state, CPRIT will also prioritize applications proposing to serve geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence. For this RFA, projects must propose to serve nonmetropolitan and/or MUAs of the state. In addition, projects addressing areas of emphasis (see [section 2.5](#)) will receive priority consideration.

Geographic and Population Balance in Current CPRIT portfolio

At the programmatic level of review conducted by the Prevention Review Council (see [section 5.1](#)), priority will be given to projects that target geographic regions of the state and population subgroups that are not adequately covered by the current CPRIT Prevention project portfolio (see <https://www.cprit.texas.gov/our-programs/prevention/portfolio-maps> and <https://www.cprit.texas.gov/grants-funded?search=prevention>).

2.5 Specific Areas of Emphasis

Applications addressing any of the services listed in [section 2.2](#) and that are responsive to this RFA will be considered. For those services, CPRIT has identified the following areas of emphasis for this cycle of awards.

<u>Primary Prevention</u>
HPV Vaccination
<ul style="list-style-type: none"> Increasing access to, delivery of, and completion of the HPV vaccine regimen to males and females through evidence-based intervention efforts in all areas of the state.¹
Tobacco Prevention and Control
<ul style="list-style-type: none"> Vulnerable and high-risk populations, including people with mental illness, history of substance abuse, youth, and pregnant women, that have higher tobacco usage rates than the general population. Areas that have higher smoking rates per capita than other areas of the state. Public Health Regions (PHR) 4, 5, and 9 have significantly higher tobacco use among adults than in other regions of the state.
Liver Cancer
<ul style="list-style-type: none"> Screening for HBV infection and HCV infection in populations at high risk of infection and 1-time screening for HCV infection in adults born between 1945 and 1965. Increasing screening rates in Public Health Region (PHR) 8, 9, 10, and 11, where the highest rates of cancer incidence and mortality are found.²
<u>Secondary Prevention - Screening and Early Detection Services</u>
Colorectal Cancer
<ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of colorectal cancer in racial/ethnic populations. Blacks have the highest incidence and mortality rates, followed by non-Hispanic whites and Hispanics.² Increasing screening/detection rates in PHR 1, 2, 4, 5, and 9, where the highest rates of cancer incidence and mortality are found. Decreasing incidence and mortality rates in nonmetropolitan counties. Incidence and mortality rates are higher in nonmetropolitan counties compared with metropolitan counties.²
Breast Cancer
<ul style="list-style-type: none"> Decreasing disparities in mortality rates of breast cancer in racial/ethnic populations. The mortality rate is significantly higher in blacks than in other populations.² Increasing screening/detection rates in medically underserved areas of the state.
Cervical Cancer
<ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of cervical cancer in racial/ethnic populations. Hispanics have the highest incidence rates while blacks have the highest mortality rates.² Increasing screening/detection rates for women in PHR 2, 4, 5, and 11. Incidence is highest in Texas-Mexico border counties (PHR 5 and 11). The mortality rate is highest in PHR 2, 4, 5, and 11.²

2.6 Outcome Metrics

Applicants are required to clearly describe their assessment and evaluation methodology. The applicant is required to describe final outcome measures for the project. Output measures that are associated with the final outcome measures should be identified in the project plan and will serve as a measure of program effectiveness. Planned policy or system changes/improvements should be identified and the plan for qualitative analysis described. **Baseline data for each measure proposed are required.** In addition, applicants should describe how funds from the CPRIT grant will improve outcomes over baseline. If the applicant is not providing baseline data for a measure, the applicant must provide a well-justified explanation and describe clear plans and method(s) of measurement to collect the data necessary to establish a baseline.

Reporting Requirements

Funded projects are required to report quantitative output and outcome metrics (as appropriate for each project) through the submission of quarterly progress reports, annual reports, and a final report. If clinical services are being paid for and provided by others, the applicant is required to report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.

- Quarterly progress report sections include, but are not limited to, the following:
 - Summary page, including narrative on project progress (required)
 - Services, other than clinical services, provided to the public/professionals
 - Actions taken by people/professionals as a result of education or training
 - Clinical services provided (county of residence of client is required)
 - Precursors and cancers detected
- Annual and final progress report sections include, but are not limited to, the following:
 - Key accomplishments, **including qualitative analysis of policy change and/or lasting systems change**
 - Progress toward goals and outcome objectives, including percentage increase over baseline in provision of age- and risk-appropriate comprehensive preventive services to eligible individuals in a defined service area
 - Materials produced and publications
 - Economic impact of the project

2.7 Eligibility

- Eligible applicants include only those with currently or previously funded CPRIT Prevention projects.
- To justify the expansion, applicants must leverage the infrastructure and networks of the most recently funded CPRIT project.
- Applicants may submit an expansion application before the end of the currently funded project but should time their submission during the last year of the current project to ensure minimal overlap of funding. Unexpended funds from the original project will not carry forward to the expansion project. To apply for an expansion of a current project, projects must have at least 1 full year of results and data.
- The applicant must be a Texas-based entity that previously received CPRIT funding through Prevention Program RFAs.
- The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted.
- The designated Program Director (PD) will be responsible for the overall performance of the funded project. The PD must have relevant education and management experience and must reside in Texas during the project performance time.
- The evaluation of the project must be headed by a professional who has demonstrated expertise in the field and who resides in Texas during the time that the project is conducted.
- If the applicant or a partner is an existing Department of State Health Services (DSHS) contractor, CPRIT funds may not be used as a match, and the application must explain how this grant complements or leverages existing state and federal funds. DSHS contractors who also receive CPRIT funds must be in compliance with and fulfill all contractual obligations within CPRIT. CPRIT and DSHS reserve the right to discuss the contractual standing of any contractor receiving funds from both entities.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.

- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- An applicant organization is eligible to receive a grant award only if the applicant certifies that the applicant organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization, (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation created to benefit CPRIT.
- The applicant must report whether the applicant organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way (whether slated to receive salary or compensation under the grant award or not), are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. CPRIT grants are funded on a reimbursement-only basis. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 6](#). All statutory provisions and relevant administrative rules can be found [on the CPRIT website](#).

2.8 Resubmission Policy

- **One resubmission** is permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PD for a project or a change of title for a project that was previously submitted to CPRIT does not constitute a new application; the application would still be considered a resubmission.

- Applicants who choose to resubmit should carefully consider the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. All resubmitted applications should be carefully reconstructed; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes. A 1-page summary of the approach to the resubmission should be included. Resubmitted applications may be assigned to reviewers who did not review the original submission. Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

2.9 Funding Information

Applicants may request any amount of funding up to a maximum of \$2 million in total funding over a maximum of 36 months for an initial expansion. For any subsequent expansion, applicants may request up to a maximum of \$2.5 million in total funding over a maximum of 5 years (60 months). A **significant expansion** in the geographic area and/or clinical services provided for the initial expansion, or number of clinical services delivered for any subsequent expansion, as described in [section 2.3](#), is required. Grant funds may be used to pay for clinical services, navigation services, salary and benefits, project supplies, equipment, costs for outreach and education of populations, and travel of project personnel to project site(s). Applicants must ensure that there is access to treatment services for patients with precancers or cancers that are detected as a result of the program and must describe access to treatment services in their application.

Requests for funds to support construction or renovation or requests to support lobbying will not be approved under this mechanism. Cost sharing for equipment purchases is encouraged. Grantees may request funds for travel for 2 project staff to attend CPRIT's conference.

The budget should be proportional to the number of individuals receiving programs and services, and a significant proportion of funds is expected to be used for program delivery as opposed to program development. In addition, CPRIT funding should not be used to replace existing funding,

supplant funds that would normally be expended by the applicant's organization, or make up for funding reductions from other sources.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

3. KEY DATES

RFA release	August 3, 2020
Online application opens	August 17, 2020, 7 AM central time
Application due	October 5, 2020, 4 PM central time
Application review	November-April 2021
Award notification	May 2021
Anticipated start date	June 1, 2021

Applicants will be notified of peer review panel assignment prior to the peer review meeting dates.

4. APPLICATION SUBMISSION GUIDELINES

4.1 *Instructions for Applicants* document

It is imperative that applicants read the accompanying instructions document for this RFA that will be available August 17, 2020 (<https://CPRITGrants.org>). Requirements may have changed from previous versions.

4.2 Online Application Receipt System

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The PD must create a user account in the system to start and submit an application. The Co-PD, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (an individual who will help manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on August 17, 2020, and must be submitted by 4 PM central time on October 5, 2020. Detailed instructions for submitting an application are in the *Instructions for Applicants* document, posted on CARS.

Submission of an application is considered an acceptance of the terms and conditions of the RFA.

4.3 Submission Deadline Extension

The submission deadline may be extended for 1 or more grant applications upon a showing of good cause. All requests for extension of the submission deadline must be submitted via email to the CPRIT Helpdesk within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

4.4 Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Refer to the *Instructions for Applicants* document for details.

Submissions that are missing 1 or more components or do not meet the eligibility requirements may be administratively withdrawn without review.

4.4.1 Abstract and Significance (5,000 characters)

Clearly explain the problem(s) to be addressed, the approach(es) to the solution, and how the application is responsive to this RFA. In the event that the project is funded, the abstract will be made public; therefore, no proprietary information should be included in this statement. Initial compliance decisions are based in part upon review of this statement.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need in the specific service area. Include rates of incidence, mortality, and screening in the service area compared to overall Texas rates. Describe barriers, plans to overcome these barriers, and the priority population to be served.
- **Overall Project Strategy:** Describe the project and how it will address the identified need. Clearly explain what the project is and what it will specifically do, including the services to be provided and the process/system for delivery of services and outreach to the priority population.
- **Specific Goals:** State specifically the overall goals of the proposed project; include the estimated overall numbers of people (public and/or professionals) reached and people (public and/or professionals) served.

- **Significance and Impact:** Explain how the proposed project, if successful, will have a major impact on cancer prevention and control for the population proposed to be served and for the State of Texas.

4.4.2 Goals and Objectives (700 characters each)

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within both the stated objective **and** the measure (eg, Measure: 2,000 individuals, age 9-12, will initiate HPV vaccination during the grant period). Refer to the *Instructions for Applicants* document for details. The **maximum** number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward outcome goals and objectives. See [Appendix B](#) for instructions on writing outcome goals and objectives.

A baseline and method(s) of measurement are required for each objective. Provide both raw numbers and percent changes for the baseline and target. If a baseline has not been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement.

4.4.3 Project Timeline (2 pages)

Provide a project timeline for project activities that includes deliverables and dates. Use Years 1, 2, 3, and Months 1, 2, 3, etc, as applicable (eg, Year 1, Months 3-5) **instead of specific months or years**. Month 1 is the first full month of the grant award.

4.4.4 Project Plan (12 pages; fewer pages permissible)

The required project plan format follows. Applicants must use the headings outlined below.

Background: Briefly present the rationale behind the proposed service, emphasizing the critical barriers to current service delivery that will be addressed. Identify the evidence-based service to be implemented for the priority population. Describe the race, ethnicity, age, and other defining characteristics of the population to be served.

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the

population and has a high likelihood of success. Baseline data for the priority population and target service area are required where applicable.

Reviewers will be aware of national and state statistics, and these should be used only to compare rates for the proposed service area. Describe the geographic region of the state that the project will serve; maps are encouraged.

Goals and Objectives: Process objectives should be included in the project plan. Outcome goals and objectives will be entered in separate fields in CARS. However, if desired, outcome goals and objectives may be fully repeated or briefly summarized here. See [Appendix B](#) for instructions on writing goals and objectives.

Components of the Project: Clearly describe the need, delivery method, and evidence base (provide references) for the services as well as anticipated results. Be explicit about the base of evidence and any necessary adaptations for the proposed project. Describe why this project is nonduplicative. Describe how the proposed project leverages the infrastructure, networks, and resources that have been put in place by the most recently funded CPRIT project while minimizing startup time.

It is important to distinguish between Texas counties where the project proposes to deliver services and counties of residence of population served (see [Appendix A](#) for definitions and *Instructions for Applicants*). Only counties with service delivery should be listed in the Geographic Area to be Served section of the application. Projecting counties of residence of population served is not required but may be described in the project plan.

Clearly demonstrate the ability to provide the proposed service and describe how results will be improved over baseline and the ability to reach the priority population. Describe the method(s) that will be used to recall for appropriate rescreening those individuals who have been screened through this project. Describe any planned policy changes or system improvements. If clinical services are being paid for and provided by others, the applicant must explain and report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program. Applicants must also clearly and thoroughly describe plans to **ensure access to treatment** services should precancer or cancer be detected.

Evaluation Strategy: A strong commitment to evaluation of the project is required. Describe the plan for outcome and output measurements, including qualitative analysis of policy and system changes. Describe data collection and management methods, data analyses, and anticipated results. Evaluation and reporting of results should be headed by a professional who has demonstrated expertise in the field. If needed, applicants may want to consider seeking expertise at Texas-based academic cancer centers, schools/programs of public health, or the like. Applicants should budget accordingly for the evaluation activity and should involve that professional during grant application preparation to ensure, among other things, that the evaluation plan is linked to the proposed goals and objectives.

Organizational Qualifications and Capabilities: Describe the organization and its track record and success in providing health programs and services. Describe the role and qualifications of the key collaborators/partners in the project. Include information on the organization's financial stability and viability. The applicant should demonstrate how the organizational environment will contribute to a successful project. If equipment or physical resources are required to carry out the project, the applicant should describe the availability of these resources and the organizational capacity to use the equipment. To ensure access to preventive services and reporting of services outcomes, applicants should demonstrate that they have provider partnerships and agreements (via memoranda of understanding) or commitments (via letters of commitment) in place.

CPRIT acknowledges that full maintenance and sustainability of projects when CPRIT funding ends may not be feasible, especially in cases involving the delivery of clinical services. However, it is important to consider sustainability early in the life cycle of a project, particularly regarding organizational characteristics and processes that are modifiable.

Washington University in St Louis has developed a useful tool ([Program Sustainability Assessment Tool](#)) to assess program capacity for sustainability. The tool assesses several factors that contribute to program sustainability. These factors include environmental support, funding stability, partnerships, organizational capacity, program evaluation, program adaptation, communication, and strategic planning. Applicants are not required to use this tool; however, it provides practical guidance on factors that should be considered and should be included in the application to describe a program's organizational capacity for sustainability.

It is expected that steps toward building sustainability capacity for the program will be taken and plans for such be briefly described in the application. The applicant should assess and describe the factors that will contribute to the organization's capacity to facilitate sustainability.

Dissemination and Replication: Dissemination of project results and outcomes, including barriers encountered and successes achieved, is critical to building the evidence base for cancer prevention and control efforts in the state. Dissemination efforts should consider the message, source, audience, and channel (Brownson, R.C., et al. [J Pub Health Manag Pract. 24\(2\):102-111](#), March/April 2018). Dissemination methods may include, but are not limited to, presentations at workshops and seminars, one-on-one meetings, publications, news media, social media, etc.

While passive dissemination methods are common (eg, publications, presentations at professional meetings), plans should include some active dissemination methods (eg, meetings with stakeholders, blogs, social media). Applicants should describe their dissemination plans. The plans should include the kinds of audiences to be targeted and methods for reaching the targeted audiences.

Replication by others is an additional way to disseminate the project. For applicable components, describe how the project or components of the project lend themselves to application by other communities and/or organizations in the state or expansion in the same communities. Describe what components of this project can be adapted to a larger or lower resource setting. Note that some programs may have unique resources and may not lend themselves to replication by others.

4.4.5 People Reached (Indirect Contact)

Provide the estimated overall number of people (members of the public and professionals) to be reached by the funded project. The applicant is required to itemize separately the types of indirect noninteractive education and outreach activities, with estimates, that led to the calculation of the overall estimates provided. Refer to [Appendix A](#) for definitions.

4.4.6 Number of Services Delivered (Direct Contact)

Provide the estimated overall number of services directly delivered to members of the public and to professionals by the funded project. Each individual service should be counted, regardless of the number of services one person receives. The applicant is required to itemize separately the

education, navigation, and clinical activities/services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.7 Number of Clinical Services Delivered

Provide the estimated overall number of clinical services directly delivered to members of the public by the funded project. Each individual clinical service should be counted, regardless of the number of services one person receives. Separately itemize the clinical services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.8 Number of Unique People Served (Direct Contact)

Provide the estimated overall number of unique members of the public and professionals served by the funded project. One person may receive multiple services but should only be counted once here. Refer to [Appendix A](#) for definitions.

4.4.9 References

Provide a concise and relevant list of references cited for the application. The successful applicant will provide referenced evidence and literature support for the proposed services.

4.4.10 Resubmission Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the approach to the resubmission and how reviewers' comments were addressed. Clearly indicate to reviewers how the application has been improved in response to the critiques. Refer the reviewers to specific sections of other documents in the application where further detail on the points in question may be found. When a resubmission is evaluated, responsiveness to previous critiques is assessed.

The summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission; the applicant is not responsible for providing this document.

4.4.11 Most Recently Funded Relevant Project Summary (3 pages)

Upload a summary that outlines the progress made with the most recently funded CPRIT award upon which this expansion is based. Applicants must describe results and outcomes of the most recently funded relevant award and demonstrate why further funding is warranted.

Please note that a different set of reviewers from those assigned to the previously funded application may evaluate this application. Applicants should make it easy for reviewers to compare the most recently funded relevant project with the proposed expansion project.

In the description include the following:

- Describe the evidence-based intervention, its purpose, and how it was implemented in the priority population. Describe any adaptations made for the population served.
- List approved goals and objectives of the most recently funded grant.
- For each objective, provide the following information:
 - Milestones/target dates and target metrics
 - Actual completion dates and metrics
- For the most recently funded project, describe major activities; significant results, including major findings, developments or conclusions (both positive and negative); and key outcomes. If the project has not yet ended, provide projections for completion dates and final metrics. Include a discussion of objectives not fully met. Explain any barriers encountered and strategies used to overcome these.
- Describe steps taken toward sustainability for components of the project. Fully describe systems or policy improvements and enhancements.
- Describe how project results were disseminated or plans for future dissemination of results.

4.4.12 CPRIT Grants Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Provide a listing of **all** projects funded by the CPRIT Prevention program for the PD and the Co-PD, regardless of their connection to this application.

4.4.13 Budget and Justification

Provide a brief outline and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, travel, equipment, supplies, contractual expenses, services delivery, and other expenses. CPRIT funds will be distributed on a reimbursement basis.

Applications requesting more than the maximum allowed cost (total costs) as specified in [section 2.9](#) will be administratively withdrawn.

- **Average Cost per Service:** The average cost per service will be automatically calculated from the total cost of the project divided by the total number of services delivered (refer to [Appendix A](#)). A significant proportion of funds is expected to be used for program delivery as opposed to program development and organizational infrastructure.
- **Average Cost per Person:** The average cost per person will be automatically calculated from the total cost of the project divided by the total number of unique people served (refer to [Appendix A](#)).
- **Average Cost per Clinical Service:** The average cost per clinical service will be automatically calculated from the total cost of the project divided by the total number of clinical services delivered (refer to [Appendix A](#)).
- **Personnel:** The individual salary cap for CPRIT awards is \$200,000 per year. Describe the source of funding for all project personnel where CPRIT funds are not requested.
- **Travel:** PDs and related project staff are expected to attend CPRIT's conference. CPRIT funds may be used to send up to 2 people to the conference.
- **Equipment:** Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application. Justification must be provided for why funding for this equipment cannot be found elsewhere; CPRIT funding should not supplant existing funds. Cost sharing of equipment purchases is strongly encouraged.
- **Services Costs:**
 - CPRIT reimburses for services using Medicare reimbursement rates. Describe the source of funding for all services where CPRIT funds are not requested. If clinical services are being paid for and provided by others, the applicant is required to explain and report on the number of clinical services and patient outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.
 - CPRIT does not allow recovery of costs related to tests that have not been recommended by the USPSTF. In several cases (eg, breast self-exams, clinical breast exams, PSA tests), the Task Force has concluded there is not enough evidence available to draw reliable conclusions about the additional benefits and harms of these tests. (See <https://www.uspreventiveservicestaskforce.org/>)

- **Other Expenses:**
 - **Incentives:** Use of incentives or positive rewards to change or elicit behavior is allowed; however, incentives may only be used based on strong evidence of their effectiveness for the purpose and in the priority population identified by the applicant. CPRIT will not fund cash incentives. The maximum dollar value allowed for an incentive per person, per activity or session, is \$25.
 - **Costs Not Related to Cancer Prevention and Control:** CPRIT does not allow recovery of any costs for services not related to cancer (eg, health physicals, HIV testing).
- **Indirect/Shared Costs:** Texas law limits the amount of grant funds that may be spent on indirect/shared expenses to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in [CPRIT's Administrative Rules](#).

4.4.14 Current and Pending Support and Sources of Funding

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the funding source and duration of **all** current and pending support for the proposed project, including a capitalization table that reflects private investors, if any.

4.4.15 Biographical Sketches

The designated PD will be responsible for the overall performance of the funded project and must have relevant education and management experience. The PD/Co-PD(s) must provide a biographical sketch that describes his or her education and training, professional experience, awards and honors, and publications and/or involvement in programs relevant to cancer prevention and/or service delivery.

- Use the Co-PD Biographical Sketch section **ONLY** if a Co-PD has been identified.
- The evaluation professional must provide a biographical sketch in the Evaluation Professional Biographical sketch section.
- Up to 3 additional biographical sketches for key personnel may be provided in the Key Personnel Biographical Sketch section.

Each biographical sketch must not exceed 2 pages and should use either the “Prevention Programs: Biographical Sketch” template provided on the CARS (<https://CPRITGrants.org>) or the NIH Biographical Sketch format. Only biographical sketches will be accepted; do not submit resumes and/or CVs. If a position is not yet filled, please upload a job description.

4.4.16 Collaborating Organizations

List all key participating organizations that will partner with the applicant organization to provide 1 or more components essential to the success of the program (eg, evaluation, clinical services, recruitment to screening). Please be sure to also include anyone listed as key personnel and/or listed under the Current & Pending Support section.

4.4.17 Letters of Commitment (10 pages)

Applicants should provide letters of commitment and/or memoranda of understanding from community organizations, key faculty, or any other component essential to the success of the program. Letters should be specific to the contribution of each organization.

5. APPLICATION REVIEW

5.1 Review Process Overview

All eligible applications will be reviewed using a 2-stage peer review process: (1) evaluation of applications by peer review panels and (2) prioritization of grant applications by the Prevention Review Council. In the first stage, applications will be evaluated by an independent review panel using the criteria listed below. In the second stage, applications judged to be meritorious by review panels will be evaluated by the Prevention Review Council and recommended for funding based on comparisons with applications from all of the review panels and programmatic priorities.

Programmatic considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service. The scores are only 1 factor considered during programmatic review. At the programmatic level of review, priority will be given to proposed projects that target geographic regions of the state or population subgroups that are not well represented in the current CPRIT Prevention project portfolio.

Applications approved by Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the

Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

Each stage of application review is conducted confidentially, and all CPRIT Peer Review Panel members, Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Peer Review Panel members and Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer Review Panel members are listed by panel on CPRIT's website. **By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).**

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Review Panel member, or a Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of

interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

5.2 Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, identified below. Review panels consisting of experts in the field and advocates will evaluate and score each primary criterion and subsequently assign an overall score that reflects an overall assessment of the application. The overall evaluation score will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application and responsiveness to the RFA priorities.

5.2.1 Primary Evaluation Criteria

Impact

- Do the proposed services address an important problem or need in cancer prevention and control? Do the proposed project strategies support desired outcomes in cancer incidence, morbidity, and/or mortality? Do the proposed project strategies reach a priority population (eg, low income, minority, rural) at high risk of cancer?
- For the proposed expansion, does the project build on its initial results (baseline)? Does it go beyond the initial project to address what the applicant has learned or explore new partnerships, new audiences, or improvements to systems?
- Will the project reach and serve/impact an appropriate number of people based on the budget allocated to providing services and the cost of providing services?
- If applicable, have partners demonstrated that the collaborative effort will provide a greater impact on cancer prevention and control than the applicant organization's effort separately?
- Does the program address adaptation, if applicable, of the evidence-based intervention to the priority population? Is the base of evidence clearly explained and referenced?

Project Strategy and Feasibility

- Does the proposed project provide services specified in the RFA?
- Are the overall program approach, strategy, and design clearly described and supported by established theory and practice? Are the proposed objectives and activities feasible within

the duration of the award? Has the applicant convincingly demonstrated the short- and long-term impacts of the project?

- Has the applicant proposed policy changes and/or system improvements?
- Are possible barriers addressed and approaches for overcoming them proposed?
- Are the priority population and culturally appropriate methods to reach the priority population clearly described?
- If applicable, does the application demonstrate the availability of resources and expertise to provide case management, including follow-up for abnormal results and access to treatment?
- Does the program leverage partners and resources to maximize the reach of the services proposed? Does the program leverage and complement other state, federal, and nonprofit grants?

Outcomes Evaluation

- Are specific goals and measurable **outcome** objectives for each year of the project provided?
- Are the proposed **outcome** measures appropriate for the services provided?
- Are the proposed outcome objectives realistic, based upon the project timeline and resources being invested?
- Does the application provide a detailed plan for data collection, data management, and data analyses?
- Do the proposed evaluation professionals demonstrate adequate and appropriate evaluation expertise and time commitment?

Organizational Qualifications and Capabilities

- Do the organization and its collaborators/partners demonstrate the ability to provide the proposed preventive services?
- Does the described role of each collaborating organization make it clear that each organization adds value to the project and is committed to working together to implement the project?

- Have the appropriate personnel been recruited to design, implement, evaluate, and complete the project?
- Is the organization structurally and financially stable and viable?
- Does the applicant describe their current activities and the program's organizational capacity for sustainability?
- Does the applicant describe steps that will be taken toward building internal capacity and partnerships?
- Does the applicant describe a plan for systems changes that are sustainable over time; eg, improve results, provider practice, efficiency, cost-effectiveness?

5.2.2 Secondary Evaluation Criteria

Budget

- Is the budget appropriate and reasonable for the scope and services of the proposed work?
- Is the cost per person served appropriate and reasonable?
- Is the proportion of the funds allocated for direct services reasonable?
- Is the project a good investment of Texas public funds?

Dissemination and Replication

- Are plans for dissemination of the project's results and outcomes, including target audiences and methods clearly described?
- Are active dissemination strategies included and described in the plan?
- Does the applicant describe whether and/or how the project lends itself to replication of all or some components of the project by others in the state?

6. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use

shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in [CPRIT's Administrative Rules](#). Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires the PD of the award to submit quarterly, annual, and final progress reports. These reports summarize the progress made toward project goals and address plans for the upcoming year and performance during the previous year(s). In addition, quarterly fiscal reporting and reporting on selected metrics will be required per the instructions to award recipients. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract.

7. CONTACT INFORMATION

7.1 Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding the scope and focus of applications. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document (posted on August 17, 2020), which provides a step-by-step guide to using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

7.2 Program Questions

Questions regarding the CPRIT Prevention program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Prevention Program Office.

Tel: 512-305-8417

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

8. RESOURCES

- The Texas Cancer Registry. <https://www.dshs.texas.gov/tcr> or contact the Texas Cancer Registry at the Department of State Health Services.
- The Community Guide. <https://www.thecommunityguide.org/>
- Cancer Control P.L.A.N.E.T. <http://cancercontrolplanet.cancer.gov>
- Guide to Clinical Preventive Services: Recommendations of the U.S. Preventive Services Task Force. <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/>
- Brownson, R.C., Colditz G.A., and Proctor, E.K. (Editors). *Dissemination and Implementation Research in Health: Translating Science to Practice*. Oxford University Press, March 2012
- Program Sustainability Assessment Tool, copyright 2012, Washington University, St Louis, MO, <https://www.sustaintool.org/about-us/>
- Getting the Word Out: New Approaches for Disseminating Public Health Science Ross C. Brownson, PhD; Amy A. Eyler, PhD; Jenine K. Harris, PhD; Justin B. Moore, PhD, MS; Rachel G. Tabak, PhD, RD, **Journal of Public Health Management & Practice**. 24(2):102-111, March/April 2018. https://journals.lww.com/jphmp/Fulltext/2018/03000/Getting_the_Word_Out__New_Approaches_for.4.aspx
- Centers for Disease Control and Prevention: The Program Sustainability Assessment Tool: A New Instrument for Public Health Programs. http://www.cdc.gov/pcd/issues/2014/13_0184.htm
- Centers for Disease Control and Prevention: Using the Program Sustainability Tool to Assess and Plan for Sustainability. http://www.cdc.gov/pcd/issues/2014/13_0185.htm
- Cancer Prevention and Control Research Network: Putting Public Health Evidence in Action Training Workshop. <http://cpcrn.org/pub/evidence-in-action/>
- Centers for Disease Control and Prevention. Distinguishing Public Health Research and Public Health Nonresearch. <https://www.cdc.gov/os/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

9. REFERENCES

1. <http://www.cdc.gov/hpv/parents/questions-answers.html>
2. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services. <https://www.cancer-rates.info/tx/>

APPENDIX A: KEY TERMS

- **Activities:** A listing of the “who, what, when, where, and how” for each objective that will be accomplished.
- **Capacity Building:** Any activity (eg, training, identification of alternative resources, building internal assets) that builds durable resources and enables the grantee’s setting or community to continue the delivery of some or all components of the evidence-based intervention.
- **Clinical Services:** Number of clinical services such as screenings, diagnostic tests, vaccinations, counseling sessions, or other evidence-based preventive services delivered by a health care practitioner in an office, clinic, or health care system. Other examples include genetic testing or assessments, physical rehabilitation, tobacco cessation counseling or nicotine replacement therapy, case management, primary prevention clinical assessments, and family history screening.
- **Counties of Residence of Population Served:** Counties where the project does not plan to have a physical presence but people who live in these counties have received services. This includes counties of residence of people or places of business of professionals who participate in or receive education, navigation or clinical services. Examples include people traveling to receive services as a result of marketing and programs accessible via the website or social media. These counties may be described in the project plan and must be reported in the quarterly progress report.
- **Counties with Service Delivery:** Counties where an activity or service will occur and the project has a physical presence for the services provided. Examples include onsite outreach and educational activities and delivery of clinical services through clinics, mobile vans, or telemedicine consults. These counties must be entered in the Geographic Area to be Served section of the application.
- **Education Services:** Number of evidence-based, culturally appropriate cancer prevention and control education and outreach services delivered to the public and to health care professionals. Examples include education or training sessions (group or individual), focus groups, and knowledge assessments. One individual may receive multiple education services.

- **Evidence-Based Program:** A program that is validated by some form of documented research or applied evidence. CPRIT’s website provides links to resources for evidence-based strategies, programs, and clinical recommendations for cancer prevention and control. To access this information, visit <https://www.cprit.state.tx.us/our-programs/prevention>.
- **Goals:** Broad statements of general purpose to guide planning. Outcome goals should be few in number and focus on aspects of highest importance to the project. ([Appendix B](#))
- **Integration:** The extent the evidence-based intervention is integrated within the culture of the grantee’s setting or community through policies and practice.
- **Navigation Services:** Number of unique activities/services that offer assistance to help overcome health care system barriers in a timely and informative manner and facilitate cancer screening and diagnosis to improve health care access and outcomes (Examples include patient reminders, transportation assistance, and appointment scheduling assistance). One individual may receive multiple navigation services.
- **Number of Clinical Services:** Number of [clinical services](#) delivered directly to members of the public by the funded project. One individual may receive multiple clinical services.
- **Number of Services (Direct Contact):** Number of services delivered directly to members of the public and/or professionals—direct, interactive public or professional education, outreach, training, navigation service, or clinical service, such as live educational and/or training sessions, vaccine administration, screening, diagnostics, case management/navigation services, and physician consults. One individual may receive multiple services.
- **Objectives:** Specific, measurable, actionable, realistic, and timely projections for outcomes; example: “Increase screening service provision in X population from Y% to Z% by 20xx.” Baseline data for the priority population must be included as part of each objective. ([Appendix B](#)). The proposed metric should be included in **both** the objective and the measure (eg, Measure: 2,000 individuals, age 9-12, will initiate HPV vaccination during the grant period).
- **People Reached (Indirect Contact):** Number of members of the public and/or professionals reached via indirect noninteractive public or professional education and

outreach activities, such as mass media efforts, brochure distribution, public service announcements, newsletters, and journals. (This category includes individuals who would be reached through activities that are directly funded by CPRIT as well as individuals who would be reached through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project).

- **Unique People Served (Direct Contact):** Number of unique members of the public and/or professionals served via direct, interactive public or professional education, outreach, training, navigation service, or clinical service. This category includes individuals who would be served through activities that are directly funded by CPRIT as well as individuals who would be served through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project.

APPENDIX B: WRITING GOALS AND OBJECTIVES

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within **both** the stated objective and the measure (eg, Measure: 2,000 individuals, age 9-12, will initiate HPV vaccination during the grant period).

The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives.

The following guide has been adapted with permission from Appalachia Community Cancer Network, NIH Grant U54 CA 153604:

Develop well-defined goals and objectives.

Goals provide a roadmap or plan for where a group wants to go. Goals can be long term (over several years) or short term (over several months). Goals should be based on needs of the community and evidence-based data.

Goals should be:

- Believable – situations or conditions that the group believes can be achieved
- Attainable – possible within a designated time
- Tangible – capable of being understood or realized
- On a timetable – with a completion date
- Win-Win – beneficial to individual members and the coalition

Objectives are measurable steps toward achieving the goal. They are clear statements of specific activities required to achieve the goal. The best objectives have several characteristics in common – S.M.A.R.T. + C:

- Specific – they tell how much (number or percent), who (participants), what (action or activity), and by when (date)
 - Example: 115 uninsured individuals age 50 and older will complete colorectal cancer screening by March 31, 2018.
- Measurable – specific measures that can be collected, detected, or obtained to determine successful attainment of the objective.

- Example: How many screened at an event? How many completed pre/post assessment?
- Achievable – not only are the objectives themselves possible, it is likely that your organization will be able to accomplish them
- Relevant to the mission – your organization has a clear understanding of how these objectives fit in with the overall vision and mission of the group
- Timed – developing a timeline is important for when your task will be achieved
- Challenging – objectives should stretch the group to aim on significant improvements that are important to members of the community

Evaluate and refine your objectives

Review your developed objectives and determine the type and level of each using the following information:

There are 2 types of objectives:

- Outcome objectives – measure the “what” of a program; should be in the Goals and Objectives form (see [section 4.4.2](#))
- Process objectives – measure the “how” of a program; should be in the project plan only (see [section 4.4.4](#))

There are 3 levels of objectives:

- Community-level – objectives measure the planned community change
- Program impact – objectives measure the impact the program will have on a specific group of people
- Individual – objectives measures participant changes resulting from a specific program, using these factors:
 - Knowledge – understanding (know screening guidelines; recall the number to call for screening)
 - Attitudes – feeling about something (will consider secondhand smoke dangerous; believe eating 5 or more fruits and vegetable is important)
 - Skills – the ability to do something (complete fecal occult blood test)
 - Intentions – regarding plan for future behavior (will agree to talk to the doctor, will plan to schedule a Pap test)

- Behaviors (past or current) – to act in a particular way (will exercise 30+ minutes a day, will have a mammogram)

Well-defined outcome goals and objectives can be used to track, measure, and report progress toward achievement.

Summary Table

	Outcome – Use in Goals and Objectives	Process – Use in Project Plan only
Community-level	<p>WHAT will change in a community</p> <p><i>Example: As a result of CPRIT funding, FIT (fecal immunochemical tests) will be available to 1,500 uninsured individuals age 50 and over through 10 participating local clinics and doctors.</i></p>	<p>HOW the community change will come about</p> <p><i>Example: Contracts will be signed with participating local providers to enable uninsured individuals over age 50 have access to free colorectal cancer screening in their communities.</i></p>
Program impact	<p>WHAT will change in the target group as a result of a particular program</p> <p><i>Example: As a result of this project, 200 uninsured women between 40 and 49 will receive free breast and cervical cancer screening.</i></p>	<p>HOW the program will be implemented to affect change in a group/population</p> <p><i>Example: 2,000 female clients, between 40 and 49, will receive a letter inviting them to participate in breast and cervical cancer screening.</i></p>
Individual	<p>WHAT an individual will learn as a result of a particular program, or WHAT change an individual will make as a result of a particular program</p> <p><i>Example: As a result of one-to-one education of 500 individuals, at least 20% of participants will participate in a smoking cessation program to quit smoking.</i></p>	<p>HOW the program will be implemented to affect change in an individual's knowledge or actions</p> <p><i>Example: As a result of one-to-one counseling, all participants will identify at least 1 smoking cessation service and 1 smoking cessation aid.</i></p>

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

21.1 Prevention Review Panel - 1 (21.1 PRV-P1)

Observation Report

Report No. 2021-01-21 21.1_PRV-P1
Program Name: Prevention
Panel Name: 21.1 Prevention Review Panel - 1 (21.1_PRV-P1)
Panel Date: January 19, 2021
Report Date: January 25, 2021

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.1 Prevention Review Panel - 1 (21.1_PRV-P1) meeting. The meeting was chaired by R. Brownson and conducted via video conference on January 19, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number of applications: Eleven (11) applications were discussed, and one (1) application was not discussed
- Panelists: One (1) panel chair, six (6) expert reviewers and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflicts of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive name that appears to be 'Mara Ash'.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

21.1 Prevention Review Council (21.1_PRC-M1)

Observation Report

Report No. 2021-03-04 21.1_PRC-M1
Program Name: Prevention
Panel Name: 21.1 Prevention Review Council (21.1_PRC-M1)
Panel Date: March 4, 2021
Report Date: March 16, 2020

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 21.1 Prevention Review Council (21.1_PRC-M1) meeting. The meeting was chaired by Stephen Wyatt and conducted via teleconference on March 4, 2021.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: eleven (11) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were zero (0) Conflict of Interest (COI) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Prevention Cycle 21.1

Prevention Cycle 21.1 Awards Announced at the May 19, 2021, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 21.1 include *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant/PD	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee:			
No conflicts reported.			
Applications not considered by the PIC or Oversight Committee:			
No conflicts reported.			

T.A.C. Section 702.19 Waiver



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: T.A.C. § 702.19 STANDING WAIVER FOR FY 2021
DATE: AUGUST 28, 2020

Summary

This is to notify the Oversight Committee that pursuant to the authority provided to the Chief Executive Officer in T.A.C. § 702.19(e), I grant CPRIT's Chief Prevention Officer Ramona Magid a waiver from the general prohibition against communicating with grant applicants. The waiver is applicable for FY 2021. Unlike the two communication waivers I granted Ms. Magid for each FY 2020 review cycle, this standing FY 2021 waiver will be effective for both review cycles planned for FY 2021. No Oversight Committee action related to this waiver is necessary.

Background and Discussion

The Chief Prevention Officer is a statutorily mandated member of the Program Integration Committee (PIC). Texas Administrative Code § 702.19 prohibits substantive communication between the grant applicant and a member of the peer review panel, the PIC, or the Oversight Committee while the application is pending a final decision. The restriction on communication prevents even the appearance of unequal treatment during the grant review process.

Traditionally, a chief program officer leads each CPRIT program with the assistance of a program manager. The program manager fields inquiries from and provides technical help to applicants completing their CPRIT grant applications. I promoted Ms. Magid to the Chief Prevention Officer position upon Dr. Becky Garcia's retirement in June 2019. However, the prevention program manager position has remained vacant since Ms. Magid's promotion. Until CPRIT fills the program manager position, she is the sole point of contact for the prevention program. The communication waiver is necessary so that Ms. Magid can assist grant applicants who have questions during the application process.

I previously granted Ms. Magid separate waivers for the two review cycles of FY 2020. It is unlikely that CPRIT will fill the prevention program manager position in FY 2021. Accordingly, I am granting a standing waiver for Ms. Magid for FY 2021 as long as she remains the sole point of contact for the prevention program. Approving this standing waiver does not favor any grant applicant over another. Ms. Magid will provide technical assistance only and will not comment on the substance of a grant application. CPRIT will include this waiver in the grant record for the FY 2021 prevention grant applications.

De-Identified Overall Evaluation Scores

Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

Prevention Cycle 21.1

The Prevention Review Council (PRC) recommended two applications to the PIC with the same score as an application on which the PRC took no action. As allowed in 25 T.A.C. § 703.6(d)(1), the PRC's numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities, programmatic review criteria, and the overall program portfolio.

Application ID	Final Overall Evaluation Score
PP210003*	1.4
PP210004*	2.3
PP210005*	2.9
PP210016*	3.3
PP210017*	3.3
a ¹	3.3
b	3.5
c	3.6
d	3.8
e	3.8
f	3.9
g	4.8

* Recommended for funding

¹ The PRC took no action on this application.

Final Overall Evaluation Scores and Rank Order Scores

Dee Margo
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to dee@deemargo.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Mr. Margo,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the cycle 21.1 Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations (EPS) awards.

The PRC met on March 4, 2021 to consider the applications recommended by the peer review panel following their January 19 meeting. The PRC recommends 5 projects totaling \$11,202,949.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cycle 21.1 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP210003	EPS	Taking Texas Tobacco Free among Substance Users within Community-based Healthcare Settings in Rural and Medically Underserved Areas Across Texas	Reitzel, Lorraine R	University of Houston	1.4	1	\$1,998,572
PP210004	EPS	BEST 3: The Breast Cancer Education Screening and Navigation Program in West and South Texas.	Shokar, Navkiran K	Texas Tech University Health Sciences Center at El Paso	2.3	2	\$2,500,000
PP210005	EPS	Southwest Coalition for Colorectal Cancer Screening (SuCCCeS) 2	Shokar, Navkiran K	Texas Tech University Health Sciences Center at El Paso	2.9	3	\$2,500,000
PP210016	EPS	Hep C - C.A.R.E (Colonias Advancing & Restoring Esperanza)	Villarreal, Roberto	University Health System	3.3	4	\$1,712,190
PP210017	EPS	Get F.I.T. to Stay Fit, Stepping up to Fight Colorectal Cancer in the Panhandle	Obokhare , Izi D	Texas Tech University Health Sciences Center	3.3	5	\$2,492,187

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210003
Expansion of Cancer Prevention Services to
Rural and Medically Underserved Populations

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations* Request for Applications (RFA). CPRIT received 12 applications in response to this RFA. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.

The Prevention Review Council (PRC) recommended two applications with the same score as an application on which the PRC took no action. As allowed in 25 T.A.C. § 703.6(d)(1), the PRC’s numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities, programmatic review criteria, and the overall program portfolio.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”

Wayne R. Roberts

Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 6 day of May, 2021, by WAYNE R. ROBERTS.

Melanie Cleveland

Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations
APPLICATION ID: PP210003
APPLICATION TITLE: Taking Texas Tobacco Free among Substance Users within Community-based Healthcare Settings in Rural and Medically Underserved Areas Across Texas
APPLICANT NAME: Reitzel, Lorraine R
ORGANIZATION: University of Houston
PANEL NAME: 21.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	07/14/2020	02/22/2021
	RFA published in Texas.gov eGrants	08/03/2020	02/22/2021
	CPRIT Application Receipt System (CARS) opened	08/17/2020	02/22/2021
	CPRIT Application Receipt System (CARS) closed	10/05/2020	02/22/2021
	Date application submitted	09/11/2020	02/23/2021
	Method of submission	CARS	02/23/2021
	Within receipt period	YES	02/23/2021
	Request for extension to submit application after CARS closed	NA	02/23/2021
	Request for extension for late application submission accepted	NA	02/23/2021
	Receipt, Referral, and Assignment	Administrative review notification	NA
Donation(s) made to CPRIT / foundation		NO	02/23/2021
Assigned to primary reviewers		11/03/2020	02/23/2021
Applicant notified of review panel assignment		11/02/2020	02/22/2021
Primary Reviewer 1 COI signed		10/26/2020	02/23/2021
Primary (Advocate) Reviewer 2 COI signed		10/26/2020	02/23/2021
Primary Reviewer 3 COI signed		10/23/2020	02/23/2021
Primary Reviewer 4 COI signed		10/25/2020	02/23/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	12/17/2020
	Primary (Advocate) Reviewer 2 critique submitted	12/16/2020	02/23/2021
	Primary Reviewer 3 critique submitted	12/02/2020	02/23/2021
	Primary Reviewer 4 critique submitted	11/13/2020	02/23/2021
	COI indicated by non-primary reviewer	NONE	02/23/2021
	COI recused from participation	NA	02/23/2021
	Discussed at Peer Review Meeting	YES	02/23/2021
	Peer Review Meeting	01/19/2021	02/23/2021
	Post review statements signed	01/19/2021	02/23/2021
	Third Party Observer Report	01/25/2021	02/23/2021
	Score report delivered to CPO	01/28/2021	02/23/2021
	Recommended for PRC review	YES	02/23/2021
	Final PRC Recommendation	COI indicated by PRC member	NONE
COI recused from participation		NA	03/24/2021
PRC Meeting		03/04/2021	03/24/2021
Third Party Observer Report		01/25/2021	04/12/2021
Recommended for grant award		YES	03/24/2021
PRC Chair Notification to PIC and OC		03/09/2021	04/22/2021
PIC Review	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NA	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210004
Expansion of Cancer Prevention Services to
Rural and Medically Underserved Populations

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations* Request for Applications (RFA). CPRIT received 12 applications in response to this RFA. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the “CEO Affidavit-Supporting Information” packet.


The Prevention Review Council (PRC) recommended two applications with the same score as an application on which the PRC took no action. As allowed in 25 T.A.C. § 703.6(d)(1), the PRC’s numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities, programmatic review criteria, and the overall program portfolio.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT’s administrative rules. This statement is true.”


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS. 


Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations
APPLICATION ID: PP210004
APPLICATION TITLE: BEST 3: The Breast Cancer Education Screening and Navigation Program in West and South Texas.
APPLICANT NAME: Shokar, Navkiran K
ORGANIZATION: Texas Tech University Health Sciences Center at El Paso
PANEL NAME: 21.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	07/14/2020	02/22/2021
	RFA published in Texas.gov eGrants	08/03/2020	02/22/2021
	CPRIT Application Receipt System (CARS) opened	08/17/2020	02/22/2021
	CPRIT Application Receipt System (CARS) closed	10/05/2020	02/22/2021
	Date application submitted	10/01/2020	02/23/2021
	Method of submission	CARS	02/23/2021
	Within receipt period	YES	02/23/2021
	Request for extension to submit application after CARS closed	NA	02/23/2021
	Request for extension for late application submission accepted	NA	02/23/2021
	Receipt, Referral, and Assignment	Administrative review notification	10/21/2020
Donation(s) made to CPRIT / foundation		NO	02/23/2021
Assigned to primary reviewers		11/03/2020	02/23/2021
Applicant notified of review panel assignment		11/02/2020	02/22/2021
Primary Reviewer 1 COI signed		10/23/2020	02/23/2021
Primary (Advocate) Reviewer 2 COI signed		10/23/2020	02/23/2021
Primary Reviewer 3 COI signed		10/24/2020	02/23/2021
Primary Reviewer 4 COI signed		10/27/2020	02/23/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	12/13/2020
	Primary (Advocate) Reviewer 2 critique submitted	12/16/2020	02/23/2021
	Primary Reviewer 3 critique submitted	12/15/2020	02/23/2021
	Primary Reviewer 4 critique submitted	12/16/2020	02/23/2021
	COI indicated by non-primary reviewer	NONE	02/23/2021
	COI recused from participation	NA	02/23/2021
	Discussed at Peer Review Meeting	YES	02/23/2021
	Peer Review Meeting	01/19/2021	02/23/2021
	Post review statements signed	01/19/2021	02/23/2021
	Third Party Observer Report	01/25/2021	02/23/2021
	Score report delivered to CPO	01/28/2021	02/23/2021
	Recommended for PRC review	YES	02/23/2021
	Final PRC Recommendation	COI indicated by PRC member	NONE
COI recused from participation		NA	03/24/2021
PRC Meeting		03/04/2021	03/24/2021
Third Party Observer Report		01/25/2021	04/12/2021
Recommended for grant award		YES	03/24/2021
PRC Chair Notification to PIC and OC		03/09/2021	04/22/2021
PIC Review	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NA	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210005
Expansion of Cancer Prevention Services to
Rural and Medically Underserved Populations

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations* Request for Applications (RFA). CPRIT received 12 applications in response to this RFA. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle


- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the "CEO Affidavit-Supporting Information" packet.

The Prevention Review Council (PRC) recommended two applications with the same score as an application on which the PRC took no action. As allowed in 25 T.A.C. § 703.6(d)(1), the PRC's numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities, programmatic review criteria, and the overall program portfolio.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations
APPLICATION ID: PP210005
APPLICATION TITLE: Southwest Coalition for Colorectal Cancer Screening (SuCCCeS) 2
APPLICANT NAME: Shokar, Navkiran K
ORGANIZATION: Texas Tech University Health Sciences Center at El Paso
PANEL NAME: 21.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	07/14/2020	02/22/2021
	RFA published in Texas.gov eGrants	08/03/2020	02/22/2021
	CPRIT Application Receipt System (CARS) opened	08/17/2020	02/22/2021
	CPRIT Application Receipt System (CARS) closed	10/05/2020	02/22/2021
	Date application submitted	10/02/2020	02/23/2021
	Method of submission	CARS	02/23/2021
	Within receipt period	YES	02/23/2021
	Request for extension to submit application after CARS closed	NA	02/23/2021
	Request for extension for late application submission accepted	NA	02/23/2021
	Receipt, Referral, and Assignment	Administrative review notification	10/21/2020
Donation(s) made to CPRIT / foundation		NO	02/23/2021
Assigned to primary reviewers		11/03/2020	02/23/2021
Applicant notified of review panel assignment		11/02/2020	02/22/2021
Primary Reviewer 1 COI signed		10/27/2020	02/23/2021
Primary (Advocate) Reviewer 2 COI signed		10/26/2020	02/23/2021
Primary Reviewer 3 COI signed		10/23/2020	02/23/2021
Primary Reviewer 4 COI signed		10/23/2020	02/23/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	12/15/2020
	Primary (Advocate) Reviewer 2 critique submitted	12/16/2020	02/23/2021
	Primary Reviewer 3 critique submitted	12/09/2020	02/23/2021
	Primary Reviewer 4 critique submitted	12/06/2020	02/23/2021
	COI indicated by non-primary reviewer	NONE	02/23/2021
	COI recused from participation	NA	02/23/2021
	Discussed at Peer Review Meeting	YES	02/23/2021
	Peer Review Meeting	01/19/2021	02/23/2021
	Post review statements signed	01/19/2021	02/23/2021
	Third Party Observer Report	01/25/2021	02/23/2021
	Score report delivered to CPO	01/28/2021	02/23/2021
	Recommended for PRC review	YES	02/23/2021
	Final PRC Recommendation	COI indicated by PRC member	NONE
COI recused from participation		NA	03/24/2021
PRC Meeting		03/04/2021	03/24/2021
Third Party Observer Report		01/25/2021	04/12/2021
Recommended for grant award		YES	03/24/2021
PRC Chair Notification to PIC and OC		03/09/2021	04/22/2021
PIC Review	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NA	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210016
Expansion of Cancer Prevention Services to
Rural and Medically Underserved Populations

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations* Request for Applications (RFA). CPRIT received 12 applications in response to this RFA. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle


- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the "CEO Affidavit-Supporting Information" packet.

The Prevention Review Council (PRC) recommended two applications with the same score as an application on which the PRC took no action. As allowed in 25 T.A.C. § 703.6(d)(1), the PRC's numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities, programmatic review criteria, and the overall program portfolio.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations
APPLICATION ID: PP210016
APPLICATION TITLE: Hep C - C.A.R.E (Colonias Advancing & Restoring Esperanza)
APPLICANT NAME: Villarreal, Roberto
ORGANIZATION: University Health System
PANEL NAME: 21.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	07/14/2020	02/22/2021
	RFA published in Texas.gov eGrants	08/03/2020	02/22/2021
	CPRIT Application Receipt System (CARS) opened	08/17/2020	02/22/2021
	CPRIT Application Receipt System (CARS) closed	10/05/2020	02/22/2021
	Date application submitted	10/05/2020	02/23/2021
	Method of submission	CARS	02/23/2021
	Within receipt period	YES	02/23/2021
	Request for extension to submit application after CARS closed	NA	02/23/2021
	Request for extension for late application submission accepted	NA	02/23/2021
	Receipt, Referral, and Assignment	Administrative review notification	NA
Donation(s) made to CPRIT / foundation		NO	02/23/2021
Assigned to primary reviewers		11/03/2020	02/23/2021
Applicant notified of review panel assignment		11/02/2020	02/22/2021
Primary Reviewer 1 COI signed		10/23/2020	02/23/2021
Primary (Advocate) Reviewer 2 COI signed		10/26/2020	02/23/2021
Primary Reviewer 3 COI signed		10/23/2020	02/23/2021
Primary Reviewer 4 COI signed		10/25/2020	02/23/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	12/17/2020
	Primary (Advocate) Reviewer 2 critique submitted	12/16/2020	02/23/2021
	Primary Reviewer 3 critique submitted	12/12/2020	02/23/2021
	Primary Reviewer 4 critique submitted	11/17/2020	02/23/2021
	COI indicated by non-primary reviewer	NONE	02/23/2021
	COI recused from participation	NA	02/23/2021
	Discussed at Peer Review Meeting	YES	02/23/2021
	Peer Review Meeting	01/19/2021	02/23/2021
	Post review statements signed	01/19/2021	02/23/2021
	Third Party Observer Report	01/25/2021	02/23/2021
	Score report delivered to CPO	01/28/2021	02/23/2021
	Recommended for PRC review	YES	02/23/2021
	Final PRC Recommendation	COI indicated by PRC member	NONE
COI recused from participation		NA	03/24/2021
PRC Meeting		03/04/2021	03/24/2021
Third Party Observer Report		01/25/2021	04/12/2021
Recommended for grant award		YES	03/24/2021
PRC Chair Notification to PIC and OC		03/09/2021	04/22/2021
PIC Review	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NA	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP210017
Expansion of Cancer Prevention Services to
Rural and Medically Underserved Populations

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations* Request for Applications (RFA). CPRIT received 12 applications in response to this RFA. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle


- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

On August 28, 2020, I notified Oversight Committee members that I granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the "CEO Affidavit-Supporting Information" packet.

The Prevention Review Council (PRC) recommended two applications with the same score as an application on which the PRC took no action. As allowed in 25 T.A.C. § 703.6(d)(1), the PRC's numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities, programmatic review criteria, and the overall program portfolio.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC. I note that the following PIC members have approved conflict of interest waivers on file for FY2021: Dr. John Hellerstedt, Department of State Health Services Commissioner, and Dr. James Willson, Chief Scientific Officer, applicable to the conflict of interest specified by V.T.C.A., Health & Safety Code § 102.106(c)(3).

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 6 day of May, 2021,
by WAYNE R. ROBERTS.



Melanie Cleveland
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 05/06/2021 14:30 PM

FY: 2021
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations
APPLICATION ID: PP210017
APPLICATION TITLE: Get F.I.T. to Stay Fit, Stepping up to Fight Colorectal Cancer in the Panhandle
APPLICANT NAME: Obokhare , Izi D
ORGANIZATION: Texas Tech University Health Sciences Center
PANEL NAME: 21.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	07/14/2020	02/22/2021
	RFA published in Texas.gov eGrants	08/03/2020	02/22/2021
	CPRIT Application Receipt System (CARS) opened	08/17/2020	02/22/2021
	CPRIT Application Receipt System (CARS) closed	10/05/2020	02/22/2021
	Date application submitted	10/05/2020	02/23/2021
	Method of submission	CARS	02/23/2021
	Within receipt period	YES	02/23/2021
	Request for extension to submit application after CARS closed	NA	02/23/2021
	Request for extension for late application submission accepted	NA	02/23/2021
	Receipt, Referral, and Assignment	Administrative review notification	NA
Donation(s) made to CPRIT / foundation		NO	02/23/2021
Assigned to primary reviewers		11/03/2020	02/23/2021
Applicant notified of review panel assignment		11/02/2020	02/22/2021
Primary Reviewer 1 COI signed		10/23/2020	02/23/2021
Primary (Advocate) Reviewer 2 COI signed		10/23/2020	02/23/2021
Primary Reviewer 3 COI signed		10/27/2020	02/23/2021
Primary Reviewer 4 COI signed		10/24/2020	02/23/2021
Peer Review Meeting		Primary Reviewer 1 critique submitted	12/14/2020
	Primary (Advocate) Reviewer 2 critique submitted	12/08/2020	02/23/2021
	Primary Reviewer 3 critique submitted	12/16/2020	02/23/2021
	Primary Reviewer 4 critique submitted	12/15/2020	02/23/2021
	COI indicated by non-primary reviewer	NONE	02/23/2021
	COI recused from participation	NA	02/23/2021
	Discussed at Peer Review Meeting	YES	02/23/2021
	Peer Review Meeting	01/19/2021	02/23/2021
	Post review statements signed	01/19/2021	02/23/2021
	Third Party Observer Report	01/25/2021	02/23/2021
	Score report delivered to CPO	01/28/2021	02/23/2021
	Recommended for PRC review	YES	02/23/2021
	Final PRC Recommendation	COI indicated by PRC member	NONE
COI recused from participation		NA	03/24/2021
PRC Meeting		03/04/2021	03/24/2021
Third Party Observer Report		01/25/2021	04/12/2021
Recommended for grant award		YES	03/24/2021
PRC Chair Notification to PIC and OC		03/09/2021	04/22/2021
PIC Review	COI indicated by PIC member	None	05/04/2021
	COI recused from participation	NA	05/04/2021
	PIC Review Meeting	05/04/2021	05/04/2021
	Recommended for grant award	YES	05/04/2021
Oversight Committee Approval	CEO Notification to Oversight Committee	NA	
	COI Indicated by Oversight Committee member	NA	
	COI Recused from participation	NA	
	Donation(s) made to CPRIT / foundation	NA	
	Presented to CPRIT Oversight Committee	NA	
	Award approved by Oversight Committee	NA	
	Authority to advance funds requested	NA	
	Advance authority approved by Oversight Committee	NA	



May 7, 2021

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendations for funding 26 grant applications totaling \$71,523,869. The PIC recommendations for 21 academic research and five prevention grant awards are attached.

Dr. Jim Willson, CPRIT's Chief Scientific Officer, and Ramona Magid, CPRIT's Chief Prevention Officer, have prepared overviews of the academic research and prevention slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all the information considered by each Review Council is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on May 19, 2021. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself and Dr. Willson, and Ms. Magid are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas.

Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts,
Chief Executive Officer

Academic Research Award Recommendations –

The PIC unanimously recommends approval of 21 academic research grant proposals totaling \$60,320,920. The recommended grant proposals were submitted in response to the *Research Training Awards*; *Recruitment of First-Time, Tenure Track Faculty Members*; and *Recruitment of Rising Stars* grant mechanisms. The Scientific Review Council provided the prioritized list of recommendations for the awards to the presiding officers on April 22, 2021. The PIC approved the award recommendations as presented by the SRC with one exception. The recommendation from the SRC included an Established Investigator award that was withdrawn by the applicant prior to the PIC meeting. The PIC did not consider the application and it is not part of the recommendations to the Oversight Committee. The PIC approved a budget reduction that was recommended by the SRC for RR210037.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
- strengthen and enhance fundamental science in cancer research;
- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
 - This factor applies to the Research Training Awards
- Address federal or other major research sponsors' priorities in emerging scientific or institutions of higher education;
 - This factor applies to the recruitment awards
- Are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
 - This factor applies to the Research Training Awards
- have a demonstrable economic development benefit to this state;
- enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources; and
- address the goals of the Texas Cancer Plan.

Academic Research Grant Award Recommendations
Research Training Awards

Rank	Application ID	PI	Application Title	Organization	Budget	Final Overall Score
1	RP210028	Keyomarsi, Khandan	The Future of Cancer Research: Training Program for Basic and Translational Scientists	The University of Texas M. D. Anderson Cancer Center	\$4,000,000	1.4
2	RP210041	Cobb, Melanie	Cancer Intervention and Prevention Discoveries Program	The University of Texas Southwestern Medical Center	\$3,748,675	1.7
3	RP210037	Spitz, Margaret	Systems Epidemiology for Cancer Training Program (SECT Program)	Baylor College of Medicine	\$3,593,867*	1.8
4	RP210043	Davies, Peter	Cancer Therapeutics Training Program (CTTP)	Texas A&M University System Health Science Center	\$3,136,872	2.5
5	RP210046	Vishwanatha, Jamboor	HSC Scholars in Cancer Research	University of North Texas Health Science Center at Fort Worth	\$3,870,641	2.9
6	RP210042	Fernandez, Maria	Collaborative Training of a New Cadre of Innovative Cancer Prevention Researchers	The University of Texas Health Science Center at Houston	\$3,998,230	2.9
7	RP210045	Zhao, Zhongming	Biomedical Informatics, Genomics, and Translational Cancer Research Training Program (BIG-TCR)	The University of Texas Health Science Center at Houston	\$3,998,553	2.9
8	RP210027	Rosen, Jeffrey	Baylor College of Medicine Comprehensive Cancer Training Program	Baylor College of Medicine	\$3,974,082	3.0

* PIC approved reduced budget that the SRC recommended.

Academic Research Recruitment Grant Award Recommendations

Rank	Application ID	Mechanism	Candidate	Organization	Budget	Final Overall Score
1	RR210028	RFTFM	Julea Vlassakis, Ph.D.	Rice University	\$2,000,000	1.0
2	RR210035	RFTFM	Chen Yao, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
3	RR210044	RFTFM	Jason Sheltzer, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
4	RR210039	RFTFM	Cornelius Y. Taabazuing, Ph.D.	Baylor College of Medicine	\$2,000,000	1.0
5	RR210029	RFTFM	Dongyin Guan, Ph.D.	Baylor College of Medicine	\$2,000,000	1.4
6	RR210037	RFTFM	Blair Benham-Pyle, Ph.D.	Baylor College of Medicine	\$2,000,000	1.8
7	RR210050	RFTFM	Cassandra Callmann, Ph.D.	The University of Texas at Austin	\$2,000,000	1.8
8	RR210031	RRS	Jeremy Wilusz, Ph.D.	Baylor College of Medicine	\$4,000,000	2.0
9	RR210034	RFTFM	Sihan Wu, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
10	RR210033	RFTFM	Brian Christopher Miller, M.D., Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
11	RR210040	RFTFM	Joshua Riback, Ph.D.	Baylor College of Medicine	\$2,000,000	2.0
12	RR210048	RFTFM	Courtney M. Schroeder, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	2.0

PIC Recommendation
FY2021 (May)

Rank	Application ID	Mechanism	Candidate	Organization	Budget	Final Overall Score
13	RR210042	RRS	Stephanie Seidlits, Ph.D.	The University of Texas at Austin	\$4,000,000	2.0

RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members

RRS: Recruitment of Rising Stars

Prevention Award Recommendations –

The PIC unanimously recommends approval of five prevention grant proposals totaling \$11,202,949. The recommended grant proposals were submitted in response to the *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations* grant mechanism. The Prevention Review Council (PRC) provided the prioritized list of recommendations for the awards to the presiding officers on March 9, 2021. The PIC approved the recommendations made by the PRC.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these prevention proposals met the following CPRIT funding priorities:

- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- have a demonstrable economic development benefit to this state; and
- address the goals of the Texas Cancer Plan.

Prevention Grant Award Recommendations
Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

Rank	Application ID	PD	Application Title	Organization	Budget	Final Overall Score
1	PP210003	Reitzel, Lorraine R	Taking Texas Tobacco Free among Substance Users within Community-based Healthcare Settings in Rural and Medically Underserved Areas Across Texas	University of Houston	\$1,998,572	1.4
2	PP210004	Shokar, Navkiran K	BEST 3: The Breast Cancer Education Screening and Navigation Program in West and South Texas.	Texas Tech University Health Sciences Center at El Paso	\$2,500,000	2.3
3	PP210005	Shokar, Navkiran K	Southwest Coalition for Colorectal Cancer Screening (SuCCCeS) 2	Texas Tech University Health Sciences Center at El Paso	\$2,500,000	2.9
4	PP210016	Villarreal, Roberto	Hep C - C.A.R.E (Colonias Advancing & Restoring Esperanza)	University Health System	\$1,712,190	3.3
5	PP210017	Obokhare, Izi D	Get F.I.T. to Stay Fit, Stepping up to Fight Colorectal Cancer in the Panhandle	Texas Tech University Health Sciences Center	\$2,492,187	3.3



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: VINCE BURGESS, CHIEF COMPLIANCE OFFICER
SUBJECT: COMPLIANCE CERTIFICATION – MAY 2021 AWARDS
DATE: MAY 5, 2021

Summary and Recommendation:

As CPRIT’s Chief Compliance Officer, I am responsible for reporting to the Oversight Committee regarding the agency’s compliance with applicable statutory and administrative rule requirements during the grant review process. I have reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the:

- Recruitment of Rising Stars
- Recruitment of First-Time, Tenure-Track Faculty Members
- Research Training Awards
- Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

I have conferred with staff at CPRIT and General Dynamics Information Technology (GDIT), CPRIT’s contracted third-party grants administrator, regarding the academic research and prevention awards and studied the supporting grant review documentation, including third-party observer reports for the peer review meetings. CPRIT received applications for the Recruitment of Established Investigators; however, the recommended application was withdrawn prior to the PIC meeting. I am satisfied that the application review process that resulted in the above mechanisms recommended by the Program Integration Committee (PIC) followed applicable laws and agency administrative rules. I certify the academic research and prevention award recommendations for the Oversight Committee’s consideration.

Background:

CPRIT’s Chief Compliance Officer must report to the Oversight Committee regarding compliance with the statute and the agency’s administrative rules. Among the Chief Compliance Officer’s responsibilities is the obligation “to ensure that all grant proposals comply with this chapter and rules

adopted under this chapter before the proposals are submitted to the oversight committee for approval.” Texas Health & Safety Code § 102.051(c) and (d).

CPRIT uses a compliance pedigree process to formally document compliance for the grant award process. The compliance pedigree tracks the grant application as it moves through the review process and documents compliance with applicable laws and administrative rules. A compliance pedigree is created for each application; the information related to the procedural steps listed on the pedigree is entered and attested to by GDIT employees and CPRIT employees. CPRIT relies on GDIT to accurately record a majority of the information on the pedigree from the pre-receipt stage to final Review Council recommendation. To the greatest extent possible, information reported in the compliance pedigree is imported directly from data contained in CPRIT’s Application Receipt System (CARS), the grant application database managed by GDIT. This is done to minimize the opportunity for error caused by manual data entry.

No Prohibited Donations:

Although CPRIT is statutorily authorized to accept gifts and grants pursuant to Texas Health & Safety Code § 102.054, the statute prohibits CPRIT from awarding a grant to an applicant who has made a gift or grant to CPRIT or a nonprofit organization established to provide support to CPRIT. I note that Texas Health & Safety Code § 102.251(a)(3) specifically addresses “donors from any nonprofit organization established to provide support to the institute compiled from information made available under § 102.262(c).” To the best of my knowledge, there are no nonprofit organizations that have been established to provide support to CPRIT on or after June 14, 2013, the effective date of this statutory change. The only nonprofit organization established to provide support to the Institute was the CPRIT Foundation; however, the CPRIT Foundation ceased operations and changed its name and its purpose prior to June 14, 2013. The institute has received no donations from the CPRIT Foundation made on or after June 14, 2013.

I have reviewed the list of donors to CPRIT maintained by CPRIT (and listed on CPRIT’s website) and compared the donors to the list of applicants. No donors to CPRIT have submitted applications for grant awards during the award cycles that are the subject of this report.

Pre-Receipt Compliance:

The activities listed on a compliance pedigree in the pre-receipt stage cover the period beginning with CPRIT’s approval and issuance of the Request for Applications (RFA) through the submission of grant applications. For the period covering these RFAs, CPRIT published the RFAs on the Texas.gov eGrants website. The RFA specifies a deadline and mandates that only those applications submitted electronically through CPRIT’s Application Receipt System (CARS) are eligible for consideration. CARS blocks an application from being submitted once the deadline passes. Occasionally, an applicant may have technical difficulties that prevent the applicant from completing the application submission. When this occurs, the applicant may

appeal to CPRIT (through the CPRIT Helpdesk that is managed by GDIT) to allow for a submission after the deadline. The program officer considers any requests for extension and may approve an extension for good cause. When a late filing request is approved, the applicant is notified, and CARS is reopened for a brief period – usually two to three hours – the next business day.

Academic Research:

For recruitment cycles 21.6, 21.7, 21.8 and 21.9, two applications were received for the Recruitment of Established Investigators RFA, five applications were received in response to the Recruitment of Rising Stars RFA, and 17 applications were received in response to the Recruitment of First-Time, Tenure Track Faculty members RFA.

In response to the academic, non-recruitment RFAs for cycle 21.1, CPRIT received 15 applications pursuant to the Research Training Awards (RTA) RFA.

All academic research RFAs were posted on the Texas.gov eGrants website and all applications were submitted through CARS. Three applicants requested an extension to submit an application after the deadline. The program officer determined that there was good cause for the three requests and the deadline was extended.

Prevention:

For prevention cycle 21.1, 12 applications were received for the Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations RFA.

The prevention RFA was posted on the Texas.gov eGrants website and all applications were submitted through CARS.

Receipt, Referral, and Assignment Compliance:

Once applications have been submitted through CARS, GDIT staff reviews the applications for compliance with RFA directions. If an applicant does not comply with the directions, GDIT notifies the program officer and the program officer makes the final decision whether to administratively withdraw the application. Recruitment grant applications are assigned to the Scientific Review Council members for peer review. All other academic research, product development research, and prevention applications are assigned by the peer review panel chair to their respective peer review panels. Prior to distribution of the applications, reviewers are given summary information about the applicant, including the Project Director and collaborators. Reviewers must sign a conflict of interest agreement and confirm that they do not have a conflict of interest with the application before they are provided with the full application.

The pedigrees attest that a conflict of interest statement was signed by each primary reviewer for each Grant Application.

Academic Research:

In total, two recruitment applications during cycle 21.7-8 were withdrawn after initial receipt. One recruitment application was administratively rejected and therefore, not assigned to the SRC for review. A second application was withdrawn by the applicant after it was recommended by the SRC but prior to the PIC meeting.

Prevention:

No applications were withdrawn during this cycle.

Peer Review:

Primary reviewers (typically three) must submit written critiques for each of their assigned applications prior to the peer review meeting. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application.

Following the peer review meeting, each participating peer reviewer must sign a post-review peer review statement certifying that the reviewer knew of and understood CPRIT's conflict of interest policy and followed the policy for this review process. After the peer review meetings, a final score report from the review committee is delivered to the Review Council for additional review.

Academic Research:

For the Recruitment Awards, the applications are reviewed by the Scientific Review Council (SRC), which assigns two members of the SRC to be primary reviewers. I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application. Two conflicts of interest were declared by the SRC for recruitment cycle 21.7-8 and two conflicts of interest were declared by the SRC for recruitment cycle 21.9. For recruitment cycle 21.6, no conflicts of interest were declared.

I reviewed and confirmed that the post review conflict of interest statements were signed by the eight SRC members that attended the 21.6 Recruitment Review Panel meeting on January 21, 2021, the six SRC members that attended the 21.7-8 Recruitment Review Panel on March 11, 2021, and the eight SRC members that attended the 21.9 Recruitment Review Panel on April 15, 2021.

Academic research applications (non-recruitment) are reviewed by peer review panels and recommended to the SRC. As documented by GDIT, reviewers with conflicts of interest did not participate in review of those applications. I reviewed supporting documentation, such as conflict of interest statements (COIs), third-party observer reports, and sign out sheets. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I also reviewed and confirmed that the post review conflict of interest statements were signed by the 16 peer review members for the 21.1 RTA review panel on February 18, 2021, as well as the five SRC members that attended the Review Council meeting on March 25, 2021.

Prevention:

Prevention applications are reviewed by peer review panels and then sent to the Prevention Review Council (PRC).

I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. As documented by GDIT and verified by third-party observer reports, reviewers with conflicts of interest did not participate in review of those applications. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I reviewed and confirmed that the post review conflict of interest statements were signed by nine peer review members for Prevention Panel 1 on January 19, 2021 and the three PRC members that attended the PRC meeting on March 4, 2021.

Programmatic Review:

Programmatic review is conducted by the Scientific Review Council, Prevention Review Council, and Product Development Review Council for their respective awards. Each review council creates a final list of grant applications it will recommend to the PIC for grant award slates.

To the extent that any Review Council member identified a conflict of interest, I reviewed documentation confirming that the review council member did not participate in the discussion or vote on the application(s).

I also reviewed the third-party observer reports for each Review Council meeting. The third-party observer reports document that the Review Council discussions were limited to the merits of the applications and established evaluation criteria and that conflicted reviewers, if applicable, exited the room or the conference call when the application was discussed.

For the Academic Research and Prevention awards, I reviewed and confirmed that the Review Council recommendations corresponded to RFAs that had been released. I also confirmed that the

pedigrees reflect the date of the Review Council meeting and that the applications were recommended by the Review Council.

Academic Research:

The SRC met on March 25, 2021 to consider eight applications recommended by the RTA peer review panel following their meeting held on February 18, 2021. After review of these applications, the SRC recommended all eight applications to the Program Integration Committee (PIC) for consideration. Of the eight RTA applications, the SRC recommended a budget reduction for one RTA grant application.

In their review of recruitment applications, the SRC did not recommend applications from recruitment cycle 21.6 to the PIC. After the SRC recommended RR210032 to the PIC, the applicant withdrew the application form consideration prior to the PIC meeting. This application was the only recommended Established Investigator award from cycles 21.6-9.

I note that on February 1, 2021, Wayne Robert's, CPRIT's Chief Executive Officer, granted Dr. Jim Willson, CPRIT's Chief Scientific Officer, a waiver from the general prohibition against communicating with grant applicants, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is available in the CEO Affidavit Supporting information for the recruitment cycles 21.6-9.

Prevention:

Out of 11 applications considered by the PRC following the peer review panel meeting on January 19, 2, five were recommended to the PIC. The PRC took no action on one application with the same score as an application on which the PRC took no action. As allowed in 25 T.A.C. § 703.6(d)(1), the PRC's numerical rank order is substantially based on the final overall evaluation score, but also takes into consideration how well the grant application achieves program priorities, programmatic review criteria, and the overall program portfolio.

I note that on August 28, 2020, Mr. Roberts granted the Chief Prevention Officer, Ramona Magid, a waiver from the general prohibition against communicating with grant applicants, pursuant to Texas Administrative Code § 702.19(e). A copy of the waiver is included in the "CEO Affidavit-Supporting Information" packet for each of the prevention mechanisms recommended by the PIC.

Program Integration Committee (PIC) Review:

Texas Health & Safety Code § 102.051(d) requires the Chief Compliance Officer to attend and observe the PIC meetings to ensure compliance with CPRIT's statute and administrative rules. CPRIT's statute requires that, at the time the PIC's final Grant Award recommendations are formally submitted to the Oversight Committee, the Chief Executive Officer shall prepare a written affidavit

for each Grant Application recommended by the PIC containing relevant information related to the Grant Application recommendations.

I attended the May 4, 2021, PIC meeting as an observer and confirm that the PIC review process complied with CPRIT's statute and administrative rules.

The PIC considered 26 applications that were recommended by the Academic Research and Prevention Review Councils; The PIC voted to recommend all 26 applications to move forward to the Oversight Committee. The PIC recommended RP210037 to the Oversight Committee with the recommended budget reduction by the SRC.

A review of the CEO affidavits confirms that such affidavits were executed and provided for each Grant Application recommendation.